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Abstract 
Positron Emission Tomography (PET) is a highly sensitive imaging technique 
used in cancer diagnosis, treatment planning and monitoring of therapy response. 
[18F] is an optimal PET label considering its half-life (110 min) and imaging resolution. 
One of the major challenges in [18F]-PET research is the installation of the weakly 
nucleophilic [18F]fluoride into a precursor molecule to access novel [18F]-tracers. 
Fluorinated nucleosides represent an important class of diagnostic probes for PET 
imaging as well as anticancer and antiviral therapeutic agents. However drug 
resistance still represents a major problem. The ProTide approach is a strategy to 
synthesize prodrugs of the nucleoside monophosphates which overcome their main 
resistance mechanisms. The challenge of the project is the [18F]-fluorination (hot 
fluorination) of ProTides which may be potential new PET imaging agents and could 
thus represent a model system to visualize pharmaceutical effects and bioactivation of 
ProTides directly in vivo.  
The pro-nucleotide multistep synthetic chemistry has been applied for the 
synthesis of ProTides. The [18F]-radiolabeling of the precursor molecules was 
performed in an Eckert & Ziegler automated synthetic Modular Lab  placed into a 
shielded hot cell. The radioactive reaction mixtures were analyzed by radio HPLC, and 
radio TLC. Two different approaches have been followed to access two chemically 
distinct radiolabelled ProTides. The 3’-[18F]FLT ProTide was synthesised via a late 
stage [18F]fluorination of ad hoc synthesised precursor molecules (Figure 1). 
Figure 1: Radiochemical synthesis of 
18
F- FLT ProTides 
The 2’-[18F]FIAU ProTide was synthesised via an early stage [18F]fluorination 
approach (Figure 2).  
Figure 2: Radiochemical synthesis of 
18
F-FIAU ProTides 
These radiolabelled probes could provide evidence for the in vivo behaviour of 
this class of compounds by answering key questions about their metabolism and 
uptake directly. 
In addition, the project focused on the synthesis of two novel classes of non-
radiolabelled fluorinated ProTides. A series of uridine based ProTides (FIAU ProTides) 
and a series of coumarin based FLT ProTides have been synthesised and evaluated for 
their antiviral activity and fluorescent properties respectively.
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1. Introduction 
 
1.1 Positron Emission Tomography (PET) 
Positron Emission Tomography (PET) is a highly sensitive non-invasive nuclear 
imaging technique widely used for cancer diagnosis and treatment planning. It is also 
used for early detection and treatment of other diseases (i.e. Parkinson’s and 
Alzheimer’s disease) by detecting metabolic changes within relevant cells.1 
Diagnostic radiology is a field that emerged after the discovery of X-rays by 
Wilhelm Rӧntgen in 1895. Nowadays, this technique is still used, together with CT 
(Computed Tomography), MRI (Magnetic Resonance Imaging) and US (Ultrasound). 
Although they can be useful in order to provide structural and anatomical information 
on different medical conditions, their biggest limitation is that they give very poor 
functional information about biological and metabolic processes.1 
PET and SPECT (Single-Photon Emission Computed Tomography) instead give 
the possibility to deeply understand the biological processes in different medical 
diseases. PET, compared to SPECT, has several advantages such as the possibility of 
having 3D and 2D physiological and biological information thank to the use of a wider 
range of positron emitting radioelements and a higher sensitivity.1 PET, more recently, 
has also been used for another important and crucial role in the drug discovery 
industry. Indeed, PET gives the possibility to provide a wide range of useful information 
on biological and pharmacological properties of several drug candidates through direct 
radiolabeling of the drug molecule.2 PET thus represents an important tool for drug 
discovery and personalized medicine, allowing for several clinical trials and monitoring 
of patient response to treatments.3 
Among different positron-emitting isotopes 18F, 11C, 13N and 15O are currently 
the most widely used in PET.4 All of them are characterized by a low molecular weight 
so that no difference in biological activity is observed compared with their non-labelled 
counterparts.5 These radioelements decay by positron emission, an anti-electron 
which encounters an electron and causes an annihilation event leading to the release 
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of antiparallel gamma-rays4. For example, [18F]fluorine decays to [18O]oxygen, a 
natural and stable isotope of oxygen, releasing a neutrino (ν) and a positron (β+) 
(Equation 1.1)6. 
Equation 1.1: Decay of 18F 
18F              18O + β+ + ν 
 
The time frame of β+ emission depends on the half-life of the radioactive 
nucleus, which varies according to its specific decay constant (λ) (Equation 1.2)7. 
 
Equation 1.2: Half-life of a radionuclide varies with the decay constant 
t1/2 = 
0.693
𝜆
 
 
The positron (β+) can encounter an electron (e-), its antiparticle, by travelling a 
short distance to the surrounding tissues. An annihilation event thus occurs, and two 
gamma-ray photons (γ) of 511 keV are generated from this event (Figure 1.1)8. 
 
Figure 1.1.1: Schematic illustration of an annihilation reaction and the subsequent 
coincidence detection 
 
 
The emitted -rays travel in the opposite direction with an angle of 180° and 
PET scanners, which encircle the patient, detect the pair of photons simultaneously, 
determining the precise 3D location of the radiolabelled compounds. 
Radioelements 13N and 15O have very short half-lives (less than 10 minutes), so 
they require a cyclotron (PET isotope generating particle accelerator) facility on site. 
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11C has a half-life of 20.3 min, which is longer, but still often not long enough for a 
multi-step tracer synthesis1.18F, on the contrary, is the most widely used radioisotope 
in PET. With its half-life of 109.77 min, it allows for efficient multi-step synthesis of 
radiolabelled tracer molecules (Table 1.1)9. 
 
Table 1.1: Selected isotopes used in PET imaging9 
Isotope Half life β-Positron emission 
18O 2 min β+, 1732keV (99.9%) 
15N 10 min β+,1199 keV (99.8%) 
11C 20.39 min β+,960 keV (99.8%) 
18F 109.8 β+,633 keV (96.7%) 
64Cu 12.7 h β+,653 keV (17.9%), β-, 578.7 keV (39%) 
124I 4.17 days β+,1199 keV (99.8%), β-, 2138 keV (11%) 
 
Additionally, the longer half-life allows investigation of biological systems with 
slower kinetics.10 
 
1.1.1 Physical principles of PET 
 
From the cyclotron to the PET scan 
Many steps are required to obtain radiolabelled tracers for PET imaging. The 
whole process starts with the production of proton rich radioisotopes produced by 
bombardment of a target by proton sources. This process takes place at very high 
velocity in cyclic particle accelerators named cyclotrons (Figure 1.2). 
The cyclotron uses a combination of electric and magnetic fields. As soon as the 
positively charged particle enters the gap between the two dees, it is accelerated by 
the electric field towards one of them. The magnetic field makes the particle do semi-
circle movements and then moves it back to the gap. The electric field accelerates the 
positive particle to the original dee, and this process is repeated with every transition 
of the particle. Eventually, the particle exits the cyclotron at high speed to bombard 
the target.11 
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Figure 1.2: Schematic illustration of a cyclotron12 
 
 
The positively charged particle, accelerated by the cyclotron, hits the target 
isotope which emits another particle from its nucleus and thus produces the desired 
radioisotope. Different targets and nuclear reactions can be used to obtain the desired 
radioisotope.11 
Details of a nuclear reaction are normally described as in the short hand in 
Figure 1.3 where A represent the target isotope, b the bombarding particle, c the 
emitted particle, D the isotope produced and z the atomic mass. 
 
Figure 1.3: Nuclear reaction short hand 
 
 
Listed below are some nuclear reactions associated with the most common targets 
(Table 1.2)11,13. 
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Table 1.2: Nuclear reactions targets and products11,13 
TARGET   NUCLEAR REACTION PRODUCT 
N2 + 0.1% O2  
14N(p,α)11C [11C]CO2 
N2 + 5% H2  
14N(p,α)11C [11C]CH4 
N2 + 0.2% O2  
14N(d,n)15O [15O]O2H2 
18O  18O(p,n)18F [18F]F-(H2O)n 
18O2 + 0.6% F2
  18O(p,n)18F [18F]F2 
20Ne  20Ne(d, α)18F [18F]F2 
H2O/ETHANOL  
16O(p,α)13N [13N]NH3 
CO2 (TRACE N2)  
12C(d,n)13N [13N]N2 
 
Once a radioisotope is produced, it has to be incorporated into a precursor 
molecule to obtain the desired radiotracer. Synthesis, purification and quality control 
(QC) analyses need to be performed in a reasonable short time (typically less than 2 or 
3 half-lives).  
To achieve this, the radioisotope has to be in a reactive form. Sometimes it is 
produced directly as its reactive species such as the [18F]F2 gas.
14 Other times, it has to 
be converted into a more reactive form. This is the case for [11C]MeI which can be 
obtained from [11C]-CO2 or [11C]-CH4.
15,16 In the case of the [18F]fluoride, because of 
its weak nucleophilicity, its reactivity has to be increased by using crown ethers and 
azeotropic drying.17 
The reactive form of the radioisotope has to be introduced into a precursor 
molecule at a late stage in the multi-step synthesis if possible. Therefore, precursors 
are usually synthesized to be highly functionalized and activated so that the labeling 
can be the last step or can be followed by a quick deprotection step only.10 To speed 
up the reaction the precursor should be used in super-stoichiometric amounts 
compared to the radioisotope.18 Radiotracers are also required to be enantiomerically 
pure (more than 98%ee) whenever possible.18 
In order to manipulate the reagents of the reaction when dealing with positron 
emitting radioisotopes, an automated synthesizer is required so that the chemical 
reaction can occur in a heavily shielded compartment called a hot cell. The radiotracer 
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has to be injected into a patient in a short time from the beginning of the synthesis, 
which means that the reaction has to be reproducible as its failure will lead to severe 
inconvenience for patients.18 
Besides these essential requirements, there are some extra desirable ones such 
as a stable and easily synthesised precursor. A high radiochemical yield (RCY) is also a 
desirable as more patients can be scanned and the tracer, accordingly to the kind of 
radioisotope used, could also be transported offsite. To simplify the synthesis, ambient 
temperature would be ideal as well as a high specific activity (SA).17 
Specific activity is an import factor when it comes to radiotracers. It is defined 
as the radioactivity per unit of material (grams or moles of tracers).The higher the SA, 
the lower the concentration of cold harmful tracer that will be administered.19To 
calculate the specific activity of a tracer, it should be taken into account that [19F]-
tracers could be present even if the fluorination was “no carrier-added”.20 Possible 
sources of 19F could be Teflon tubing21 or ion exchange cartridges22.To calculate the 
exact amount of tracer desired, HPLC with a UV detector can be used for UV sensitive 
tracers. First, a calibration curve of the cold tracers should be done and then compared 
with the concentration of the UV signal of the radioactive tracer.19 
 
Automated modules for the synthesis 
When dealing with radioactive tracers, the synthetic process is obviously 
influenced by the short time available for the synthesis, purification and QC analyses 
(usually not more than 3 half-lives of the radionuclide). For these reasons, for both 
preclinical and clinical purposes, use of computer controlled synthetic automated 
modules are required.22 This will, on one hand, reduce the exposure to radioactivity for 
operators as modules will be placed into shielded hot cells but will also assure a 
reproducible synthesis reducing the possibility of human errors and the overall 
synthesis time. Many companies have developed in recent years automated modules 
that can be adaptable for many kind of synthesis. The Eckert & Ziegler (E&Z) modular 
lab (Figure 1.4) is currently one of the most commonly used for the routine synthesis 
of the gold standard PET tracer [18F]FDG. 
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Figure 1.4: Eckert & Ziegler automated modular lab22 
 
 
Tracers like [18F]FDG, which require a nucleophilic fluorination followed by a 
single deprotection step, can be synthesised by these automation modules. Other 
automation modules like Fastlab from GE healthcare and Trasis (Figure 1.5) allow also 
more complex synthesis with better radiochemical yields (RCY) and radiochemical 
purity. 
 
Figure 1.5: a) Fastlab from GE healthcare23 and b) Trasis24 
a.   b.  
 
Analysis and quality control of radiotracers 
Finally, before using the tracer, purification and quality control analyses have to 
be performed. Again fast purification is required and it can be performed either by 
preparative HPLC attached to automation modules, ideally just using purification 
cartridges. Once purified, the tracer is usually isolated in a generally isotonic solution 
and is passed through sterile filters. One of the samples produced is designated to the 
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quality control section to make sure all the criteria required are met (this is particularly 
true when the tracer has to be produced under GMP standards for clinical purposes).25 
Listed below are some of the routine analyses performed for quality control of 
radiopharmaceuticals: 
- Dose calibration of the radioisotope. 
- Filter test to determine its integrity. 
- Visual inspection of the product. 
- pH measures. 
- Endotoxin test. 
- Analytical HPLC to determine the radiochemical purity and identity of tracer and side 
products. 
- Radio TLC for RCY, purity and identity calculation. 
- Analysis of residual Kryptofix left in the solution. 
- GC to determine quantity of residual solvents in the product.26 
 
When it comes to the development of novel tracers for R&D purposes, Radio-
TLC and Radio-HPLC are the main tools used for high quality analyses. Radio-HPLCs are 
characterized by a UV, a refractive index or conductivity, and a radioactive detector. 
This allows straightforward determination of the radioactive profile of the tracer.26 
Real time analyses are provided either by flow-cell radioactivity measures or by the use 
of microplates scintillation counting. The radioactivity is detected by using NaI or 
Bismuth Germanium Oxide  (BGO) scintillation crystals. They register the annihilation-
photons and re-emit low energy photons that are eventually converted into an 
electrical signal thanks to coupled photomultiplier tubes.27 
 
Radiation safety and monitoring 
When dealing with radioactivity, health and safety legislation becomes more 
stringent when compared to normal organic chemistry synthesis. All the staff must be 
trained through a radiation safety and monitoring course prior to perform any kind of 
work according to the current UK Ionisation Radiation Regulations (IRR99).28 In 
addition, standard protective clothing and personal radiation film badges must be 
worn to monitor torso, fingers and head. The IRR99 established a certain annual dose 
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limit for operators; 200 mSV for the body, 500 mSV for hands, forearms and feet and 
150 mSV for the lens of the eye. In order to reduce the risk of exposure, the amount of 
time spent near to a radiation source must be reduced,28 the distance from the 
radioactive material has to be increased as much as possible and lead shields should 
also be used to minimize the exposure. Lab walls and hot cells should have a width of 4 
cm to effectively shield the 511 keV photons.29 In conclusion, respecting these basic 
rules as well as using electronic personal dosimeters (EPD) and personal film batch 
dosimeters will protect the operator as well as the environment in which all the 
process happens. 
 
1.1.2 [18F]fluorine  
Often the fluorination occurs in the last synthetic step but several synthetic 
schemes plan it at an earlier stage since it needs to be followed by a deprotection step. 
The fluorination, in fact, is often a non-regiospecific reaction, especially under the 
conditions used in hot chemistry (i.e. high temperature), therefore usually precursor 
molecules need to be protected in order to avoid degradation of the starting material 
during the synthesis.19 
The 18F half-life of 110 minutes, additionally, permits the [18F]-radiolabelled 
pharmaceuticals to be transported out of the site of production and also gives the 
possibility to use them for physiological studies that require scanning times of several 
hours.17 Another huge advantage of using [18F]fluorine instead of other radioisotopes, 
is that it is also characterized by a low percentage of positron emitting energy which is 
the distance traveled by the positron before the annihilation event. The shorter the 
distance, the better the image resolution.10 
The main properties of [18F]fluorine are summarised in the table below (Table 
1.3)17. 
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Table 1.3: Main properties of [18F]fluorine17 
PROPERTY VALUE 
half life 110 min 
maximum energy of e+ 0.64 MeV 
mode of decay β+ (97%) 
decay product 18O 
 
Besides their advantageous half-life, [18F]-tracers provide high resolution images 
thanks to the low positron energy emission of the 18F (0.64 MeV).17 This implies that, 
once emitted, the positron has to travel a very short distance (≈2mm) before 
encountering an electron in the surrounding tissue. From this annihilation event two 
gamma rays of 511 KeV are generated and are detected by the PET scanner.22 
[18F]fluorine is produced from the nuclear reaction 18O(p,n)18F in high yields 
with low energy protons (<16 MeV) and high specific activity (Equation 1.3).1 
 
Equation 1.3: [18F]fluorine production equation 
                                                                               18 
8O + 
1
1p             
18
9F+ 
1
0n+ γ 
 
 The high specific activity of [18F]-tracers allows their use in very low concentration 
(picomolar range).23 [18F]fluorine can be obtained from the cyclotron or linear charged 
particle accelerators. Most PET facilities accomplish the generation of [18F]fluorine by 
irradiation of target molecules in a cyclotron.10 
To perform a nucleophilic fluorination, the target of proton bombardment is 
the oxygen-18 enriched water via the nuclear reaction 18O(p,n)18F. Once the [18F]F- is 
generated, it is entrapped in an ion-exchange cartridge with a base such as KF to afford 
[18F]KF. The aqueous fluoride thus produced, is a weak nucleophilic agent and, for this 
reason, a chelator agent like Kryptofix K[222] (Figure 1.6), is used to chelate the 
potassium and release free [18F]fluoride ion which is thus activated and desolvated 
ready for the nucleophilic attack.17 
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Figure 1.6: Structure of Kryptofix K[222] 
 
 
If an electrophilic fluorination reaction is required, the target is Neon-20 which 
is bombarded with deuterons via the nuclear reaction 20Ne(d,α)18F generating 18F[F2], 
although the nucleophilic reaction is commonly preferred for the introduction of 
[18F]fluorine into a bioactive molecule.30 
There are several methodologies used to measure the radiochemical yield of a 
reaction. Usually the radioactivity of the purified [18F]-labeled compound is compared 
to the initial radioactivity received from the cyclotron. The unit used for radioactivity in 
PET is the Becquerel (Bq) or, less frequently, the Curie (Ci). 1Ci is equal to 37 GBq. 
[18F]-radiolabelled compounds are analyzed by high-performance liquid 
chromatography (HPLC) or gas chromatography (GC) where they are co-eluted with 
the standard cold reference with a known mass.1 
Most radiolabelled compounds are prepared with a no-carrier added method 
which means that no carrier [19F]fluorine has been added in the generation of the 
radionuclide, meaning that no cold fluorine has been purposely added.17 Even though 
levels of radioactivity produced by a cyclotron run can be very high, the concentration 
of [18F]fluoride produced will still be lower than the concentration of the precursor 
used in the synthesis. Even high radioactivity of [18F]fluorine will rarely exceed low 
micromolar concentration levels.31 
 
1.1.2.1 Fluorination 
Fluorination reactions are harsh to perform in most cases, so when it comes to 
synthesise non-radioactive fluorinated molecules, it is usually preferable to start the 
synthesis with an already fluorinated building block whether possible. On the contrary, 
when dealing with [18F]fluorine, it is very important to perform the fluorination at a 
late stage of the multi-step synthesis because of the short half-life of the radioisotope. 
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In recent years many studies have been carried out to optimise late stage fluorination 
showing better conditions to enable this step efficiently and rapidly.1,6,7,18 
Nucleophilic Fluorination 
Nucleophilic fluorinations are the most common kind of [18F]-fluorinations (hot 
fluorination) in use today. The nucleophilic [18F]fluoride is produced by the nuclear 
reaction on enriched water [18O]H2O through bombardment of protons. The 
[18F]fluoride anion produced is a very weak nucleophile and a strategy has been 
developed to increase its nucleophilicity. It is first dehydrated through a ion exchange 
cartridge, and then activated by crown ethers such as Kryptofix K[222] and potassium 
carbonate.6,7 Aliphatic nucleophilic fluorinations normally occur with an SN2 
stereochemistry. Good leaving groups should be used for the precursors and aprotic 
solvents are suggested because of the low reactivity of the fluoride.6,32 In Figure 1.7 
two synthetic approaches towards [18F]FLT, the first in-human approved [18F]-
labelled nucleoside as a tumour proliferation biomarker, are shown. The two 
precursors (1.1 and 1.2) need to be deprotected to give [18F]FLT (1.4) after the 
fluorination step.33,34 
 
Figure 1.7: Synthesis of [18F]FLT via two approaches34 
 
Reagents and conditions: a) K/(K222)
18
F, anh. DMSO, 160°C, 10min; b) K/(K222)
18
F, anh. CH3CN, 135°C, 
5min; c) 1N NaOH, 55°C, 10 min or 1N HCl, 105°C, 5 m. 
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Recently many studies have been carried out to look for improved methods and 
substrates for these [18F]-nucleophilic reactions. Modern organic chemistry 
technology has been applied to radiochemistry and an example of the results obtained 
by this combination is the use of a metal-catalyst for allylic fluorination reactions 
(Figure 1.8).35,34 
 
Figure 1.8: Metal catalysed allylic fluorination reaction 
 
 
 
Nucleophilic aromatic fluorination is more challenging than aliphatic fluorination, and 
is often used in PET radiochemistry for the synthesis of radiolabelled arenes. Harsh 
conditions such as high reaction temperature and activated substrates with electron 
withdrawing groups on the aromatic moieties in the ortho or para positions relative to 
the position of fluorination are required. This becomes necessary to overcome the 
normally disfavoured SNAr reaction. When there are electron rich groups on the 
aromatic ring, a strategy has been developed to circumvent this issue. The electron-
donating group is masked as an electron withdrawing one using appropriate protecting 
groups. An example of this strategy is the synthesis of [18F]flutemetamol (1.6), a PET 
imaging agent of the brain used as diagnostic tool for Alzheimer’s disease (Figure 
1.9).36,1 
 
Figure 1.9: Synthesis of the [18F]flutemetamol 
 
Reagents and conditions: a) K/ (K222)
18
F, anh. DMSO, 150°C, 30min; b) 1N HCl, 105°C, 5 min. 
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The radiolabeling of an ortho-nitroaniline was thus enabled by masking the 
amine group as a formamide group. Therefore the displacement by [18F]fluoride of 
the nitro group becomes possible. 
Often [18F]fluoride is introduced into the aromatic moiety thanks to the use of 
aryliodonium salts, to generate an extremely effective leaving group.7,37,38Recently to 
improve the outcome of these types of fluorination, a number of transition metal 
catalysed nucleophilic fluorinations have been developed. One of these uses pre-
catalysts such as nickel σ-aryl complexes to access [18F]fluorouracil (1.9), a PET tracer 
for cancer imaging (Figure 1.10). This is the first time that a transition-metal-mediated 
fluorination has been used for clinical application.34,39 
 
Figure 1.10: Synthesis of [18F]fluorouracil (1.9) via transition-metal-mediated 
fluorination34,39 
 
Reagents and conditions: a) LnNi
II
X2, pyridine, 70°C, 1h; b) PhI(4-OMe-pyridine)2(OTf)2, (18-c-6)K
18
F, 
CH3CN (0.5% H2O), 23°C, 1 min; c) HCl, EtOH, 23°C, 2 min. 
 
 Electrophilic Fluorination 
Electrophilic fluorination reactions were commonly used for the preparation of 
radiopharmaceuticals but they have been mostly replaced nowadays by nucleophilic 
reactions where possible. Aromatic rings and/or electron rich-double bonds can be 
readily fluorinated using electrophilic-fluorinating agents.40The reason for avoidance of 
electrophilic fluorination is due to the high reactivity and toxicity of the hazardous 
fluorine gas ([18F]F2), the simplest fluorinated reagent, generated by the nuclear 
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reaction 20Ne(d,α)18F. This kind of reaction is characterized by a low chemical and 
radiochemical yield and a poor selectivity. 
Another method used to produce the fluorine gas ([18F]F2)  is the bombardment 
of oxygen-18(18O(p,n)18F) and a carrier fluorine gas. Also in this case the specificity and 
the yields are very low because of the carrier-added production but mostly because of 
the necessity to isolate by purification the desired radiolabelled compound which can 
be a difficult procedure.41,7To increase both the yields and the selectivity of 
electrophilic fluorination, several intermediate electrophilic reagents have been 
produced. Among them [18F]XeF2 and [
18F]AcOF are common even though they can 
never reach a radiochemical yield greater than 50%.1 
Since most applications preclude the use of fluorine gas, fluorine must bind to 
an electronegative atom such as nitrogen, activated by a strongly withdrawing group 
such as the sulfonyl group. An example of a convenient relatively non-toxic 
electrophilic fluorinated reagent is Selectfluor®. It is synthesized using an anion 
exchange, diazabicyclo[2.2.2]octane, which is chloromethylated, followed by a 
fluorination with F2 or [
18F]F2 to furnish the bis(tetrafluoroborate) compounds and the 
[18F] (Figure 1.11). Bis(tetrafluoroborate) salts have been used for the preparation of 
several fluoroaromatic compounds and have proved to be more selective than 
[18F]F2.
42 
 
Figure 1.11: Synthesis of the fluorinating agent Selectfluor 
 
 
[18F]Selectfluor can be used in cases where fluorination of sugar moieties 
bearing an electron-rich double bond is also required. Besides its application in PET 
chemistry, Selectofluor is also used for non-radioactive electrophilic fluorinations 
(Figure 1.12)42. 
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Figure 1.12: Electrophilic fluorination with Selectfluor 
 
Reagents and conditions: a) Selectfluor, HOAc-H2O. 
 
Another electrophilic fluorination agent has been recently synthesized is the 
[18F]fluoride-derived palladium (IV). This is the first electrophilic agent derived directly 
from [18F]fluoride. Its use has been limited because it involves a two-step sequence 
reaction and because of the potentially sensitive organometallic reagents.42 
 
Other synthetic strategies to access fluorinated molecules 
When later-stage fluorination is either not possible or convenient, other 
synthetic approaches involve the use of already fluorinated building blocks or, in the 
case of PET chemistry, the early fluorination of a moiety of the molecule. N-
glycosylation reaction is for instance used to access some fluorinated nucleosides. It 
consists of the reaction between already fluorinated nucleobases and sugar moieties. 
This is considered a convergent approach and is particularly used to access 2’-β-fluoro 
nucleosides. The fully protected sugar is first brominated to form the 1-α-glycosyl 
bromide. The β-nucleoside is usually the most favoured product of this reaction as 
reported in the synthesis of the antineoplastic agent Clofarabine (1.13)(Figure 
1.13).43,34 
 
Figure 1.13: Synthesis of Clofarabine (1.13) 
 
Reagents and conditions: a) HBr, AcOH, rt; b) 2-chloroadenine, KOt-Bu, CH3CN, t-AmOH, DCE, 55C; c) 
cat. NaOCH3, CH3OH, rt. 
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As mentioned before, this synthetic approach is used also in PET chemistry to 
access a number of [18F]-β nucleosides. [18F]FIAU (1.16), a reporter gene for the 
expression of the herpes simplex virus type-1 thymidine kinase (HSV1-tk), is for 
instance synthesised using the same synthetic convergent approach (Figure 1.14).44,45 
Schinazi et al have recently reviewed synthetic strategies for the convergent 
approach.46 
 
Figure 1.14: Synthesis of [18F]FIAU (1.16) 
 
Reagents and conditions:  a) K/(K222)
18
F, anh. CH3CN, 80°C, 30 min; b)5-iodouridine, HMDS, TMSOTf, 
anh. CH3CN, 80°C, 1h; c)KOCH3, CH3OH, 80°C, 10 min. 
 
1.1.2.2 [18F]FDG 
[18F]FDG ( 2[18F]fluoro-2-deoxy-D-glucose) (1.17) is the most widely used PET 
tracer, being used in perhaps as many as 90% of all PET oncology scans. 
 
Figure 1.15: Structure of the most widely used PET tracer [18F]FDG 
 
 
Glucose is a major source of energy for different biological systems. It is first 
transported by membrane transporters (GLuT) into cells and through the BBB (blood 
brain barrier). Glucose is there phosphorylated by a hexokinase using ATP as a source 
of phosphate. [18F]FDG is transported inside the cells with high metabolic activity by 
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the same transporter as for glucose and it is phosphorylated by the same kinase. But, 
unlike glucose, it is not metabolized by the glucose-6-phosphate isomerase and it stays 
entrapped into the cells. Once [18F] decays into [18O], the resulting 2-[18O]-
deoxyglucose-6-phosphate is metabolized while the [18F]FDG is excreted.47 [18F]FDG 
has many applications in different areas such as oncology, neurology, and cardiology.48 
It can be synthesized using both electrophilic and nucleophilic substitution reactions. 
The electrophilic substitution can be performed using either [18F]F2 or 
[18F]acetyl hypofluorite as the source of [18F]-fluorine. The hypofluorite gives better 
yields than [18F]F2. The precursor molecule used is 3,4,6-tri-O-acetyl-D-glucan.
49 
Another approach for electrophilic substitution used for production of [18F]FDG uses 
[18F]XeF2 as the source of electrophilic fluoride.
50Unfortunately none of these methods 
give very good yields so radiochemical facilities have abandoned them in favour of 
nucleophilic substitutions. 
Nucleophilic reactions can be performed using Cs[18F], Et4N[
18F], or KH[F]F2 as 
source, however 18F- in Kryptofix is the most commonly used for everyday routine 
synthesis, using 1,3,4,6-tetra-O-acetyl-2-O-triflate-β-D-mannose as the precursor 
molecule. Since the first time this synthesis was published, in 198651, several 
improvements have been made and different modular systems have been used. Taking 
into account the radioactive decay, radiochemical yields can be even higher than 60 % 
and the total reaction time can be even less than 26 minutes.52 Figure 1.16 shows the 
method mostly used for clinic production of [18F]FDG.  
 
Figure 1.16: Routine clinical synthesis of the radiotracer [18F]FDG 
 
1.1.2.3 [18F]-nucleosides 
[18F]fluorouracil (5-[18F]FU) (1.9) 
5-FU is a chemotherapeutic agent used in the treatment of solid tumours such 
as breast and colon cancer, however because of its in vivo rapid catabolism, its use for 
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therapeutic purposes is limited.53 5-[18F]FU (1.9) was synthesized to study the 
behaviour of 5-FU in vivo and 5-ethyluracil, an analogue of 5-FU, was used to block the 
catabolism of 5-[18F]FU. Through this experiment, it was possible to monitor the 
transport of 5-FU in vivo and its anabolism. The study showed very useful information 
to predict the response of the tumour to 5-FU. However 5-FU is not routinely used for 
PET imaging because of its rapid catabolism.10 
 
[18F]-analogues of pyrimidine nucleosides 
Several pyrimidine nucleoside analogues were radiolabelled with [18F]fluorine 
for PET research or diagnosis purposes. The most important are [18F]FAU (1.19), 
[18F]FIAU (1.16), [18F]FMAU (1.18), [18F]FFAU, [18F]FEAU, [18F]FBAU, [18F]FCAU and 
[18F]FLT (1.4) (Figure 1.17).54 
 
Figure 1.17:  [18F] analogues: pyrimidine nucleosides 
 
 
Among them, the only one that has been well studied as a tumour proliferation 
marker for PET-imaging and also to understand the response to treatment in cancer 
patients is [18F]FLT (1.4).55 [18F]FMAU (1.18) has seen limited use in humans but has 
been widely used in animal models to perform imaging of DNA synthesis. The other 
pyrimidine analogues [18F]FIAU, [18F]FFAU, [18F]FEAU, [18F]FBAU, [18F]FCAU, 
[18F]FFAU and also [18F]FMAU have also been used as markers for imaging of Herpex 
simplex virus type 1 thymidine kinase (HSV1-tk) gene expression.10 
[18F]FLT 
[18F]FLT (1.4) is used as a tumour proliferation marker in PET imaging and 
sometimes to assess response to treatment in cancer patients. [18F]FLT has been 
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widely studied on different types of tumours and is currently the subject of ongoing 
clinical trials, having been widely investigated since 1998.10 Indeed it represents a valid 
alternative to [18F]FDG when assessing tumours with high proliferation rates. Among 
different types of cancer, it has been used especially for lung, brain (glioma) and 
colorectal cancer.10 
As it is an analogue of thymidine, [18F]FLT targets human thymidine kinase 
(TK1). It is thus phosphorylated into [18F]FLT monophosphate which is trapped into 
growing cells. The enzyme TK1 takes part in the synthesis of the DNA (deoxyribonucleic 
acid) and in particular shows a very high activity during the S phase, the synthesis 
phase of the cell cycle. [18F]FLT thus represents an indicator of cell proliferation rate 
when accumulated into the cell. Lately it has been shown that [18F]FLT reflects 
proliferative indices to potentially unreliable extents because it cannot discriminate 
among high proliferative index tumour, which relies on thymidine salvage pathway, 
from high proliferation tissues which instead rely especially upon the de novo synthesis 
of thymidine (Figure 1.18).56 
 
Figure 1.18: Thymidine salvage and de novo synthesis pathways56 
 
 
 
[18F]-purine analogue: acycloguanosine 
The first radiolabelled purine analogue nucleoside synthesized was [18F]FHPG 
(1.20).57 After that, the PCV analogue [18F]FHBG (1.21) was developed and has been 
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widely studied in animal models for a mutated HSV1-tk gene, the sr39-HSV1-tk (Figure 
1.19). 
Figure 1.19: Structures of some purine nucleoside analogues 
 
 
Many imaging studies on the HSV1-tk gene expression have been carried out, 
but until now just a few clinical studies using [18F]FHBG have been performed on 
humans.57 
[18F]-purine adenosine analogues 
[18F]FAA (1.22) and [18F]FXA (1.23) (Figure 1.20) are two adenosine analogues 
that have been tested as substrates of HSV1-tk but their uptake was very low. 
Nevertheless, as their biodistribution was studied by micro-PET images, [18F]FAA 
showed a high uptake in tumour visualization, whereas [18F]FXA showed a high uptake 
in heart. These agents could thus represent respectively a new potential tumour 
imaging agent and a new potential heart imaging agent. Further studies need to be 
undertaken to confirm this prospect.58 
 
Figure 1.20: Structures of some [18F]-purine adenosine analogues 
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[18F]FAC 
[18F]FAC (1.24) has been studied as a PET tracer for the metabolism of glial 
cells, being evaluated in rodent models of stroke, glioblastoma, and ischemia-hypoxia. 
Several studies suggest that it may be used for evaluation of glial cell metabolism 
associated with neuroinflammation.59 
 
Figure 1.21: Structure of [18F]FAC 
 
1.1.2.4 Other [18F]-labelled PETprobes 
[18F]fluorodopa 
[18F]fluorodopa (1.25) is a PET probe extensively used in Parkinson’s disease to 
measure progression and the effects of treatments. In particular this agent is used in 
PET to verify the integrity of the area of the brain damaged by this disease, the 
nigrostriatal dopaminergic neurons.60 
 
Figure 1.22: Structure of the Parkinson’s disease PET probe [18F]fluorodopa 
 
Other radionuclides are used in PET imaging and their biological applications 
vary according to their affinity to different classes of biomolecules. Detailed discussion 
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of further types [18F]-labelled PET tracers is beyond the scope of this introductory 
chapter. 
1.1.3 Short lived radioisotopes 
Carbon – 11 
Another commonly used radioisotope in PET imaging is [11C]carbon.  The 
nuclear reaction most widely used for its production is 14N(p,α)11C. When this reaction 
happens in the presence of oxygen, the product is  [11C]CO2, whereas [11C]CH4 is 
obtained in the presence of hydrogen. These two radiolabelled compounds can be 
used as reagents for many other chemical reactions.61 
[11C]CO2 is used as intermediate to synthesise [11C]CH3I, the most widely used 
reagent to perform methylation of heteroatoms to obtain a large number of [11C]-
tracers. [11C]CH3I can be produced by two methods known as wet or dry methods. The 
wet method uses a reducing agent such as LiAlH4 to reduce [11C]CO2. This step is 
followed by an iodination step with HI to finally obtain the methylating reagent 
[11C]CH3I.
60 The dry method uses instead high temperature to perform iodination with 
I2 using as a substrate [11C]CH4.
16,62 The ‘dry or gas’ method is nowadays the method 
of choice for the synthesis of [11C]CH3I because of the high SA of the radiolabelled 
product obtained.63 
 
Nitrogen – 13 
Because of its very short half life (9.96 min), [13N]nitrogen has a limited 
application in PET chemistry and, together with [15O]oxygen and other short lived 
radioisotopes, is commonly used for perfusion studies. However, many attractive 
applications of [13N]-tracers have incentivised the development of many synthetic 
strategies for its incorporation into drug molecules. This is due to the fact that nitrogen 
is present in a large number of natural and synthetic molecules with biologically 
interesting activities. 
[13N]nitrogen is normally incorporated into molecules using the reagent 
[13N]NH3. The radioisotope is commonly produced by the nuclear reaction 
16O(p,α)13N 
using water as a target. A mixture of [13N]NO3, [13N]NO2 and [13N]NH3 are thus 
produced. By using DeVarda’s alloy, nitrate and nitrite are reduced to ammonia.64 
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[13N]NH3 is used in nucleophilic reactions using substrates such as acyl chloride 
derivatives, or for enzymatic aminoacids synthesis.65,13 [13N]NH3 has also been used to 
study blood flow and to measure perfusion in myocardium and brain. Under the form 
of [13N]N2, produced by the 
12C(d,n)13N nuclear reaction, it has been used for studies 
of nitrogen fixation and ventilation.66,67 
 
Oxygen – 15 
The most challenging radioisotope in terms of time constraints is [15O]oxygen 
with its 2 mins radiochemical half-life. It is normally used just for simple reactions such 
as production of [15O]H2O and [15O]O2 to study blood flow and monitor levels of 
oxygen.68 
 
1.1.4 Long-lived radioisotopes: Positron emitting metals 
Long-lived radiometals such as [89Zr], [68Ga] and [64Cu] have been and still are 
commonly used for PET imaging studies.69–71 Unlike short-lived radioisotopes, they are 
not incorporated into molecules directly but, thanks to coordination chemistry and 
click chemistry, they are attached to ligands which are then coupled to the 
biomolecules of interest such as antibodies.72,70 
In the table below (Table 1.4) a summary of the most common PET tracers in 
clinical use and in clinical development is shown. 
 
Table 1.4: Common PET Tracers73 
TRACER BIOLOGICAL TARGET 
Carbon 11 
[11C]methionine Amino-acid transport 
[11C]leucine Protein synthesis 
[11C]methyl- spiperone Dopamine and serotonin receptors 
[11C]PK-11195 Peripheral benzodiazepine receptors 
[11C]diprenorphine Non-selective opiate receptors 
[11C]carfentanil μ-Opioid receptor 
[11C]flumazenil (FMZ) Central benzodiazepine receptors 
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[11C]raclopride Dopamine type 2 (D2) receptor 
[11C]Schering-23390 Dopamine type 1 (D1) receptor 
[11C]nomifensine Dopamine transporter (DAT) 
[11C]deprenyl Monoamine oxidase type-B (MAO-B) 
[11C]McNiel 5652 Serotonin transporter (SERT/5-HTT) 
[11C]WAY 100635 Serotonin 5-HT1A receptor 
[11C]FBL 457 Dopamine (D2/3) receptors 
L-1-[11C]tyrosine Brain tumor protein synthesis 
[11C]MDL 100907 Serotonin 5-HT2A receptor 
[11C]-CIT-FE Dopamine transporter (DAT) 
[11C]PMP Acetylcholinesterase (ACE) 
[11C]verapamil P- glycoprotein (P-gp) substrate 
[11C]MP4A Acetylcholinesterase (ACE) 
[11C]NNC112 Dopamine (D1) receptor 
[11C]-methyl-l-tryptophan Tryptophan activity 
[11C]DASB Serotonin transporter (SERT/5-HTT) 
[11C]Rol5-4513 GABA-benzodiazepine receptors 
[11C]temozolomide Temozolomide pharmacokinetics 
[11C]PIB β-Amyloid 
[11C]harmine Monoamine oxidase type-A (MAO-A) 
[11C]methylreboxetine (MRB) Norepinephrine transporter (NET) 
[11C]ABP688 Glutamate receptor 5 (mGluR5) 
Fluorine 18 
[18F]FDG Glucose utilisation 
[18F]F-DOPA Dopamine synthesis 
[18F]A-85380 Nicotine acetylcholine receptors 
[18F]fallypride Dopamine (D2) receptor 
[18F]SPA-RQ Neurokinin-1 receptor 
[18F]fluoroethyl-L-tyrosine Brain tumour protein synthesis 
[18F]fluorothymidine Brain tumour proliferation 
[18F]MK-9470 Cannabinoid receptor type 1 (CBR-1) 
[18F]fluoromisonidazole Brain tumour hypoxia 
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Oxygen 
[15O]oxygen Oxygen utilisation 
[15O]water Blood flow 
 
1.1.5 PET imaging: application in drug discovery 
PET Imaging has been used not just as a diagnostic tool but more recently as a 
means to answer key questions in drug discovery on biological and pharmacological 
behaviour of certain compounds in vivo. Matthews and co-workers have recently 
reviewed this area of study.74 By radiolabelling certain drug candidates, it is possible to 
gain useful information on their biodistribution in vivo such as whether or not they 
reach the target tissue primarily in rodents and primates, and secondarily in humans. 
This technique is also useful to understand whether some compounds can cause side 
effects by accumulating at non-target sites and additionally biodistribution studies can 
give information on dose-limiting toxicity. These kinds of studies can also give the 
possibility, through PET scans, to have data on pharmacokinetics and 
pharmacodynamics of drug candidates by comparing radio-TLC and radio-HPLC of the 
parent compound to the metabolism products.1 
PET imaging can also give knowledge of receptor occupancy. Bergstrom et al. 
have studied in particular the substance P (NK1) antagonist Aprepitant (1.26). This 
agent was evaluated as an antidepressant and for chemotherapy-induced nausea. 
They used [18F]SPA–RQC (1.27) , a selective radiomarker of NK1, to understand the 
minimal dose necessary to have the required anti-emetic effects75 (Figure 1.23). 
 
Figure 1.23: Aprepitant (1.26) and a radiomarker of NK1(1.27) 
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Bergstrom et al. understood that 100 mg/day was an effective dose for its 
antiemetic purpose but that this dose was not effective as an antidepressant. Indeed 
Merck was evaluating Aprepitant’s application as an anti-depressive in Phase III clinical 
trial where the dose of 300 mg/day was still a not effective dose to have the anti-
depressive effect. The PET studies, which demonstrated that that dose was definitely 
enough to achieve the occupancy of the target receptor, saved Merck several million 
dollars through interruption of the ongoing Phase III clinical trial on this compound.1 
 
1.2 Nucleosides 
Nucleosides are endogenous compounds critically involved in DNA and RNA 
synthesis but also in enzyme regulation, metabolism and cell signaling.76,77 Several 
nucleoside and nucleotide analogues have been synthesized to act as antimetabolites 
of their physiological counterparts in several biochemical pathways. They inhibit viral 
replication and cellular metabolism by incorporation into DNA and RNA and thus they 
represent cornerstones in the treatment of patients with cancer and viral infections. 
Nucleosides can inhibit several essential enzymes like kinase, pyrimidine and purine 
nucleoside phosphorylase, several viral and human polymerases, DNA methyl 
transferase, thymidylate synthase, and ribonucleotidereductase. Chemically they 
consist of a purine or pyrimidine nucleobase, which is linked to a sugar moiety78 
(Figure 1.24). 
 
Figure 1.24: Structures of ribose and 2’deoxyribose nucleosides 
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When nucleosides have a phosphate group in the 5’ position of the sugar 
moiety they are named nucleotides. Their activity depends on certain modifications on 
the nucleobase that gives them different specific properties. Nucleosides can act as 
antimetabolites, where the metabolic pathway of these synthetic nucleosides and 
nucleotides is the same one of their endogenous counterparts.79 After cellular uptake 
performed by nucleoside-transporter systems, NAs become substrates for specific 
nucleo(s)(t)ide kinase enzymes which convert them to the 5’-mono, -di and 
triphosphate forms.26 The active triphosphate form can interfere with the de novo 
synthesis of DNA/RNA precursors, leading to the inhibition of DNA and RNA synthesis 
and to suppression of cell growth and division.26 
The first phosphorylation is the rate-limiting phosphorylation step of their 
activation pathway. Thymidine kinase (TK1) or deoxycytidine kinase (dCK) can carry out 
this phosphorylation according to the substrate. For instance, TK1 is specific for 
thymidine (1.28) and its analogues, while dCK is specific for cytidine (1.30) and its 
analogues (e.g. gemcitabine 1.31). 
Figure 1.25: Thymidine and cytidine and their analogues 
 
When nucleosides are monophosphorylated, they are effectively entrapped 
inside the cellular cytoplasm as charged nucleotides. Nucleosides are hydrophilic 
molecules that diffuse slowly across cell membranes, therefore cells have developed a 
complex transport system to facilitate membrane transport. This system consists of 
multiple carrier proteins, the nucleoside transporters (NTs), which facilitate their 
cellular uptake for nucleotide biosynthesis. The monophosphorylated nucleosides are 
therefore further phosphorylated by other kinases to form the diphosphates and the 
triphosphates which finally take part in the biosynthesis of DNA and RNA.80 
 1. Introduction 
29 
 
 
1.2.1 ProTides 
Despite the enormous importance of nucleoside analogues as both antiviral 
and anticancer agents, drug resistance still represents a major issue for their clinical 
application. As already described above, to exert their therapeutic activity, nucleoside 
analogues need to be phosphorylated by intracellular kinases to the 5’-mono-, di- and 
triphosphate forms. Many synthetic strategies have been developed to access directly 
the active 5’-triphosphate form, but these compounds are not viable drug candidates 
because of their chemical instability and high polarity which disallow their effective 
crossing through cell membranes. Nevertheless, the first phosphorylation is considered 
to be rate-limiting step of their activation pathway, therefore many approaches to 
develop prodrugs of nucleoside monophosphate forms have been developed.81 
The phosphoramidate-based technology, also known as the ProTide 
(PronucleoTide) approach, developed by McGuigan and co-workers in 1995 is 
considered one of the most effective pro-nucleotide strategies currently used in the 
clinic.82,83 It consists in masking the negatively charged 5’-O-monophosphate form as a 
phosphoramidate. This masked derivative, after passive diffusion through cell 
membrane and subsequent intracellular metabolism, delivers the 5’-O-
monophosphate form 84 which is thus trapped into the cell and available for further 
phosphorylations (Figure 1.26).82,83 
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Figure 1.26: Pro-nucleotides mechanism of action81 
 
 
Chemically ProTides are aryloxyphosphoramidate prodrugs synthesized 
through a coupling reaction between a phosphorochloridate and the 5’-OH of the 
nucleoside. The phosphorus atom  is attached to an amino acid alkyl ester and to an aryloxy 
group enabling passive transmembrane transport and masking the negative charge.84,85  
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Figure 1.27 below shows a proposed activation pathway for this class of 
compounds that leads to the intracellular delivery of active nucleoside 
monophosphates. Once crossed the cell membrane the monophosphate is firstly 
deprotected by an esterase or cathepsin A producing the carboxylate intermediate. A 
spontaneous cyclization occurs forming a five-member ring and releasing a phenol or a 
naphtol. The cyclic intermediate then undergoes through chemical opening by water 
producing the phosphoramidate diester. The diester is finally cleved by an an 
intracellular phosphoramidase or by an histidine triad nucleotide-binding protein 1 
(HINT-1) releasing the active nucleoside monophosphate.83 
 
Figure 1.27: Proposed activation pathway of Protides 
 
Other phosph(on)ate prodrugs strategies comprise the carbonyloxymethyl, including 
POM and POC groups, that have shown to increase oral bioavailability and systemic 
exposure when compared to the parent phosphonic acids. This class includes the FDA 
approved adefovir and tenofovir.  
S-Acyl-2-thioethyl (SATE) is another pronucleotide strategy developed in 1990 where 
the phosphotriesters incorporate a thioethyl chain with the thiol masked as a thioester 
(Sate group). CycloSal phosphate and phosphonate prodrugs developed by Chris 
Meier, use instead salicylic alcohols to mask the NA- monophosphate form. It was 
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successfully applied to some antiviral nucleotides such as AZT, d4t and acyclovir. All 
these and other pronucleotide strategies have been recently reveiwed by Scinazi et al. 
 
 
 
1.2.2 Fluorinated nucleosides and ProTides 
An important class of antiviral and anticancer drugs is represented by 
fluorinated 2’- and 3’-substituted nucleosides where one or more hydrogens on the 
sugar moiety are substituted by fluorine atoms. Figure 1.28 shows all the FDA-
approved fluorinated anticancer and antiviral nucleoside analogues.34 
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Figure 1.28: FDA-approved fluorinated anticancer and antiviral nucleoside analogues. 
 
 
1.2.2.1 Importance of fluorine in drug molecules 
Despite the widespread occurrence of fluorine as an element on earth, 
organofluorine compounds are almost absent in nature. Nevertheless, 20-25% of 
synthetic drugs are thought to contain in their structure at least one fluorine.86,87,34 
Fluorine plays a crucial rule in the optimisation of clinical candidates. It increases the 
lipophilicity (logP) which is a major factor, together with the molecular size, that 
influences membrane permeability that can lead to an optimization of drug 
candidates’ oral bioavailability. Modulation of pKa can also have a huge impact on 
compounds bioavailability as well as on their absorbance. Fluorine is the most 
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electronegative element (3.98 on the Pauling scale) and, when included into a 
molecule, can strongly affect the acidity or the basicity of the surrounding functional 
groups in the molecule.34,88,89 
Additionally, when the fluorine is bonded to the carbon, the highly polarised 
bond formed can provide a remarkable stability to the molecule itself.  All these factors 
can have a positive impact on selectivity, toxicity, potency, and on pharmacokinetic 
and pharmacodynamic properties of the molecule. The size of fluorine (van der Waals 
radius of 1.47Å) is also very similar to that of hydrogen (1.20 Å), therefore it is 
frequently used to replace the H or the hydroxyl group in drug molecules without 
causing steric perturbation. However, from the chemical point of view its replacement 
does not lead to dramatic changes whereas from the biological point of view it can 
block oxidative metabolism and therefore block the formation of unwanted 
metabolites. Drug molecules are indeed usually metabolised by enzymes such as 
Cytocrome P450 (CYP450) monooxygenases that decrease compounds lipophilicity and 
therefore increase their clearance. Fluorine substitution bypasses that problem by 
blocking these sites from enzymatic cleavage and, therefore, increases the metabolic 
stability of many drug molecules.34,88,89 
Fluorine has a major impact on nucleosides and when placed on the ribose ring 
of nucleoside analogues, it can significantly affect the conformation of nucleosides. It 
causes changes in the dipole-dipole and gauche interactions, on the F-base 
interactions and influences the anomeric effect. Generally, when placed in the 2’--
position of the ribose, fluorine favours a south conformation of the molecule, which 
has often conferred to the molecule an enhanced anti-HIV activity, whereas the 
fluorine in the 2’--position favours a north conformation (Figure 1.29). Nevertheless, 
a general rule that correlates the position of the fluorine with the biological activity of 
the molecule is difficult to define. A research group working on pro-nucleotide CycloSal 
triesters of 2′-fluorinated-2′,3′-dideoxyadenosines (F-ddA) studied the effects induced 
by two opposite  and  configurations of the fluorine at C2′ of the dideoxyribose 
moiety. They showed that 2’--F-ddA is active as an anti-HIV agent, whereas the - 
analogue did not show any antiviral activity. Interestingly, when the -configured 
phosphotriesters of the inactive 2’--F -ddA were tested, they showed a higher anti-
HIV activity compared to 2’--F- ddA (Figure 1.29).34,90 
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Figure 1.29:  North and south conformation of two anomers of F-ddA 
 
 
Fluorinated anticancer nucleosides and ProTides 
Nowadays many fluorinated nucleosides are used in the clinic as anticancer and 
antiviral drugs. 5-fluorouracil (1.32) was one of the first to be approved by the FDA 
and, along with FdUrd (its nucleoside analogue)(1.33) is currently used for the 
treatment of patients with solid tumours such as gastric, breast, colon and pancreatic 
carcinoma (Table 1.5). Both compounds are metabolised by FdUMP to the 5’-
monophosphate form to exert their biological activity. FdUMP forms a complex 
together with thymidylate synthase (TS) and the reduced co-factor 5,10-
methylenetetrahydrofolate (5,10-CH2-THF) which is the source of the methyl group. 
Herein the fluorine exerts an essential role in the metabolism of the molecule. As it is 
more tightly bound to carbon in the 5-position compared to the hydrogen in FdUMP, it 
prevents the -elimination reaction and the consequent release of TS enzyme. The 
complex TS/FdUMP/mTHF causes the irreversible inhibition of enzymatic function. 
Therefore, the formation of TMP which is the building block for the DNA synthesis 
decreases.34,91,92 Nevertheless, inherent and acquired resistance is commonly 
associated with the nucleoside analogue 5-FU (such as diminished cellular uptake, and 
a decreased activation to the 5’-monophosphate form by thymidine kinase or 
overexpression of TS). Many prodrugs of 5-FU and of other nucleosides have been 
developed and are currently in use in the clinic to address these key resistance 
mechanisms.93 
The application of the ProTide strategy to FdUrd led to development of L-
alanine-based 5’-ProTide NUC-3373 (1.43). Compared to its parent nucleoside, NUC-
3373 showed cytostatic activity independently of thymidine kinase (TK) in TK-deficient 
cell lines.85 Moreover, NUC-3373 is resistant to the degradation by catabolic enzymes 
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such as thymidine phosphorylase (TP), which is often upregulated in tumour cells, and 
dihydropyrimidine dehydrogenase (DPD), an enzyme overexpressed in the liver. In 
addition, within in vitromodels, NUC-3373 generates up to 363-fold higher intracellular 
levels of FdUMP compared to 5-FU in the human colorectal cancer cell line HT29.94In 
vivo studies showed greater tumour volume reduction in the human colorectal cancer 
HT29 mouse xenograft model when NUC-3373 was tested compared to 5-FU.95A Phase 
I clinical study of NUC-3373 started in 2016 on patients with advanced solid tumours 
(Table 1.5).34,96 
Another clinically widely used fluorinated anticancer agent is gemcitabine (2’-
deoxy-2’,2’-difluorocytidine, dFdC) (1.31) which has been approved for the treatment 
of pancreatic, non-small cell lung, ovarian and breast cancers.97,98 Again its clinical 
effectiveness is reduced because of resistance mechanisms such as poor cellular 
uptake and poor conversion of gemcitabine into active metabolites by deoxycytidine 
kinases, plus rapid deamination by cytidine deaminase into the inactive and toxic by-
product dFdU.99–101 The triphosphate metabolite (dFdC-TP), which is the active form of 
dFdC, is thus incorporated into the growing DNA chain in the S-phase of cell cycle and 
therefore causes chain termination of DNA synthesis leading eventually to cell death. 
The diphosphate form (dFdC-DP) of dFdCalso contributes significantly to its anticancer 
activity by inhibiting ribonucleotidereductase (RNR). As a result dFdC-TP is 
incorporated as a substrate for DNA polymerase instead of natural 
deoxynucleotides.34,102 
To improve the clinical efficacy of gemcitabine many modifications have been 
applied to its original chemical structure. Novel gemcitabine-based prodrugs such as 
LY2334737 (1.48), CO-101(1.49) and more interestingly the phosphoramidate NUC-
1031 (1.46) have therefore been developed. NUC-1031 is a phosphoramidate L-
alanine-based ProTide of gemcitabine designed to overcome the resistance 
mechanisms of the parent nucleoside. Its cellular uptake is indeed independent of 
nucleoside transporters compared to the parent lead. Once into the cell, it releases the 
5’-monophosphate form via consecutive steps which are mediated by a 
carboxyesterase-type enzyme and phosphoramidase-type enzyme that catalyses the P-
N bond cleavage.34,103 Phase I clinical studies conducted in patients with advanced solid 
tumours in 2012 showed promising pharmacokinetics and a favourable safety profile 
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and efficacy. NUC-1031 demonstrated the ability to achieve 217x higher intracellular 
dFd-CTP levels compared to the parent compound.  The plasma half-life of this ProTide 
was also much more favourable (7.3 h) than the one reported with gemcitabine (1.5 
hours). In conclusion these studies indicated that NUC1031 was able to achieve a 
durable disease control in a high number of patients including the ones who were 
refractory to, or who relapsed on prior gemcitabine treatment. NUC-1031 is currently 
investigated in several clinical trials for the treatment of patients with ovarian, biliary 
and pancreatic cancers.104,34 Figure 1.30 shows all anticancer fluorinated nucleobase, 
nucleoside and nucleotide analogues in clinical development. 
 
Figure 1.30:  Fluorinated anticancer nucleobase, nucleoside and nucleotide 
analogues in clinical studies34 
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Purine-based anticancer fluorinated nucleoside analogues 
Fludarabine (FAMP) (1.34) is the 5’-monophosphate form of the purine 
nucleoside analogue 2’-fluoro-arabinofuranosyladenine used for the treatment of B-
cell chronic lymphocytic leukaemia (B-CLL). It is also used in chemoimmunotherapy in 
combination with the monoclonal antibody rituximab and the DNA-alkylating agent 
cyclophosphamide, to treat CLL patients.34,105 As it is a monophosphate, it is negatively 
charged at physiological pH, therefore is unable to enter cells. To reach the active 5’-
triphosphate form (F-ara-ATP), it is therefore first dephosphorylated to F-ara-A, 
incorporated into the cell by nucleoside transport systems, and re-phosphorylated by 
deoxycytidine kinase to the original 5’-monophosphate form. Subsequently the 
adenylate kinase and nucleoside diphosphate kinase catalyse the phosphorylation to 
the 5’-di and 5’-triphosphate forms, respectively. F-ara-ATP thus inhibits DNA 
polymerases by acting as an alternative substrate to the natural deoxynucleotide 
(dATP).34,106,107 Interestingly here the fluorine is essential as it increases the relative 
resistance of F-ara-A to the deamination performed  by adenosine deaminase.34,107 
Nevertheless, some clinical trials of fludarabine showed severe central nervous 
toxicity, somnolence and an increase of liver enzyme levels. This is probably due to the 
phosphorolytic cleavage of F-ara-A which releases the metabolite 2-fluoroadenine (F-
Ade) that can  accumulate as the toxic triphosphate F-AdeTP. Many resistance 
mechanisms have been associated with the nucleoside analogue fludarabine. Mainly 
they are related to alterations in membrane nucleoside transporters, deoxycytidine 
kinase and cytoplasmic 5-nucleotidase cN-II activities, and to changes in the expression 
of miR-34a, a small non-coding RNA molecule which mediates post-transcriptional 
gene silencing.34,107,109 
Clofarabine (Cl-F-ara-A)(1.36) is a second-generation chemotherapeutic agent 
similar in structure to fludarabine, which compared to fludarabine, shows resistance to 
phosphorolytic cleavage and deamination. Clofarabine is currently approved for clinical 
use in the treatment of relapsed and refractory paediatric acute lymphoblastic 
leukaemia. Clofarabine triphosphate is the active form of the nucleoside analogue and 
it exerts its anticancer activity by inhibition of ribonucleotidereductase and inhibition 
of DNA synthesis after incorporation into the DNA chain thus inducing 
apoptosis.34,107,109 The fluorine atom in clofarabine has also an essential rule as it has 
 1. Introduction 
39 
 
been postulated that, because of the electron-withdrawing properties, it modifies the 
reactivity of the 3’-OH group and the three-dimensional structure of DNA so that 
incorporation of other nucleotide analogues and extension of the DNA chain is 
inhibited.34,107,109 The resistance mechanisms associated with the other nucleoside 
analogues have also been reported for clofarabine. However, recent studies showed 
that this agent, besides its anticancer activity, has also been reported to inhibit DNA 
polymerase activity of HIV-1 reverse transcriptase and to limit the dNTP substrates 
pool for the synthesis of viral DNA.34,110,111 
Antiviral fluorinated nucleosides and ProTides 
Nucleoside analogues also represent a significant class of antiviral therapeutic 
agents. They are currently used in the clinic for the treatment of hepatitis b virus 
(HBV), hepatitis c virus (HCV), human immunodeficiency virus (HIV), human respiratory 
syncytial virus (HRSV), human cytomegalovirus (HCMV), and Varicella zoster virus 
(VZV). Compared to the anticancer nucleoside analogues, they are chemically more 
diverse and they are characterised by a better tolerance profile due to low levels of 
activity on mammalian enzymes.34,110 The active antiviral form is again the 5’-
triphosphate nucleoside analogue. They are classified as nucleoside reverse 
transcriptase inhibitors (NRTis) including both compounds mimicking the endogenous 
natural nucleosides and those that need to be phosphorylated to their 5’-triphosphate 
form to be active. Their targets are the catalytic residues of the viral polymerase that 
interact with the template, the primer and the incoming nucleoside 5’-triphosphates. 
The introduction of fluorine in their chemical structure helped to improve their 
biological profiles and to provide an improved metabolic stability.110 Figure 1.31 
reports the fluorinated antiviral nucleoside analogues and derivatives available in the 
clinic as well as some that are currently undergoing clinical trials.34 
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Figure 1.31: Fluorinated antiviral nucleoside analogues and derivatives in clinical 
trials34
 
Pyrimidine-based antiviral fluorinated nucleosides and prodrugs 
One of the first antiviral fluorinated nucleoside analogue synthesised in 1971 
was the 3'-fluoro-3'-deoxythymidine (FLT)(1.29), known as Alovudine. Its anti-HIV 
activity was only discovered in 1988, when studies showed that this agent had a major 
potency when compared to the established anti-HIV agent azidothymidine 
(AZT).34,112In vitro studies proved that FLT inhibits replication of highly resistant 
nucleoside reverse transcriptase inhibitor (NRTI) HIV strains. However FLT did not 
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progress further in clinical trials because of dose-dependent safety concerns.113 
ProTides of FLT have also been synthesised and early in vitro studies showed potent 
inhibition of HIV-1 and HIV-2 replication, although they showed less potency when 
compared to the parent nucleoside therefore did not proceed to the clinical stage.34,114 
FIAU (Fialuridine) (1.61) was another 2’-F-nucleoside analogue that was selected as a 
Phase I clinical trial candidate for the treatment of HBV, but it showed mitochondrial 
toxicity resulting in lactic acidosis and hepatic failure (Figure 1.32).113 
 
Figure 1.32: Suggested mechanism by which FIAU causes widespread mitochondrial 
injury, and disturbance in metabolic processes115 
 
After its failure in a Phase II clinical trial in 1993, [18F]FIAU (1.16) has been used 
in PET imaging as a reporter-gene of HSV1-TK.116 Emtricitabine (FTC) is an anti HIV 
agent included into the list of the essential medications compiled by the World Health 
Organization. Chemically emtricitabine is a 5-fluorodeoxycytidine derivative 
characterised by an oxathiolane ring as sugar. Its active triphosphate form acts by 
inhibiting the reverse transcriptase (NRTI). Compared to the antiviral agent 
Lamivudine, the presence of the fluorine atom boosts its bioavailability and its half-
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life.117–119Mericitabine (RG-7128)(1.53) is another potent anti-HCV agent that has 
recently successfully completed Phase I and II clinical trials. Chemically mericitabine is 
a 3’,5’-diisobutyrate prodrug of the well studied 2′-deoxy-2′-fluorocytidine (FdC).120 
Sofosbuvir (Sovaldi®, GS7977)(1.51) is an anti-HCV phosphoramidate prodrug 
of -D-2’-deoxy-2’--fluoro-2’--C-methyluridine. It is an inhibitor of the NS5B RNA 
polymerase, a protein responsible for the synthesis of both positive and negative-
strand genomic RNA.  Sofosbuvir mimics the natural substrate of NS5B polymerase, is 
incorporated into the growing RNA strand and thus induces chain termination. It was 
initially synthesized and commercialised as a diastereoisomeric mixture (GS-9851), 
which comprised Sofosbuvir (GS-7977, Sp isomer) and GS-491241 (RP isomer). 
Cathepsin A (CatA) and carboxyl esterase 1 (CES1) convert GS-9851 into an inactive and 
achiral intermediate that is then hydrolysed by a histidine triad nucleotide-binding 
protein 1 (Hint1) into the 5’-monophosphate form. A second phosphorylation 
performed by uridine-monophosphate-cytidine-monophosphate kinase (UMP-CMP) 
leads to the 5’-diphosphate form which is eventually converted into the active 5’-
triphosphate form by nucleoside diphosphate kinase.34,121,122 The single stereoisomer 
drug Sofosbuvir, compared to the diastereoisomeric mixture, is characterised by a 
more specific metabolism that leads to a lower potential for cytochrome P450-
mediated drug-drug interactions. Compared to other anti-HCV agents, Sofosbuvir 
showed a high genetic barrier to resistance and remarkable sustained virological 
response rates (SVR) (over 90% of patients). Sofosbuvir was approved by FDA 2013 in 
the USA for the treatment of chronic HCV infection in patients with genotypes 1, 2, 3 
or 4. In combination with Ribavirin, it showed effects also in co-infected subjects with 
HIV. In addition, Sofosbuvir prevented a recurrence of HCV infection in most of the 
patients awaiting liver transplant.34,122,123 Recently, Sofosbuvir has been also evaluated 
for the treatment of Zika virus and first in vitro studies showed promising results but 
further studies need to be undertaken.124 
Purine-based fluorinated antiviral nucleosides and prodrugs 
Many fluorinated purine-based nucleosides and prodrugs have also been 
synthesised and, among them, PSI-353661 (1.56) and PSI-352938 (1.57) (prodrugs of β-
D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine-5'-monophosphate), have shown a 
promising in vitro anti-HCV activity. Both of them showed a unique resistance profile 
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making them good candidates for a combination therapy with other anti-HCV agents 
including other nucleosides analogues.125 The phosphoramidate agent GS9131 (1.58) is 
another 2’-F’-purine based prodrug which has been shown to inhibit HIV-1 reverse 
transcriptase (RT) together with a remarkable resistance profile toward N(t)RTI 
resistance mutations. GS9131 is currently under clinical evaluation.34,126 
 
Table 1.5: Fluorinated NAs and their prodrugs in clinical use and clinical development 
for cancer34 
Drug Name Originator/Developer Phase Disease Target                
Fluorouracil (5-FU, 
1.32) 
Roche 
Approved 
(1962) 
Colorectal, breast, 
pancreatic, stomach 
cancer 
TS 
Floxuridine (FdUrd, 
1.33) 
Roche 
Approved 
(1970) 
Liver metastasis  TS 
Capecitabine (1.35) Roche 
Approved 
(1998) 
Metastatic breast, 
colorectal cancer 
TS 
Tegafur (1.40) + 
Uracil  
Taiho Pharmaceutical 
Used in 
Japan, 
Taiwan 
II 
II/III 
Advanced GI 
cancers 
Colon, combination 
therapy for 
hepatocellular 
carcinoma 
Gastric cancer 
TS, DNA synthesis 
 inhibition 
Tegafur (1.40) + 
Gimeracil + Oteracil  
Taiho Pharmaceutical III 
Advanced gastric 
cancer in 
combination with 
cisplatin 
TS 
Doxifluridine (1.41) Aida Pharmaceuticals III 
Combination 
therapy for GI 
cancer 
TS 
FdCyd(1.45) + THU 
National Cancer 
Institute 
I and II Neoplasms 
DNA 
methyltransferase 
Flucytosine (1.44)  Tocagen 
I/II 
I 
Combination 
therapy for solid 
tumours 
Brain tumours 
TS 
NUC-3373 (1.43) NuCana  I 
Colorectal and 
breast cancer 
TS 
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Gemcitabine (1.31) Eli Lilly 
Approved 
(1996) 
Non-small cell lung, 
breast, 
pancreatic,ovarian, 
soft tissue sarcoma 
DNA polymerase 
RNR, dCMP 
deaminase 
LY2334737 (1.48) Eli Lilly Discontinued  
Malignant and 
metastatic solid 
tumours 
DNA synthesis  
inhibition 
CO-101 (1.49) Clavis Pharma Discontinued  
Advanced solid 
tumours 
Metastatic 
pancreatic dual 
adenocarcinoma 
DNA synthesis  
inhibition 
NUC-1031 (1.46) NuCana 
III 
II 
I 
Pancreatic cancer 
Ovarian cancer  
Combination 
therapy for ovarian 
and biliary tract 
cancers 
DNA synthesis  
inhibition 
RX-3117 (1.47) 
Rexahn 
Pharmaceuticals/TEVA 
Pharmaceuticals 
I/II 
I 
Solid tumours 
Combination 
therapy for ovarian 
cancer 
DNA 
methyltransferase 
Tezacitabine (1.50) 
Aventis/Chiron 
Corporation 
Discontinued  
Hematological 
malignancies  
RNR 
Trifluorothymidine 
(1.37) + Tipiracil 
HCl (TAS-102) 
Taiho Pharmaceutical 
Approved 
(2015) 
Metastatic 
colorectal cancer 
TS 
Fludarabine (1.34) 
Southern Research 
Institute/Bayer 
HealthCare 
Pharmaceuticals 
Approved 
(1991) 
Hairy cell leukemia, 
B-cell CLL 
DNA polymerase,  
RNR, DNA 
primase 
Clofarabine (1.36) Bioenvasion  
Approved 
(2004) 
Pediatric refractory 
ALL 
DNA polymerase, 
RNR 
 
Information about status of clinical trials available from www.clinicaltrials.gov. 
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Table 1.5 (cont.): Fluorinated NAs and their prodrugs in clinical use or clinical 
development for viral infections34 
Drug Name 
Originator/Develope
r 
Phase Disease Viral Target            
Trifluorothymidi
ne (1.38)  
Viroptic  
GlaxoSmithKline 
Approved 
(1998) 
Herpes Simplex 
Virus (HSV) 
DNA 
polymerase 
Emtricitabine  
Emtriva  
Emory 
University/Gilead  
Approved 
(2003) 
Human 
Immunodeficien
cy Virus (HIV)  
Nucleoside 
reverse  
transcriptas
e 
Sofosbuvir  
(1.51) 
Sovaldi  
Gilead 
Approved 
(2013) 
Hepatitis C 
(HCV) 
NS5B RNA-
dependent 
RNA 
polymerase 
Mericitabine 
(1.53) 
Pharmasset/Hoffman
n-LaRoche 
II HCV 
NS5B RNA-
dependent 
RNA 
polymerase 
Favipiravir (1.55) 
Toyama 
Chemical/MediVecto
r 
Approved in 
Japan 
(2014) 
III 
JIKI trial 
As stockpiling 
against Influenza 
Pandemics 
Influenza 
Ebola 
RNA-
dependent  
RNA 
polymerase 
Fiacitabine (1.52, 
FIAC) 
Memorial Sloan-
Kettering Cancer 
Center/Oclassen 
Pharmaceuticals  
II 
Cytomegalovirus 
and HIV 
infections  
DNA 
polymerase 
RNR 
Elvucitabine 
(1.39) 
Yale 
University/Achillion 
Pharmaceuticals 
II 
Chronic HIV 
infections 
Nucleoside 
reverse  
transcriptas
e 
Racivir (1.54) 
Emory 
University/Pharmass
et  
II HIV 
Nucleoside 
reverse  
transcriptas
e 
Fialuridine (1.61, 
FIAU) 
Oclassen 
Pharmaceuticals/Eli 
Lilly 
Discontinue
d  
HSV, HIV, and 
Hepatitis B 
(HBV) 
DNA 
polymerase 
Clevudine (1.60, Bukwand/Pharmasse Discontinue HBV DNA 
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L-FMAU) t d  polymerase 
Alovudine (1.29, 
FLT) 
Medivir/Beijing 
Mefuvir Medicinal 
Technology 
Discontinue
d  
HIV 
DNA 
polymerase 
PSI 353661 (1.56) Pharmasset  
Preclinical 
developme
nt  
HCV 
NS5B RNA-
dependent  
RNA 
polymerase 
PSI 352938 (1.57) Pharmasset  I HCV 
NS5B RNA-
dependent  
RNA 
polymerase 
GS9131 (1.58) Gilead I HCV 
Nucleoside 
reverse 
transcriptas
e 
Information about status of clinical trials available from www.clinicaltrials.gov.
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2. Research aims and objectives 
 
As a proof of concept, this project aims to develop [18F]-radiolabelled ProTides 
that will be used as PET imaging agents and a model system to visualize 
pharmaceutical and biological effects of ProTides directly in vivo. Although many 
synthetic routes towards [18F]-radiolabelled nucleosides have been accomplished in 
the past,127 to our knowledge the synthesis of [18F]-radiolabelled ProTides has never 
been achieved until now. Two different ProTides will be synthesised as model 
standards of two classes of fluorinated ProTides, the 2’ and the 3’-fluorinated ProTides. 
The 3’-[18F]FLT ProTide (2.1) and the 2’-[18F]FIAU  ProTide(2.2) will be synthesised 
exploring different synthetic routes using both late stage and early stage fluorination 
following different synthetic pathways. 
In order to obtain the [18F]FLT ProTide, suitable precursor molecules will first be 
synthesised using cold chemistry methods.128 The main goal will consist in finding good 
leaving groups that could be easily replaced by the weak anhydrous nucleophile 
[18F]fluoride. Several leaving groups will thus be explored and tested for 
radiofluorination compatibility under different reaction conditions. (Figure 2.1) 
 
Figure 2.1: Late stage [18F]fluorination of ProTides 
 
 
A second approach could consist in synthesising the 2’-[18F]FIAU ProTide 
through an early stage hot fluorination. Although more challenging because of the 
short half-life of the 18F- allowing a limited time to perform the multistep synthesis, this 
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last approach could lead to the desired product avoiding the formation of undesired 
radiolabelled by-products (Figure 2.2). 
 
Figure 2.2: Early stage [18F]fluorination for the synthesis of ProTides 
 
 
Once a [18F]-radiolabeled ProTide will be synthesised in reasonable chemical 
and radiochemical yields, it could finally be used for early in vivo experiments to study 
absorption, distribution, metabolism,  excretion and toxicity  (ADMET) properties of 
this class of compounds as well as investigate their potential as a novel class of PET 
diagnostic probes. 
Besides the aim of translating fluorinated ProTides into PET tracers, a 
secondary objective of this project, is to synthesise a novel class of non-radiolabelled 
2’-fluoro- 5-iodo uridine based ProTides as potential antiviral drugs. Starting from the 
observation that many uridine based nucleosides, and particularly fluorinated ones, 
showed promising antiviral properties against many DNA and RNA viruses,34 it was 
speculated that the application of ProTide strategy will lead to a new more potent and 
less toxic class of antiviral compounds. A series of 2’-deoxy-2’ fluoro- 5-iodouridine 
ProTides will therefore be synthesised, and studies of cytotoxicity will be performed on 
Zika and Dengue viruses strands (Figure 2.3). 
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Figure 2.3: ProTide approach applied to the 2’-deoxy-2’ fluoro- 5-iodouridine 
 
 
Lastly, a further goal of this research project, is to synthesise FLT non-
radiolabelled hybrid fluorescent ProTides. These compounds, compared to 
conventional ProTides, will be characterised by a coumarin residue that could provide 
fluorescent properties to further develop our knowledge on their metabolism for 
future in vitro studies. Besides the fluorescent properties, the substitution of the 
common aromatic moiety with a coumarin derivative ring, could possibly lead to less 
toxic metabolic products and potentially increase their antiviral activity through a co-
drug approach, given the known biological activity associated with coumarin 
derivatives129 (Figure 2.4). 
 
Figure 2.4: ProTide approach for the synthesis of hybrid ProTides 
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3. Radiochemical synthesis of [18F]FLT ProTide 
 
3.1 Introduction 
The main goal of this research project is the synthesis of [18F]-radiolabeled 
ProTides as a proof of concept for the ProTide strategy through future in vivo 
biodistribution studies. Several ProTides are currently either approved therapies or 
under clinical evaluation and have proved to be more active than their parent 
nucleoside analogues by circumventing their main resistance mechanisms.83 
Radiolabelling these compounds with a radioisotope with a relatively short half life, 
such as [18F]fluorine, would enable their use as PET imaging probes in order to have a 
deeper understanding of their ADMET properties directly in vivo. Eventually, this could 
be a first step towards the future of a Protide based personalized medicine. 
Two [18F]-radiolabelled ProTides have been chosen as targets for this project, 
the [18F]FLT ProTide (2.1) and the [18F]FIAU ProTide (2.2), as a model standard of 3’-
fluorinated and 2’-fluorinated ProTides respectively, following two different synthetic 
approaches. In this chapter the late stage fluorination approach for the synthesis of 
the [18F]FLT ProTide (2.1) will be discussed.   
 
Figure 3.1: Structure of an [18F]FLT ProTide 
 
 
[18F]FLT ProTide has been chosen as a model standard for the class of the 3’-
fluorinated ProTides for the reasons listed below: 
- It already contains a fluorine in its original structure hence radiolabelling this 
Protide with [18F]fluorine comes as a natural and convenient choice.  
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- [18F]FLT (1.4) is an established PET imaging agent (proliferation biomarker), 
therefore convenient strategies for its synthesis have already been extensively 
studied and can be a guide for the synthesis of 2.1.130 
- It is a thymidine based ProTide, thus the absence of other reactive sites on the 
nucleosidebase moiety of the molecule (i.e. the amino group on the cytidine 
based Gemcitibine (1.31)) will avoid further protection and deprotection steps 
that will make the radiosynthesis longer and more difficult to perform. 
- A series of FLT ProTides have already been synthesised showing a safe 
toxicological profile and a moderate anti HIV activity.114 
 
3.2 [18F]fluorination (Hot): late stage approach 
As stated before, convenient syntheses to access [18F]FLT (1.4) have 
extensively been studied. In the examples reported above (Figure 1.6, Chapter 1), the 
[18F]fluorination occurred at a late stage in the synthesis. Wherever possible, this 
approach should always be the one of choice considering the limited time available 
when dealing with [18F]fluorine. Similarly, a late stage approach has also been chosen 
for the synthesis of the [18F]FLT ProTide following the synthetic scheme below (Figure 
3.2), starting with commercially available thymidine and making use of a preformed 
ProTide intermediate (3.1-3.4) containing a good leaving group such as mesyl, tosyl or 
nosyl. 
 
Figure 3.2: Late stage fluorination approach for the synthesis of the [18F]FLT ProTide 
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3.3 Synthesis of the precursor molecules 
Keeping in mind what was stated in the introduction regarding the use of 
precursors with good leaving groups to allow the weak nucleophile [18F]fluoride to 
perform the nucleophilic substitution (Chapter 1, pg 11), five possible precursor 
molecules of the [18F]FLT ProTide (2.1) have been synthesised following the general 
synthetic scheme reported in Figure 3.3. 
 
Figure 3.3: General scheme for the synthesis of precursor molecules for the synthesis 
of [18F]FLT ProTide 
 
Reagents and conditions: a) PPh3, DIAD, anh. CH3CN, -20°C to 0°C, 5h, 65%; b) Phosphorochloridate, 
NMI, anh. THF, 25°C, 18h, nitrogen atm., 0.6%; c) NaOH[1.5M], CH3OH, 90°C, 3h, 64%; d) L-alanine ethyl 
ester hydrochloride salt, Et3N, -78°C to rt, anh. CH2Cl2, 3h, 95%; e) Phosphorochloridate, NMI, anh. THF, 
25°C, 18h, nitrogen atm., 21%; f) Mesyl chloride, Et3N, anh. CH2Cl2, nitrogen atm., 0°C to 25°C, 1.5hr, 
29,5%; g)Tosyl chloride, pyridine, AgOTf, 0°C to rt, 2h, 60%; h) Nosyl chloride, pyridine, AgOTf, 0°C to rt, 
2h, 30%; i) di-tert-butyl dicarbonate, pyridine, rt, 16h, 56%. 
 
3.3.1 Synthesis of cyclised precursor (3.8) 
The synthesis of the first anhydride ProTide precursor for fluorination was 
performed according to the scheme shown below (Figure 3.4), making use of 
Mitsunobu reaction131 on the commercially available starting material thymidine. The 
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“anhydro” intermediate (3.5) was then reacted with the ProTide precursor phosphoryl 
chloride (3.10) according to a previously reported ProTide protocol.128 
 
Figure 3.4: Synthesis of the anhydride precursor 
 
Reagents and conditions: a) PPh3, DIAD, anh. CH3CN, -20°C to 0°C, 5h, 65%; b) L-alanine ethyl ester 
hydrochloride salt, Et3N, -78°C to rt, anh. CH2Cl2, 3h, 95%; c) Phosphorochloridate, NMI, anh. THF, 25°C, 
18h, nitrogen atm.,0.6%. 
 
 Firstly it was investigated whether 2’ and 3’ fluorinated nucleoside analogues 
can be accessed via fluorination of anhydrous precursors with applications also in 
radiochemistry.132 For this reason a Mitsunobu reaction was performed using 
thymidine (1.28) as starting material in order to obtain the six membered 2,3’-
anhydride derivative via an intramolecular cyclisation. For this purpose DIAD 
(diisopropylazadicarboxylate) and PPh3 (triphenylphosphine) were used (Figure 3.5).
133 
PPh3 combines with DIAD to form a zwitterionic phosphonium intermediate which 
deprotonates the 3’-OH on the thymidine to form the anionic nuclephile. This 
intermediate binds to the zwitterionic phosphonium ion to perform an SN2 attack 
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leading to the 2,3’-anhydrothymidine, that is now characterised by an inverted 
stereochemistry at C-3’ position. The reaction is driven forward also by the formation 
of the strong P=O bond in the byproduct triphenylphosphine oxide-Figure 3.6 shows 
formation of 3.5 together with other side products. 
 
Figure 3.5: Mitsunobu reaction 
 
Reagents and conditions: a) PPh3, DIAD , anh. CH3CN, -20°C to 0°C, 5h, 65%. 
 
 
 
 
 
 
 
Figure 3.6: Mechanism of the Mitsunobu reaction134 
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The formation of the desired product was confirmed by NMR spectroscopy. In 
particular the disappearance of the proton signal at 9.5 ppm of the NH of the 
pyrimidine ring, confirmed the positive outcome of the reaction. Column 
chromatography on silica gel using a gradient elution of CH2Cl2 and CH3OH has been 
used for the purification. A moderate yield of 65% was obtained as also reported in the 
literature;133 comparison of NMR data with this previously published compound 
confirmed the identity of product 3.5. 
In the meantime a phosphorochloridate was synthesized following the standard 
procedure of McGuigan et al. for the synthesis of ProTides.84 The ethyl ester of the L-
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alanine hydrochloride salt was used under anhydrous conditions to react with the 
commercially available phenyl dichlorophosphate. Triethylamine was used as a base 
necessary to trigger the nucleophilic attack of the L-alanine amine moiety on the 
phosphorus of the phosphorochloridate. The formation of the desired product was 
monitored by 31P NMR. To avoid the oxidation of the phosphorodichloridate and 
phosphorochloridate, the reaction and the work up were performed under nitrogen 
atmosphere (Figure 3.7). 
Figure 3.7: Synthesis of Phosphorochloridate 
 
Reagents and conditions: b) L-alanine ethyl ester hydrochloride salt, Et3N, -78°C to rt, anh. CH2Cl2, 3h, 
95%. 
Due to the formation of the chiral phosphorus center, two diastereoisomers 
have been produced from this reaction in a ratio of 1:1. 31P NMR in fact shows two 
distinctive peaks for the phosphorus of the two diastereoisomers. These products 
were used for the next coupling reaction with the nucleoside moiety without further 
purification. No separation of the diastereoisomers was performed as this is outside 
the remit of this project. 
The first precursor molecule, the anhydride derivative (3.8), was then 
synthesized by coupling the product of the Mitsunobu reaction (3.5) with the 
phosphorochloridate using NMI as per the previously reported procedure128 (Figure 
3.8). 
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Figure 3.8:  Formation of the anhydride ProTide 
 
Reagents and conditions: c) Phosphorochloridate, NMI, anh. THF, 25°C, 18h, nitrogen atm., 0.6%. 
 
The product was obtained in very poor yields and the first purification of the 
product by column chromatography on silica gel did not give the clean product 
because of the formation of several by-products with similar polarity. A second 
purification by preparative TLC was then performed to furnish eventually a clean 
diastereoisomeric mixture of 3.8 as a yellowish oil. This precursor molecule was then 
used for both [19F]fluorination (cold fluorination) and [18F]fluorination (hot 
fluorination) attempts. 
 
3.3.2 Synthesis of the mesyl, tosyl and nosyl precursors 
All the other precursor molecules were synthesised following the scheme 
below (Figure 3.9). 
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Figure 3.9: Synthetic procedure for the mesyl, tosyl and nosyl precursors 
 
Reagents and conditions: a) PPh3, DIAD , anh. CH3CN, -20°C to 0°C, 5h, 65%; b) L-alanine ethyl ester 
hydrochloride salt, Et3N, -78°C to rt, anh. CH2Cl2, 3h, 95%; d) NaOH[1.5M], CH3OH, 90°C, 3h, 64%; e) 
Phosphorochloridate, NMI, anh. THF, 25°C, 18h, nitrogen atm, 60%; e) Mesylchloride, Et3N, anh. CH2Cl2, 
nitrogen atm., 0°C to 25°C, 1.5hr, 29.5%; f) Nosyl chloride, pyridine, AgOTf, 0°C to rt, 2h, 30%; g) Tosyl 
chloride, pyridine, AgOTf, 0°C to rt, 2h, 60%; h) Di-tert-butyl dicarbonate, pyridine, rt, 16h, 56%. 
 
The first two steps (a, b) are the same as shown for the synthesis of the first 
precursor. The Mitsunobu product (3.5) was then hydrolysed to obtain the free 
hydroxyl group in 3’-β position of the sugar moiety.135 The hydrolysis was carried out in 
basic conditions to obtain the 1-(2-deoxy-β-lyxofuranosyl thymidine) (3.6) with a good 
yield (Figure 3.10). 
 
Figure 3.10: Hydrolysis 
 
Reagents and conditions:  d) NaOH[1.5M], CH3OH, 90°C, 3h, 64%. 
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The phosphophorochloride (3.10) was again synthesised as a diastereoisomeric 
mixture following the standard procedure.84 
 These products were used for the next coupling reaction with the nucleoside 
moiety without further purification. A coupling reaction was then performed between 
the phosphorochloridates and the nucleobase moiety (Figure 3.11). 
 
Figure 3.11: ProTide coupling 
 
Reagents and conditions: e) Phosphorochloridate, NMI, anh. THF, 25°C, 18h, nitrogen atm., 18%. 
 
For this synthetic step 1-methylimidazole (NMI) was used as a base to form an 
imidazolium intermediate with the phosphorochloridate that can then readily react 
with the nucleoside. Below is shown the mechanism of action of this reaction when 
using the base NMI (Figure 3.12). 
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Figure 3.12: Reaction mechanism for the final coupling step in the synthesis of the 
FLT ProTide135 
 
 
The hydroxylic group in the 5’ position of the sugar moiety is a primary alcohol 
therefore it is more prone to act as a nucleophile compared to the secondary hydroxyl 
group in the 3’ position. For this reason, no protecting groups were necessary at this 
stage of the synthesis.  
The successful formation of the ProTide was confirmed by 1H NMR, 13C NMR 
and 31P NMR, and mass spectometry. Again, two diastereoisomers were formed 
showing two separate characteristic peaks of the phosphoramidate group around 
3ppm on the 31P NMR. As the hydroxylic group is a poor leaving group,135 and the 
fluoride is a weak nucleophilic agent (even when rigorously dried and complexed with 
the crown ether Kryptofix to enhance nucleophilicity), the hydroxylic group was 
converted into better leaving groups. In particular three organosulfonates, the 
methansulfonate (mesyl), the p-toluenesulfonate (tosyl) and the p-
nitrobenzenesulfonate (nosyl) have been chosen as leaving groups because of their 
ability to be easily replaced by the fluoride via an SN2 reaction
19 (Table 3.1). 
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Table 3.1: Structures of mesyl, tosyl and nosyl leaving groups and pKa of their 
equivalent acids 
STRUCTURE NAME ABBREVIATION PKA OF THE 
CONJUGATE BASE 
 
 
 
Methanesulfonate 
Mesylate 
(-OMs) 
pKa-2           
 
 
 
 
p-Toluenesulfonate 
Tosylate 
(-OTs) 
pKa-3 
 
 
 
 
p-Nitrobenzensulfonate 
Nosylate 
(-ONs) 
pKa-6 
 
 
From this series of precursors the first synthesised product was the mesyl 
derivative (3.1). Figure 3.13 shows the reaction mechanism of the mesylation of the 3’-
alcohol with mesyl chloride as reagent.The presence of a base such as pyridine or Et3N 
can be used to speed up the reaction rate.136 
 
Figure 3.13: Reaction mechanism of the Mesylation 
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Figure 3.14: Mesylation reaction 
 
Reagents and conditions: e) Mesylchloride, Et3N, anh. CH2Cl2, nitrogen atm., 0°C to 25°C, 1.5hr, 29,5%. 
 
An excess of triethylamine (10 eq) was used as a base to activate the hydroxyl 
group to react with an excess of mesyl chloride (4 eq). The reaction was monitored by 
TLC and was stopped when all the starting material was converted into the product. 
The crude product was then purified by silica gel column chromatography to afford the 
desired clean compound. 
For the synthesis of the tosylate (3.2) and nosylate (3.3) precursors the same 
procedure was used but a very low and slow conversion was noted, hence the use of a 
different base combined with the use of a catalyst helped to speed up the reaction and 
have a better conversion rate. 
 
Figure 3.15: Nosylation and Tosylation 
 
Reagents and conditions: f) Nosyl chloride, pyridine, AgOTf, 0°C to rt, 2h, 30%; g) Tosyl chloride, 
pyridine, AgOTf, 0°C to rt, 2h, 60%. 
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In both cases the reaction was carried out in the presence of pyridine and silver 
triflate (AgOTf), a halide-abstracting reagent that could increase the reaction 
rate.137Both compounds were purified by silica gel column chromatography to furnish 
the final products in yields ranging from 30 to 60%. The fifth precursor molecule 
synthesized was a derivative of the nosyl precursor. The nosyl derivative (3.3), as 
discussed later on in the [18F]fluorination section, proved to be a very good potential 
precursor for the [18F]fluorination but its lack of stability led to a partial 
decomposition of the starting material before the radiolabelling step could happen. 
For this reason a new more stable version of the nosylate precursor was synthesised. 
The aim was originally to protect the NH moiety on the pyrimidine ring in order to 
avoid the formation of the undesired byproducts during the fluorination step.138 The 
diprotected ProTide (on both the NH of the pyrimidine ring and the NH of the 
phosphoramidate moiety) was instead the major product of the reaction.  
 
Figure 3.16: N-Protection using the BOC group 
 
Reagents and conditions: h) Ditert-butyl dicarbonate, pyridine, rt, 16h, 56%. 
 
Although the product obtained was not the expected one, it anyway proved to 
be the perfect candidate as a precursor for the [18F]fluorination enhancing stability on 
both the pyrimidine ring and on the phosphoramidate moiety. Its fluorination is 
discussed later on in the [18F]fluorination section.  
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3.4 Synthesis of the cold standard 
For the synthesis of the cold standard (3.11) a few attempts to perform cold 
fluorination of the mesyl precursor (3.1) have been carried out but none of them gave 
the desired product. Tetrabutyl ammonium fluoride tri-hydrate (TBAF.3H2O), KF or CsF 
were used as source of fluorine. Kryptofix was used to enhance the weak 
nucleophilicity of the fluorine. None of the reactions gave the desired fluorinated 
compound returning only unreacted starting material and other by-products (Table 
3.2).1 
 
Figure 3.17: Fluorination of the Mesyl precursor 
 
 
Table 3.2: Attempts of cold fluorination of mesyl precursor (3.1) 
Starting 
material 
T °C Fluorine 
source 
Solvent Reaction 
time 
Product 
3.1 70 °C TBAF THF 1h No 
3.1 120 °C KF DMF 1h No 
3.1 120 °C CsF DMF 1h No 
 
When the fluorination was performed on the nosyl derivative (3.3), the 
formation of the FLT ProTide (3.11) was observed even if the yield was low. 
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Figure 3.18: Fluorination of the Nosyl precursor (3.3) 
 
Reagents and conditions: a) TBAF 1M in THF, anh.DMF, rt, 1h, 3%. 
 
The poor yield of this reaction was due to the formation of many by-products. 
Another synthetic strategy was also used to access the FLT ProTide (3.11) in better 
yields (Figure 3.19). 
 
Figure 3.19: Synthesis of FLT ProTide using FLT as starting material 
 
Reagents and conditions: a) Phosphorochloridate, t-BuMgCl, anh. THF, 18h, 23.5%. 
 
The commercially available FLT (1.29) was used as starting material and the 
Grignard reagent t-BuMgCl was used to perform the coupling reaction with the 
phosphorochloride (Figure 3.19, 3.20) giving the desired compound in better 
yields.114,128 
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Figure 3.20: Mechanism of reaction of the Grignard reagent 
 
 
 
This compound was eventually used as cold standard for the [18F]fluorination 
step. It has indeed to be co-spiked with the radiolabelled compound on an HLPC 
system in order to compare the retention time of the cold and the hot FLT ProTide. The 
same HPLC gradient elution (H2O-CH3CN 99%-1% to 50%-50%) was used for the 
analyses of the [18F]fluorination reactions. 
 
Figure 3.21: Analytical HPLC (UV detector) of the cold [19F]FLT ProTide.  
(H2O-CH3CN 99%-1% to 50%-50%). RT: 9.7 min 
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3.5 Studies of ProTide stability 
Studies of stability of the FLT-ProTide (3.11) were then performed in order to 
prove that, once formed, the [18F]FLT ProTide is stable under the harsh conditions 
used in radiochemistry (i.e high temperature, excess of a fluoride source and 
Kryptofix). 
 
Figure 3.22: Studies of stability of the FLT ProTide 
 
Reagents and conditions: a) KF(10eq), Kryptofix(10 eq), anh.solvent, 40-120 °C. 
 
To a stirring solution of FLT-ProTide in anhydrous DMF, a solution of KF and 
Kryptofix in DMF anhydrous was added at rt. The reaction mixture was heated for 1h 
at 40°C, 80°C, 100°C and 120°C. Each reaction was monitored by TLC, 31P NMR, and 19F 
NMR to observe the potential degradation of the starting material and eventually the 
formation of side products. No decomposition was observed up to 120°C which is the 
maximum temperature that was going to be used for the [18F]fluorination step. 
The reaction mixture was then purified by silica gel column chromatography 
and the starting material was recovered and was analyzed by 1H NMR, 13C NMR, 19F 
NMR, 31P NMR, which all confirmed its stability and purity. 
 
3.6 [18F]fluorination 
Before starting attempts of hot fluorination of the precursor molecules 
synthesised, the fully automated synthetic system (Eckert and Ziegler Nuclear Interface 
Module) for the introduction of 18F- into the precursor molecule had to be been 
configured. This system, located into a shielded hot cell, was set up as shown in Figure 
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3.23. The process consists mainly in the entrapment of the 18F-, which comes in a water 
solution (2 mL) directly from the cyclotron, into a QMA cartridge (a silica-based, 
hydrophilic, anion-exchanger designed for the extraction of anionic analytes such as 
18F-). A Kryptofix solution passes through it to form the complex KF-K222. An 
azeotropic distillation of this aqueous solution is performed two times with 1mL of 
anhydrous acetonitrile at 120°C. Finally the precursor molecule dissolved in 1mL of 
anhydrous solvent is added and the reaction mixture is allowed to stir. Temperature 
and time of the reaction can be modified for each experiment.139 
 
Figure 3.23: Modular Lab Eckert and Ziegler (E&Z) at PETIC centre 
 
 
The module set up consists of 9 elements (Figure 3.24): 
(A)  Reaction vial. 
(B) QMA cartridge preconditioned with 5 mL of an 8.4% aqueous solution of 
NaHCO3solution followed by 10 mL of water, to trap 
18F- from the cyclotron. 
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(C) Kryptofix [2.2.2] vial. 
(D) Anhydrous acetonitrile vial for the azeotropic evaporation. 
(E) Precursor vial filled with the precursor dissolved in the reaction solvent. 
(F) Acid vial filled with 0.05M HCl for eventual deprotection. 
(G) Base vial filled with 0.25M NaOH for eventual neutralization. 
(H) Vacuum pump for solvent removal. 
(I) Final product vessel for product isolation. 
 
Figure 3.24: Sketch of EZ Modular Lab 
 
 
A flow chart of the process performed by the software program is shown in Figure 
3.25. 
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Figure 3.25: Flow chart of the synthetic steps in modular lab 
 
 
Several conditions have been explored for the hot fluorination. In particular the 
three essential requirements that can deeply influence the outcome of the 
radiolabelling are the time of the reaction (15-30 mins), the absolute anhydrous 
conditions (i.e absence of water and use of anhydride solvents) and the high 
temperature (90-120°C). 
Reaction mixtures were analyzed by using a radio TLC and a radio HPLC. The 
reaction mixture was co-eluted with the cold reference standard in order to compare 
the retention time of the cold standard (detected with the UV detector) and of the 
radiolabelled compound (detected with the radioactive detector) on the HPLC 
system.52,140 
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Figure 3.26: General conditions for the hot fluorination of the precursors 
 
Reagents and conditions: a)
18
F
-
, Kryptofix [K222], anh. solvent, x mins, T °C. 
 
3.6.1 [18F]-Fluorination of the anhydride precursor (3.8) 
The first attempts of [18F]-Fluorination have been carried out on the anhydride 
precursor (3.8) because of the easily accessible intermediate 3.5. Several reaction 
conditions have been explored as reported in Table 3.3. 
 
Table 3.3: [18F]fluorination attempts on the anhydride precursor 
Precursor Solvent mg T(°C) Time (18F-) 18F-FLTProtide 18F-by-products 
3.8 CH3CN 10 90°C 15min 3.1 GBbq No No 
3.8 CH3CN 10 90°C 20min 2.4 GBq No No 
3.8 CH3CN 10 90°C 30min 1.3GBq No No 
3.8 DMF 10 120°C 15min 876MBq No No 
3.8 DMF 10 120°C 20min 2.1GBq No No 
3.8 DMF 10 120°C 30min 2.9 G Bq No No 
 
None of the reactions gave the desired radiolabelled product or any other 
radiolabelled by-products, returning just unreacted [18F]fluorine as shown also from 
the radio HPLC chromatograms (Figure 3.27). 
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Figure 3.27: [18F]fluorination of compound 3.8  
a) Radioactive chromatogram of the reaction mixture showing free 18F- at 3min; b) UV 
chromatogram of the reaction mixture co-spiked with the cold standard (3.11).(Rt of 
compound 3.11: 10 min) 
a)  
b)  
 
No other attempts have been performed as this precursor didn’t show any 
reactivity towards the [18F]fluorination. This could be due to the poor reactivity of the 
3’-position suggesting that the use of better leaving groups such as the mesyl, tosyl or 
nosyl is required for this type of reaction. 
 
3.6.2 [18F]fluorination of the mesyl precursor (3.1) 
The second precursor tested was the mesyl precursor (3.1) because of its 
synthetic accessibility and because of its balance between reactivity and stability as 
leaving group. Similar reaction conditions to the ones used for the anhydride derivative 
have been tested for this step (Table 3.4). 
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Table 3.4: [18F]fluorination attempts on the mesyl precursor 
Precursor Solvent Mg T(°C) Time (18F-) 18F-FLTProtide 18F-by-products 
3.1 DMF 10mg 120°C 15min 810 MBq No No 
3.1 DMF 10mg 120°C 20min 2.35 GBq No No 
3.1 DMF 10mg 120°C 30min 910 MBq No No 
3.1 DMF 20 mg 120°C 15min 580 MBq No No 
3.1 DMF 20 mg 120°C 20min 970 MBq No No 
3.1 DMF 20 mg 120°C 30min 780 MBq No No 
 
Figure 3.28: [18F]fluorination of compound 3.1 
a)Radioactive chromatogram of the reaction mixture showing a major peak of free 18F- 
at 3min; b)UV chromatogram of the reaction mixture co-spiked with the cold standard 
(3.11). (Rt of compound 3.11: 10 min) 
a)  
b)  
 
As again no radiolabelled products were formed and only [18F]fluorine was 
returned unreacted, a larger amount of starting material was used (20 mg) to test 
whether this variable could influence the outcome of the reaction. In this case, the 
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reaction also did not give the desired product indicating that the amount of ProTide 
used as starting material was not a limiting factor for the successful outcome of the 
reaction. 
 
3.6.3 [18F]fluorination of the tosyl precursor (3.2) 
The third precursor used was the tosyl precursor (3.2) because of its reactivity 
towards fluorination but also better stability compared to the nosyl derivative (3.3) 
(Table 3.5).141 
 
Table 3.5: [18F]fluorination attempts on the tosyl precursor 
Precursor Solvent Mg T(°C) Time (18F-) 18F-FLTProtide 18F-by-products 
3.2 CH3CN 10 mg 90°C 15min 2GBq No Yes 
3.2 CH3CN 10 mg 90°C 20min 1.2 GBq No Yes 
3.2 CH3CN 10 mg 90°C 30min 2.5 GBq No Yes 
3.2 DMF 10 mg 120°C 15min 2.3 GBq No No 
 
The tosyl precursor, compared to the previous anhydro and mesyl substituted 
precursors, finally gave, together with unreacted [18F]fluorine, a unique radiolabelled 
compound (Rt:7min) when the reaction was stirred for 30 mins at 90°C using 
acetonitrile as solvent.  
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Figure 3.29: [18F]fluorination of compound 3.2 
 a)Radioactive chromatogram of the reaction mixture showing free 18F- at 3.5min and a 
18F-product at 7 min; b)UV chromatogram of the reaction mixture co-spiked with the 
cold standard (3.11). (Rt of compound 3.11: 10.6 min) 
a)  
b)  
 
Unfortunately the radiolabelled product did not have the expected retention 
time on the HPLC (Rt cold standard: 10 min) but the product proved to be slightly more 
polar than the cold standard, suggesting that the reaction time was a key factor and, 
that 90°C was enough as no precursor was left at the end of the reaction. In order to 
understand the identity of the product formed, a step back to cold chemistry was 
required. An attempt of cold fluorination on the tosyl derivative was performed and 
similar reaction conditions were tested. The reaction was indeed stirred at 90°C for 30 
mins using KF as source of fluorine. Purification was performed by silica gel column 
chromatography but no clear 1H NMR and 13C NMR spectra were obtained because of 
the formation of many by-products and the challenging purification. Nevertheless, the 
19F NMR showed two peaks at -200ppm as for the FLT ProTide (3.11). 31P NMR was also 
performed and showed the two characteristic peaks of the phosphoramidate moiety at 
around 3 ppm. This suggested that probably, the slight change in retention time was 
due to a loss of a moiety such as the ester on the L-alanine. Mass spectrometry did not 
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confirm this hypothesis showing a major peak at 453 that does not correspond to any 
of the substructures hypothesised. 
 
3.6.4 [18F]fluorination of the nosyl precursor (3.3) 
The fourth precursor, the nosyl derivative (3.3), was then used for the 
[18F]fluorination attempt. Among all precursors synthesised, although the nosyl is 
supposed to be the more reactive one, it is likely characterised by a lack of stability 
that could be a deterrent for its usage. All the conditions explored for this reaction are 
reported in Table 3.6. 
 
Table 3.6: [18F]fluorination attempts of the nosyl precursor 
Precursor Solvent Mg T(°C) Time (18F-) 18F-FLTProtide 18F-by-products 
3.3 CH3CN 10 mg 90°C 15min 1.2 GBq No Yes 
3.3 CH3CN 10 mg 90°C 20min 1.5 GBq Yes Yes 
3.3 CH3CN 10 mg 90°C 30min 2.3 GBq Yes Yes 
3.3 CH3CN 10 mg 90°C 40min 2.2 GBq Yes Yes 
3.3 DMF 10 mg 120°C 15min 734 MBq No Yes 
3.3 DMF 10 mg 120°C 20min 1.1 GBq No Yes 
 
Similarly, to the fluorination of the tosyl derivative, the major radiolabelled 
products had retention times of 5 and 8 mins as the major products of the reaction, 
together with many other more polar by-products. However, when the reaction was 
performed at 90°C for 30 mins in acetonitrile, also the desired [18F]FLT ProTide (2.1) 
was formed although in poor yields (Figure 3.30). 
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Figure 3.30: [18F]fluorination of compound 3.3 
a) Radioactive chromatogram of the reaction mixture showing free 18F- at 3min, [18F]-
by-products at 5 and 8 min and [18F]FLT ProTide at 10 min; b) UV chromatogram of 
the reaction mixture co-spiked with the cold standard (3.11). (Rt of compound 3.7: 10 
min) 
a)    
b)  
 
To re-confirm this positive result, the same reaction was performed also on 
another automated synthetic modular lab (the GE FxFnTracerlab), at the Molecular 
Imaging Chemistry Laboratory (MICL) in the Wolfson Brain Imaging Centre of  
Cambridge University to prove the reproducibility of this reaction with different 
automated synthesisers (Figure 3.31). 
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Figure 3.31: GE Healthcare TracerlabFxFn142 
 
 
The set up of this synthesiser was similar to the one of the E&Z one (Figure 3.32): 
(A)  Reaction vial. 
(B) QMA cartridge preconditioned with 5 mL of a 8.4% aqueous solution of NaHCO3 
solution followed by 10 mL of water, to trap 18F- from the cyclotron. 
(C) Kryptofix [2.2.2] vial. 
(D) Anhydrous acetonitrile vial for the azeotropic evaporation. 
(E) Precursor vial filled with the precursor dissolved in the reaction solvent. 
(F) Vacuum pump for solvent removal. 
(G) Final product vessel for product isolation. 
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Figure 3.32: Sketch of TracerlabFxFn 
 
 
For QC control the cold standard (3.11) was again run on a C18 column on an 
HPLC system this time using an isocratic elution (Figure 3.33).140 
 
Figure 3.33: Analytical HPLC chromatogram of the cold standard  
Isocratic system: 65%H2O-35%CH3CN, Rt of the two diastereoisomers: 11.8 and 12.2 
min. 
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Again the results of the hot fluorination were the same obtained as with the 
E&Z modular lab. A slight decrease in the yield of the reaction was observed but results 
obtained with the E&Z synthesiser were generally confirmed (Figure 3.34). 
Figure 3.34: [18F]fluorination of compound 3.3 with TracerLabFxFn 
a)Radioactive chromatogram of the reaction mixture showing many 18F-by-products 
and [18F]-FLT ProTide at 12 min; b)UV chromatogram of the reaction mixture co-
spiked with the cold standard (3.11). (Rt of compound 3.11: 11.8-12-2 min) 
   
a)  
 
b)  
 
Bearing in mind the future desired clinical application of the tracer, another 
variable was then introduced in the system to understand whether the reaction could 
be performed even without the use of Kryptofix which, despite being a good enhancer 
for the nucleophilicity of the [18F]-fluorine, is considered to be toxic when used in high 
quantity.143 
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This method replaces Kryptofix with the base tetraethylammoniumhydrogen 
carbonate that is dissolved in a polar aprotic solvent (MeCN, DMF, DMSO) containing 
up to 5% of water and it  can be used to efficiently elute [18F]-fluoride from an anion-
exchange cartridge (QMA, carbonate form) to produce tetraethylammonium 
[18F]fluoride. This method has been widely applied for different aliphatic and aromatic 
radiosyntheses allowing [18F]-nucleophilic substitution by avoiding the use of Kryptofix 
and eliminating the long azeotropic drying procedures144 (Figure 3.35). 
 
Figure 3.35: Hot fluorination of the nosyl derivative without the use of Kryptofix as 
reagent 
 
Reagents and conditions: a)
18
F
-
(2.3 GBq), Et3NHCO3, anh. CH3CN, 90°C, 30 min. 
 
As no positive increase in the yield was observed, the next step was the 
protection of the two NH moieties of the nosyl derivative that could interfere with the 
reaction outcome thus decreasing the percentage of formation of the desired product. 
3.6.5 [18F]fluorination of the nosyl BOC protected precursor 
(3.4) 
  The addition of the two BOC protecting groups should avoid the formation of 
some of the by-products hypothesised and in particular of the anhydride derivative 
and of the cyclised ProTide. In this case the fluorination does not represent the last 
step but it has to be followed by a short deprotection step.145,146 In order to perform 
this reaction, the E&Z modular lab was re-programmed in order to add a deprotection 
step to the reaction. When the reaction was tested, the first attempt eventually gave 
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the desired radiolabelled [18F]-BOC protected FLT ProTide under the following 
conditions (Figure 3.36). 
 
Figure 3.36: Hot fluorination of the BOC protected nosyl derivative (3.4) 
 
Reagents and conditions: a)
18
F
-
(2.5GBq), Kryptofix, anh. CH3CN, 90°C, 30 min. 
 
After 30 mins of radiolabelling at 90°C, the reaction mixture was passed 
through an Al cartridge to remove the excess unreacted 18F-. An aliquot of the reaction 
mixture was then taken and injected into the HPLC  showing a major product with a 
retention time at around 15 mins. This suggested that the desired BOC radiolabelled 
product was formed therefore supporting the hypothesis that the BOC protection 
provides a better stability to the nosyl precursor. 
 
Figure 3.37: [18F]fluorination of compound 3.4 
a)Radioactive chromatogram of the reaction mixture showing BOC-protected [18F]FLT 
ProTide at 15 min 
a)  
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The solvent was then removed from the reaction mixture at 95 °C under a 
stream of nitrogen in a separate heating module. The deprotection step was carried 
out by adding product 3.12 to the stirring reaction mixture of 1mL of 2N HCl for 10 
mins at 95°C.1 
 
Figure 3.38: Deprotection of the BOC [18F]-intermediate 
 
Reagents and conditions: a) 2M HCl, 95°C, 10 min. 
 
Neutralisation was then performed with a 2M NaOH solution. An aliquot of the 
reaction mixture was taken and co-injected with the cold standard into the HPLC. 
Gratifyingly the major product of this reaction was the [18F]FLT ProTide with few other 
minor by-products 
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Figure 3.39: Deprotection of compound 3.12 
a)Radioactive chromatogram of the reaction mixture showing [18F]FLT ProTide as 
major peak at 10.8 min; b)UV chromatogram of the reaction mixture co-spiked with 
the cold standard (3.11). (Rt of compound 3.11: 10.7 min) 
a)  
b)  
 
The compound was then purified by semi-preparative HPLC and was eluted 
after 35 minutes at a flow rate of 3.5 mL/min using 30% CH3CN/70% H2O as the mobile 
phase. The HPLC solvent was then removed from the mixture under a stream of 
nitrogen. The radioactive product was taken up in saline and subsequently flushed 
through a sterility filter to obtain a sterile and clean aqueous solution of [18F]FLT 
ProTide. 
An aliquot of the purified sample was analysed by HPLC (Figure 3.39) via co-
elution with the cold standard. Radiochemical reactions were carried out using starting 
activities between 1.5-8 GBq, leading to final product activities of 240-480MBq in a 
highly respectable RCY of 15-30% (n=5, decay-corrected from end of bombardment 
(EoB)), with high radiochemical purities (97%) and specific activities_1800 mCi/μmol. 
The total synthesis time was 130 min after the end of bombardment (EoB). 
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Figure 3.40: Purified [18F]FLT ProTide  
a) Radioactive chromatogram of the purified [18F]FLT ProTide with Rt: 10.8 min , 
b) UV chromatogram of the reaction mixture co-spiked with the cold standard 
with Rt: 10.7 min. 
                 a)   
b)        
 
Figure 3.41: Radio-TLC chromatogram of the purified [18F]FLT ProTide 
 
 
3.7 Conclusions 
Five potential precursor molecules of the [18F]FLTProTide (2.1) and a cold 
reference standard, the [19F]FLT ProTide (3.11), have been synthesised using cold 
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chemistry methods. Late stage [18F]fluorination was performed on all the precursors 
synthesised exploring different reaction conditions. The nosyl derivate (3.3) furnished 
the desired product in poor yield therefore protection of the NH moieties of the 
molecule was performed in order to minimize the formation of undesired side 
products. This protection markedly increased the yield of the reaction furnishing the 
desired radiolabelled BOC protected compound. This compound was then deprotected 
to finally furnish the desired target compound 2.1. This is the first time to our 
knowledge that a radiolabelled ProTide has been synthesised. 
However, the results here presented should be regarded as first trials of the 
synthesis of [18F]radiolabelled ProTides. Further investigations with different set-ups 
(e.g. different automated synthetic modules, microwave-assisted synthesis) should be 
carried out to validate the reproducibility and clinical potential application of this 
radiosynthesis.9,45,145 
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4. Radiochemical synthesis of [18F]FIAUProTide 
 
4.1 Introduction 
Besides the late stage [18F]fluorination approach discussed in Chapter 3, 
another synthetic pathway involving an early stage [18F]fluorination has been followed 
to access a different class of radiolabelled compounds, the 2’-[18F]FIAUProTides 
(Figure 4.1). 
 
Figure 4.1: Structure of the2’-[18F]FIAU ProTide target (2.2) 
 
 
[18F]FIAU (1.16) is already a well known PET imaging probe used as a 
biomarker for imaging HSV1-tkgene expression.146 Reporter gene imaging is a non 
invasive technique used in live subjects to determine location, duration and extent of 
expression of the gene of interest.147–150 In particular Herpes simplex virus-1 thymidine 
kinase (HSV1-tk) is one of the genes most widely used as a reporter in molecular 
imaging to visualise and monitor many biological processes including lymphocyte 
migration151, transcriptional regulation152, and stem-cell tracking.153,154 Radiolabelled 
nucleoside analogues, such as [18F]FIAU, can be used for monitoring HSV1-tk gene 
expression using PET imaging.54 
*18F+FIAU ProTide has been chosen as a model standard for the class of the 2’-
fluorinated ProTides for the following reasons: 
- Fluorine is placed in position 2’ on the sugar moiety therefore it can be used as 
model standard for the radiochemical synthesis of other 2’-[18F]ProTides. 
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-  [18F]FIAU (1.16) is a PET imaging probe and many synthetic strategies have 
already been extensively explored45,116,132,155 and can be used as a guide for the 
synthesis of its ProTide. Additionally studies of retention of [18F]-FIAU on HEK 
(human equilibrative kidney) cells engineered to express HSV- tk1 can be useful 
to prove the successful synthesis of this tracer. 
- It is a uridine based ProTide, thus the absence of other reactive sites on the 
nucleobase moiety of the molecule will avoid further protection and 
deprotection steps. 
 
4.2 [18F]fluorination (Hot): early stage approach 
Among many synthetic approaches, the only one reported in the literature 
which gives [18F]FIAU in good yields consists of an early stage hot fluorination of the 
sugar moiety followed by a multi-step synthesis155 that has to be performed in a 
relative short time taking into account the half life of the [18F]fluorine (an ideal 
synthesis should not exceed three half lives)1. A similar synthetic pathway to that of 
[18F]FIAU will be applied for the synthesis of its ProTide according to the scheme 
outlined in Figure 4.2. 
 
Figure 4.2: Early stage fluorination approach for the synthesis of the 
[18F]FIAU ProTide (2.2) 
 
 
Although the early stage hot fluorination is considered not to be ideal when a 
multi-step synthesis has to be performed, the advantage consists in the radiolabelling 
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step that does not give any by-products thus providing a compound that can be used 
for the next steps without further purification. 
4.3 Synthesis of the cold standard (4.3) 
Again a cold standard, the FIAU ProTide (4.3), was synthesised in order to have 
a reference compound to co-inject into the analytical HPLC together with the 
radiolabelled compound as a proof of the successful outcome of the reaction.140 As the 
synthesis of [18F]FIAU is well known, no attempts at cold fluorination were performed 
to test the reactivity towards nucleophilic substitution performed by the fluoride on 
the triflate group of the precursor molecule 4.1. Therefore the synthesis of the cold 
standard was accomplished following the synthetic scheme in Figure 4.3. 
 
Figure 4.3: Synthesis of the cold standard FIAU ProTide (4.3) 
 
Reagents and conditions: a) I2, Ceric ammonium nitrate, CH3CN, 75°C, 1h, 60%; b) L-alanine benzyl ester 
hydrochloride salt, Et3N, -75°C to rt, anh. CH2Cl2, 3h, 88%; c) NMI, anh. THF, 0°C to rt, 16h, 12%. 
 
The commercially available 2'-deoxy-2'-β-fluoro-uridine (4.4) was used as 
starting material of the synthesis (Figure 4.4). I2 was used as reagent to perform the 
iodination reaction in position 5 of the pyrimidine ring and ceric ammonium nitrate 
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was used as catalyst and oxidant to speed up the reaction rate.156,157 After 1 hour of 
refluxing at 75°C the starting material was all converted into the product.  The reaction 
was then quenched with a saturated solution of Na2S2O3 to remove any unreacted 
highly toxic iodine, and the product was extracted into ethyl acetate and used for next 
step without any further purification. 
 
Figure 4.4: Iodination of the starting material (4.4) 
 
Reagents and conditions: a) I2, Ceric ammonium nitrate, CH3CN, 75°C, 1h, 60%. 
 
Step b and c were performed according to the standard procedure for the synthesis of 
ProTides128 to furnish the final compound 4.3 with a yield of 11%. 
 
4.3 Synthesis of [18F]FIAU (1.16) 
For the synthesis of the [18F]FIAU the following synthetic procedure reported 
in literature has been followed (Figure 4.5).45 
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Figure 4.5: Radiochemical synthesis of [18F]FIAU (1.16) 
 
Reagents and conditions: a) 
18
F
- 
, Kryptofix, anh. CH3CN, 95°C, 30 min; b) Hexamethyldisilaxane, TMSOTf, 
anh. dichloroethane, 85°C, 2h; c) anh. CH3CN, 85°C, 1h; d) NaOCH3/CH3OH, 80°C, 10 min. 
 
Compared to the other reported radiosyntheses of this tracer, this one has the 
advantage of avoiding the bromination step in position 2 of compound 4.2 before the 
coupling with 4.7.54,155Therefore a shorter synthesis is obtained with also the 
advantage of avoiding the usage of the highly toxic Br2 reagent. 
The first step consists of the hot fluorination of the commercially available 
starting material sugar 4.1. In this case the leaving group is the triflate, one of the best 
leaving groups amongst the organosulfonates.158 The reaction was carried out using 
the E&Z modular lab following the same procedure described in Chapter 3. The 
conditions for the radiolabelling are reported below. 
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Figure 4.6: Synthesis of the [18F]-sugar (4.2) 
 
Reagents and conditions: a) 
18
F
- 
, Kryptofix, anh. CH3CN, 95°C, 30 min. 
After purification with an alumina cartridge (characterized by an extremely 
polar surface for analyte retention) to eliminate the excess of free 18F-,41 the 
radiolabelled sugar (4.2) was produced and used for next step without further 
purification. When an aliquot of the hot mixture was co-spiked with the cold standard 
(commercially available), it showed the same retention time at around 8 min as shown 
in Figure 4.7. 
 
Figure 4.7: [18F]fluorination of compound 4.1  
a) Radioactive chromatogram of the reaction mixture showing the [18F]-sugar 4.2 
as the unique product of the reaction with Rt of 8.2 min; b) UV chromatogram 
of the reaction mixture co-spiked with the cold standard. (Rt of commercially 
available cold standard: 7.9 min). b) HPLC system: 98% CH3CN, 2% H20. 
a)  
b)  
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The second step consists in the protection of the base moiety that was freshly 
synthesised while the hot fluorination was ongoing in a second heating module placed 
into the hot cell next to E&Z modular lab. Hexamethyldisilaxane was used as protecting 
reagent and trimethylsilyltrifluoromethanesulfonate (TMSOTf) was used as catalyst to 
activate the following glycosylation reaction45(Figure 4.8). To confirm that the reaction 
was complete, HPLC and LC-MS were performed. 
 
Figure 4.8: Protection of the 5-Iodouracil (4.5) 
 
Reagents and conditions: b) Hexamethyldisilaxane, TMSOTf, anh. DCE, 85°C, 2h. 
 
Compound 4.7 was dried at 90°C under compressed air to remove the 
dichloroethane solvent, obtaining a yellowish oil. The radiolabelled sugar (4.2) (in 
CH3CN solution) was then delivered directly from the E&Z unit to the vial containing 
the protected uracil (4.7) to perform the glycosylation reaction followed by a quick 
deprotection step as shown in Figure 4.9. The glycosylation is known to be a non-
stereoselective reaction because of the formation of a new sterogenic centre.159 
Indeed two anomers were formed from this reaction, the β-anomer  (the [18F]FIAU) 
(1.16) and the α-anomer (4.7).155 
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Figure 4.9: Synthesis of protected β-anomer of [18F]FIAU (1.16) and the α-anomer 
(4.8) 
 
Reagents and conditions: c) anh. CH3CN, 85°C, 1h ; d) NaOCH3/CH3OH, 80°C, 10 min. 
 
An aliquot of the reaction mixture was the taken for analytical evaluation. The 
α and the β anomers were formed in a ratio 1 to 2 as also reported in 
literature.45,132,155 
 
Figure 4.10: Deprotection reaction  
a)Radioactive chromatogram of the reaction mixture showing the two anomers at 2.1 
min (α anomer, 4.8) and at 2.9 min (β anomer, *18F+FIAU+, 1.16). HPLC system: 98% 
H20, 2% CH3CN. 
a)  
 
The anomeric mixture was then purified by semi-preparative HPLC and was eluted 
after 7.3 minutes at a flow rate of 3.5 mL/min using 20% CH3CN/80% H2O as the 
0:00 5:00 10:00 15:00 mm:ss
0.0
200.0
400.0
600.0
Counts
 
 
 4. Radiochemical synthesis of [18F]FIAU ProTide 
95 
 
mobile phase. An aliquot of the purified compound was taken for analytical HPLC 
evaluation and co-spiked with the cold standard. 
 
Figure 4.11: [18F]FIAU purification 
a) Radioactive chromatogram of the [18F]FIAU (1.16) showing the product with Rt of 
2.3 min; b) UV chromatogram of the reaction mixture co-spiked with the cold standard 
(1.61). (Rt of cold standard: 2.1 min). HPLC system: 98% H20, 2% CH3CN. 
a)  
b)  
 
The radiolabelled compound showed the same retention time as the standard 
and also literature strongly supports that the elution time of the β-anomer is longer 
than the α.45 Nevertheless an additional biological evaluation of the tracer was 
performed to support the isolation of the correct anomer (see section 4.6). 
In order to optimise and speed up the glycosylation step, several conditions 
and combination of catalysts were explored (Table 4.1).10,45 
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Table 4.1: Attempts for the hot glycosylation reaction 
Solvent Temperature Time Catalyst Ratio β:α 
CH3CN 85:C 30min TMSOTf Incomplete 
CH3CN 85:C 45min TMSOTf Incomplete 
CH3CN 85:C 1h TMSOTf 2:1 
CH3CN 95:C 30 min TMSOTf Incomplete 
CH3CN 85:C 15 min TMSOTf+SnCl4
1 1:1.3 
 
However, despite improving the rate of the synthesis when using a 
combination of catalysts, also the ratio changed favouring the formation of the α-
anomer (Figure 4.12). 
 
Figure 4.12: Deprotection reaction when using TMSOTf and SnCl4 as catalysts 
a) Radioactive chromatogram of the reaction mixture showing the two anomers at 2.2 
min (α anomer, 4.8) and at 2.4 min (β anomer, *18F-FIAU], 1.6). HPLC system: 98% 
H2O, 2% CH3CN. 
a)  
 
Therefore, based on these attempts at optimisation of reaction conditions, the 
synthetic pathway in Figure 4.9 was established as the more suitable for synthesis of 
[18F]FIAU. 
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4.5 Synthesis of the [18F]FIAUProTide (2.2) 
Finally the last step consisted in the coupling between the [18F]FIAU (1.16) and 
the phosphorochloridate (4.5) previously synthesised according to the standard 
procedure described in Chapter 3.128 
 
Figure 4.13: Synthesis of the [18F]FIAUProTide (2.2) 
 
Reagents and conditions:a) NMI, anh. THF, 50°C, 20 min. 
This step, as reported in literature, normally takes 16h or more to be 
completed. Therefore, preliminary studies to optimise the duration of this step were 
performed via cold chemistry. The cold reaction was carried out at rt, 30°C, 40°C and 
50°C to reduce the reaction time as much as possible. When this step was performed 
at 50°C, the coupling was completed after 20 mins. Hence these conditions were 
applied for the radiochemical synthesis. 
A solution of the phosphorochloridate (4.5) in anhydrous THF was added 
manually to the vial containing [18F]FIAU (1.16) which was previously dried under 
compressed air to eliminate the solvent residue from the semi-preparative HPLC 
separation. The reaction was allowed to stir for 20 min at 50°C and then dried under a 
flow of nitrogen, re-dissolved in CH3CN and an aliquot was taken to perform an 
analytical HPLC run. [18F]FIAU ProTide (2.2) was the main product of the reaction as 
shown in Figure 4.14. The major peak was isolated via semi preparative HPLC and was 
eluted after 23 minutes at a flow rate of 3.5 mL/min using 50% CH3CN/50% H2O as the 
mobile phase. The HPLC solvent was removed from the mixture under a stream of 
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nitrogen. The radioactive product was taken up in saline and subsequently flushed 
through a sterility filter to obtain a sterile and clean aqueous solution of [18F]FIAU 
ProTide. 
An aliquot of the purified sample was analysed by analytical HPLC via co-elution 
with the cold standard as shown in Figure 4.14. Radiochemical reactions were carried 
out using starting activities between 7-15 GBq, leading to final product activities of 8-
56 MBq in a RCY of 1-5% (n=7, decay-corrected from end of bombardment (EoB)), with 
high radiochemical purities (98%) and specific activities of 1800 mCi/μmol. The total 
synthesis time was 240 min after the end of bombardment (EoB). 
 
Figure 4.14: Synthesis of [18F]FIAU ProTide 
a) Radioactive chromatogram of the [18F]FIAU ProTide reaction mixture showing a 
major peak with Rt of 13 min; b) Radioactive chromatogram of the [18F]FIAU ProTide 
purified with Rt of 12.3 min; c) UV chromatogram of the [18F]FIAU ProTide co-spiked 
with the cold standard (4.3). (Rt of cold standard: 12.2 min). HPLC system: 90% H2O-
10% CH3CN to 50% H2O-50% CH3CN. 
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c)  
 
4.6 Evaluation of the radiotracer [18F]FIAU (1.16) on 
HSV-TK engineered HEK cell lines 
Human embryonic kidney cells 293, also referred to as HEK 293 or simply HEK 
cells, are specific cell lines originally derived from human embryonic kidney cells grown 
in tissue culture. They have been widely used in cell biology because of their reliable 
growth and propensity for transfection. Additionally, they are used in 
the biotechnology industry and gene therapy.160 
This series of experiments was carried out alongside Dr. Stephen Paisey of the 
Positron Emission tomography Imaging Centre (PETIC) at Cardiff University. The 
hypothesis of these experiments is that HEK cells engineered to express the herpes 
simplex thymidine kinase will retain higher levels of radioactivity, than the wild type 
cells, after radiolabelling with [18F]FIAU (H1).  
HeKTK
HeKTK
H
H




:
:
1
0
 
This will be additional proof for the successful synthesis of the correct anomer 
(β) (*18F+FIAU, 1.16) discussed in section 4.4 because of the known affinity of HSV-tk 
cells towards this tracer.138 
HEK 293 cells were previously transfected to contain PC-DNA expressing the 
herpes simplex virus thymidine kinase (TK-HEK), ampicillin resistance and neomycin 
were also used. The [18F]FIAU synthesised was used for the radiolabelling. 8.1 MBq of 
activity of [18F]FIAU in 1mL of water were diluted in 30ml of phosphate buffered saline 
solution and split into 6 samples of 5 mL. The radioactive FIAU PBS solution was then 
used to re-suspend the 6 cell pellets (3 regular and 3 thymidine kinase HEK 
populations) and samples were incubated with shaking for 30 minutes. The cells were 
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then centrifuged at 1500rpm for 5 minutes with isolation of the supernatant and a 1mL 
sample collected for activity measurement. The cells were then re-suspended in 5mL 
of regular phosphate buffered saline solution and centrifuged at 1500rpm for 5 
minutes. The supernatant was again decanted with a 1mL sample collected for activity 
measurement. The cells were then re-suspended in 2mL PBS with 15L taken for 
counting and 2 x 1ml aliquots taken for activity measurement for each sample.151,161 
Counts per minute were recorded using an automatic gamma counter. 
Table 4.2 shows the results of the radiolabelling procedure. The cells were 
radiolabelled using [18F]FIAU with the KBq of radioactivity retained calculated using 
the 18F standard curve in Appendix 1. KBq retained per 104 cells was calculated using 
the raw data in Appendix 2. The T-test (performed assuming group means have equal 
variance) clearly show that the TK cells retained significantly more [18F]FIAU  
(Appendix 4). 
 
Table 4.2: Radiolabelling of wild HEK cells and tk engineered HEK cells 
Sample 
Live cells/mL 
(x104)before 
Live cells/mL 
(x104)after 
KBq retained/ 
104cells labelled 
Cell % survival after 
radiolabelling 
HEK 1 17 3 0.1057 17.6 
HEK 2 14 1.5 0.1172 10.7 
HEK 3 22.5 2 0.1263 8.9 
TK-HEK 1 4.5 0.5 1.4355 11.1 
TK-HEK 2 5.5 1 1.2698 18.2 
TK-HEK 3      5 0.5 1.3134 10.0 
 
In conclusion the evidence strongly supports the claim that the TK-HEK cells 
retain more [18F]FIAU than the wild type cells (Table 4.3). 
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Table 4.3: Preliminary radiolabelling experiment results 
Cell type Cell count ( x 104) CPM KBq KBq retained per 104 cells labelled 
HEK 53.0 170190.8 16.2713 0.307 
TK 32.5 433802.4 38.5619 1.18 
 
4.7 Conclusions 
In conclusion [18F]FIAU ProTide (2.2) was synthesised via an early stage hot 
fluorination with an overall synthesis time of 4h. Although this approach cannot 
currently find any clinical application in PET imaging because of the duration of the 
radiosynthesis, it can be used for preliminary studies to monitor the behaviour of the 
2’-fluorinated ProTides in animal models. In order to increase the yield of the reaction 
and reduce its duration, the use of microfluidic systems would be advisable.6 Another 
synthetic approach that could be pursued to access the [18F]FIAU ProTide (2.2) would 
involve the synthesis of a suitable precursor molecule to perform a late stage 
fluorination as shown in the retrosynthesis suggested in Figure 4.15. 
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Figure 4.15: Proposed retrosynthetic pathway to access the [18F]FIAU ProTide (2.2) 
via a late stage hot fluorination 
 
 
Additionally studies of retention of [18F]FIAU on HEK cells engineered to express 
HSV-TK1 were performed and further evidenced the successful synthesis of this tracer 
showing a major retention compared to wild type cells. 
 5. Synthesis of novel 2’-deoxy-2’-fluoro-5-iodouridine Protides as novel antiviral agents 
103 
 
5. Synthesis of novel 2'-deoxy-2'-fluoro-5-
iodouridine ProTides as novel antiviral agents 
 
5.1 Introduction 
Viral infections can be classified into three main groups. The first class includes 
life-threatening chronic viruses like the Human Immunodeficiency Virus (HIV), the 
Hepatitis B virus (HBV), and Hepatitis C Virus (HCV). The second class comprises acute 
viral infections that are generally non-lethal and self-resolving in otherwise healthy 
patients such as influenza viruses. The third class includes non-lethal viral infections 
but with a significant economic impact, such as the common cold caused by 
rhinoviruses.162 In the last two decades important achievements have been made in 
the treatment of these viral infections. Nevertheless the spread of new viral diseases 
such as Zika, Ebola and new strains of hepatitis and herpes viruses has characterised 
recent years with potential for a pandemic outbreak,163–165 therefore there is 
significant unmet medical need for new antiviral agents. 
Nucleoside analogues (NA), particularly fluorinated nucleosides, represent an 
important class of antiviral agents and act as inhibitors of nucleoside reverse 
transcriptase (NRTis). Their active form is the 5’-triphosphate form and their targets 
are the catalytic residues of the viral polymerase that interact with the template, the 
primer and the incoming nucleoside 5’-triphosphates.34,166–169Uridine based 
nucleosides and ProTides have been of particular interest for the treatment of viral 
infections.34,81,122,170 
For example, Sofosbuvir (1.72), the ProTide of -D-2’-deoxy-2’--fluoro-2’--C-
methyluridine, is a recently approved anti-HCV agent characterised by a uridine 
backbone, and a fluorine in the 2’--C position of the ribose moiety.122,123,171 FIAU 
(Fialouridine) was another 2’-F-nucleoside analogue (Figure 5.1) that was selected as a 
Phase I clinical trial candidate for the treatment of HBV, however it showed 
mitochondrial toxicity resulting in lactic acidosis and hepatic failure.172,173 
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Figure 5.1: Structures of 2’-deoxy-2’-β-fluoro-5-iodouridine (FIAU, 1.66) and its 
anomer 2’-deoxy-2’-α-fluoro-5-iodouridine (2.3) 
 
After a successful Phase I clinical trial, Fialouridine (1.66) was selected to 
progress to Phase II in order to assess its safety and efficacy using a 24-week treatment 
course in 15 patients.172 After 4 weeks of treatment, a decrease in HBV-DNA levels of 
more than 90% was shown proving a clear virological response of HBV to this agent. 
Nevertheless, during the 13th week of treatment, one patient was found with an 
unexpected and sudden onset of severe hepatotoxicity and lactic acidosis leading to an 
immediate termination of the ongoing trial. Despite the termination of the trial, 7 out 
of 15 patients continued to develop a severe form of lactic acidosis and severe 
declining hepatic synthetic function and some others also showed pancreatitis, 
neuropathy and myopathy. Five patients eventually died because of these persistent 
side effects and the other two survived after an emergency liver transplant.174 
It was observed that the organs that were affected by these toxicities were the 
ones that are largely dependent on mitochondrial function. A tissue biopsy was then 
performed for further investigation, showing abnormally enlarged and irregularly 
shaped mitochondria as well as an abnormal accumulation of macrovesicular and 
microvesicular fat droplets. All these features of the multisystem toxicity can be 
somehow connected to a widespread mitochondrial injury and a disturbance in energy 
metabolism processes.115,175 
After Fialouridine trials were halted due to this unexpected and severe toxicity, 
an in-vitro study was conducted by Colacino et al. showing how Fialuridine is efficiently 
incorporated into mitochondrial-DNA (mt-DNA) by DNA polymerase-γ replacing 
thymidine therefore leading to an increased cellular toxicity.176,177 Its incorporation 
into nascent mt-DNA chains is due to the unblocked hydroxy group in the 3' position of 
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the deoxyribose moiety that allows the addition of nucleotides to the growing mt-DNA 
chain (and to a lesser extent on the nuclear-DNA (N-DNA)). This results in the 
formation of non-functional mt-DNA and N-DNA thus affecting gene expression, 
essential for the cells survival and correct functioning.176 
After the failure in 1993 of Fialouridine in Phase II clinical trial no further 
studies were conducted on its therapeutic activity or its toxicity. It was instead 
investigated as a diagnostic probe leading to the PET tracer agent [18F]FIAU (1.16) 
discussed in Chapter 4. Furthermore, no studies have been conducted on its isomer 2'-
deoxy-2'-α-fluoro-5-iodouridine that therefore represents a novel and interesting 
chemical entity. As the uridine backbone represents an already validated starting point 
to design antiviral agents, uridine based Protides and particularly fluorinated ones, 
could represent novel antiviral agents for the treatment of new viral diseases such as 
Zika, Ebola and new strains of hepatitis and herpes viruses for which there is no 
established treatment.163,178 
The aim of this project is to synthesise a novel class of 2'-deoxy-2'-fluoro-5-
iodouridine ProTides and evaluate them as antiviral agents for the treatment of newly 
arising viral diseases. It is expected that the application of the ProTide strategy could 
potentially lead to potent antiviral agents with an increased antiviral activity compared 
to their parent NA and reduced toxicity. It will be also discussed how the fluorine in the 
α- or β-2’-C position of the ribose can play a role in the activity of these NAs and their 
prodrugs.90 The synthesis of a series of 2'-deoxy-2'-α-fluoro-5-iodouridine ProTides will 
be the main target of the project as the α-anomer (2.3) represents a novel and more 
convenient starting material for the synthesis compared to the β-anomer (FIAU, 1.66). 
Nevertheless a ProTide of the β-anomer (FIAU, 1.66), will also be synthesised to 
understand whether the position of the fluorine can lead to any change in their 
antiviral activity (Figure 5.2). 
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Figure 5.2: Application of the ProTide strategy to fluorinated uridine based ProTides 
 
 
5.2 Synthesis of novel 2'-deoxy-2'-fluoro-5-iodouridine ProTides 
The synthesis of 2’-deoxy-2’-fluoro-5-iodouridine ProTides was based on 
standard ProTide chemistry84 discussed earlier in the thesis, via five major steps as 
shown in Figure 5.3. 
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Figure 5.3: General synthetic scheme for the 2’-deoxy- 2’-fluoro-5-iodouridine 
ProTides 
 
Reagents and conditions: a) I2, ceric ammonium nitrate, CH3CN, 75°C, 1h, 57-60%; b) POCl3, Et3N, -78°C 
to rt, 3h, 91%; c) Alcohol, thionyl chloride or p-toluensulfonic acid, 90°C, 3-5h, 78-89%; d) Et3N, -78°C to 
rt, anh. CH2Cl2, 3h, 80-91%; e) NMI, anh. THF, 0°C to rt, 16h, 3-12%. 
  
The first step consisted in the iodination of both the α- and β-anomers of the 
2'-fluoro-2'-deoxyuridine with I2 and ceric ammonium nitrate as catalyst (Figure 5.4) as 
described in Chapter 3.156 The purified compounds were analysed via MS and NMR. 1H-
NMR showed a singlet at δ=8.53ppm for the proton in the 6-position of the pyrimidine 
confirming the successful outcome of the reaction. 
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Figure 5.4: Iodination of the α- and β-anomers 
 
Reagents and conditions: a) I2, ceric ammonium nitrate, CH3CN, 75°C, 1h, 57-60%. 
  
Whereas phenylphosphorochloride is commercially available, the naphthyl 
derivative is not. Therefore compound 5.4 (R’’ = naphthyl) was synthesised by coupling 
naphthol with phosphorus oxychloride using triethylamine as the base and salt 
scavenger. Anhydrous solvent and nitrogen atmosphere were essential for the positive 
outcome of the reaction. The crude reaction mixture was reduced in vacuo and used 
without further purification for next step (Figure 5.5).128 
 
Figure 5.5: Formation of the naphtyl-phosphorodichloridate 
 
Reagents and conditions: b) POCl3, Et3N, -78°C to rt, 3h, 91%. 
 
L-alanine was chosen as the aminoacid for the phosphoramidate moiety 
because, as widely reported in literature, the replacement of natural amino acids with 
other amino acids such as the D-alanine179, or simple amines leads to a slight or 
complete loss of activity of these derivatives in most ProTide cases.180 L-alanine is the 
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most commonly used natural amino acid used in ProTide chemistry.181 Several esters 
of the L-alanine were used and, among them, methyl, ethyl and tert-butyl L-alanine 
esters were commercially available therefore were used directly for the coupling with 
the phosphorodichloridate.182 Isopropyl, neopentyl and benzyl L-alanine ester were 
instead synthesised via an esterification reaction of the L-alanine.  
Two methods were used to access two kinds of salts, the chloride and sulfonate 
salts of the L-alanine esters (Figure 5.6).103 The first method consisted in the reaction 
between the alcohols with L-alanine and thionyl chloride to obtain the chloride salts. 
However, sulfonate salts are considered to be more stable then the chloride salts183 
therefore the alcohols were also reacted with L-alanine and para-toluene sulfonic acid 
(p-TSA) to access also the equivalent L-alanine ester sulfonate salts (Figure 5.6). In this 
second method, to shift the equilibrium to the right and therefore to push the reaction 
to completion, Dean-stark apparatus was used to condense and thus collect the water 
produced during the reaction. To monitor the reaction, thin layer chromatography 
(TLC) was used. To confirm the formation of the product, a ninhydrin solution capable 
of detecting the amino groups of the aminoacid, was sprayed on the TLC plate eluted 
in a system of 2-propanol/water (7:3). A different Rf between the L-alanine and the 
ester salt was observed. All the L-alanine ester salts were thereafter used for the next 
step without further purification. 
 
Figure 5.6: Synthesis of the L-alanine ester salt via two methods 
 
Reagents and conditions: c) Alcohol, thionyl chloride or p-toluenesulfonic acid, 90°C, 3-5h, 75-89%. 
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Table 5.1: Structures and yields of 5.6a-e 
ID R’-X Yield 
5.6a Neopentyl chloride 75% 
5.6b Neopentyl sulfonate 83% 
5.6c Isopropyl chloride 89% 
5.6d Isopropyl sulfonate 78% 
5.6e Tert-butyl chloride 84% 
 
The phosphorochloridates were synthesised according to the standard 
procedure by the reaction of the L-alanine ester salts with aryl dichlorophosphonates 
at low temperatures under nitrogen atmosphere with TEA used as a base84 (Figure 
5.7). Formation of phosphorochloridates was confirmed by 31P-NMR. Once the 
reaction was complete, the solvent was evaporated under reduced pressure and the 
resulting solid was re-dissolved in anhydrous diethyl ether and filtered under nitrogen. 
The filtrate was then evaporated in vacuo to obtain yellowish oils that were used for 
the next step without further purification. 
 
Figure 5.7: Synthesis of the phosphorochloridates 
 
Reagents and conditions: d) L-alanine ester salt, Et3N, -78°C to rt, anh. CH2Cl2, 3h, 80- 95%. 
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Table 5.2: Structures and yields of Phosphorochloridates synthesised 
ID R R’ Yield 
3.10 Ethyl Phenyl 95% 
4.5 Benzyl Phenyl 88% 
5.7a Methyl Phenyl 80% 
5.7b Isopropyl  Phenyl 83% 
5.7c Neopentyl Phenyl 91% 
5.7d Tert-butyl Phenyl 82% 
5.7e Methyl Phenyl 85% 
5.7f Ethyl Naphtyl 94% 
5.7g Isopropyl Naphtyl 82% 
5.7 h Neopentyl Naphtyl 80% 
5.7i Tert-butyl Naphtyl 81% 
 
Finally, the methyl, ethyl, isopropyl, benzyl, neopentyl and tert-butyl 
phosphorochloridates were reacted with 2'-deoxy-2'-α-fluoro-5-iodouridine in 
anhydrous THF using N-methylimidazole to form an imidazolium intermediate with the 
phosphorochloridates that can readily react with 2'-deoxy-2'-fluoro-5-iodouridine to 
form the ProTides (Figure 5.8). 
After 24 h the reactions were stopped and the solvent was evaporated in 
vacuo. The residues were extracted with CH2Cl2 and 0.5N HCl necessary to neutralise 
the base used in the reaction. The organic layer was then concentrated under reduced 
pressure to obtain yellowish oils. All ProTides were purified by column 
chromatography using a gradient system of CH2Cl2/CH3OH (100% to 95% CH2Cl2) and, 
where necessary, also by the use of preparative TLC plates.  
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Figure 5.8: Synthesis of the ProTides 
 
Reagents and conditions: e) NMI, anh. THF, 0°C to rt, 16h, 3-12%. 
 
Table 5.3: Structures and yields of 4.3, 5.8a-5.8l 
ID Nucleoside R R’ Yield 
4.3 β Benzyl Phenyl 9% 
5.8a α Methyl Phenyl 7% 
5.8b α Ethyl Phenyl 12% 
5.8c α Isopropyl  Phenyl 3% 
5.8d α Neopentyl  Phenyl 3% 
5.8e α Tert-butyl Phenyl 6% 
5.8f α Benzyl Phenyl 11% 
5.8g α Methyl Naphtyl 4% 
5.8h α Ethyl Naphtyl 7% 
5.8i α Isopropyl  Naphtyl 5% 
5.8l α Benzyl  Naphtyl 3% 
 
The yields of the ProTides were poor for several reasons. Firstly synthesis and 
purification consisted of several steps that normally lead to an expected loss of 
products. Secondly, some intermediates were used as crude compounds without any 
purification resulting in the formation of several by-products. Finally, the hydroxyl 
group in the 3’ position of the ribose can compete with the one in 5’ position when 
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reacting with the phosphorochloridates causing the formation of several by-products. 
The use of NMI in this final step can reduce the formation of by-products. Indeed the 
Grignard reagent t-BuMgCl has proved to be very successful for the phosphorylation of 
many nucleoside analogues,85 but its use can lead to phosphorylation of the other free 
hydroxyl groups in the molecule. This can result in the formation of mixtures of 5'-
mono and 3',5'-bisphosphorylated by-products, thereby reducing the overall yield of 
the reaction. Although mixtures can be separable by column chromatography, the 
isomeric mixtures can be very difficult to separate resulting in a loss of pure product. 
 
5.3 Antiviral evaluation  
Initially antiviral evaluation was performed against Zika virus within the facility 
of Dr. Joachim Bugert at the Institut für Mikrobiologie der Bundeswehr, in Munich. Zika 
is a mosquito-borne flavivirus transmitted primarily by Aedes mosquitoes. It was first 
identified in 1947 in monkeys and later in humans in 1952 in Uganda and the United 
Republic of Tanzania. Recent outbreaks of Zika virus disease have been recorded in 
Africa, the Americas, Asia and the Pacific. Typical symptoms are similar to other 
arbovirus infections such as dengue, and include mild fever, skin rash, conjunctivitis, 
muscle and joint pain, malaise or headache. It can also lead to microcephaly and 
Guillain-Barré syndrome, and other neurological complications are also being 
investigated. There is currently no vaccine available.184 
Zika antiviral effect was first tested on DBGRT cells, glioma cells derived from 
an adult female with glioblastoma multiforme who had been treated with local brain 
irradiation and multidrug chemotherapy184,185. When the Zika antiviral effect was 
tested on DBGRT cells, none of the compounds tested (1.66, 2.29, 2.9, 4.3, 5.8a-l) 
reached the threshold of 50% protection at 10 M. Lead compounds of this series 
were interestingly the two nucleosides 2.29 and 1.66. Ribavirin (Riba) was used as 
positive control at 100 µM (Figure5.9). 
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Figure 5.9: Antiviral effect on Zika virus at 10 m on DEPG cells (n=3) 
 
 
HUH7 cells have been chosen as second line for the antiviral testing of 
compounds 1.61, 2.29, 4.3, 5.8a-l. They are well differentiated hepatocyte-
derived carcinoma cell lines, originally taken from a liver tumour in a 57-year-old 
Japanese male in 1982.184,186 They are extensively used in hepatitis C and dengue virus 
and more recently in Zika virus research conducted by Bluemling et al.187–189 When 
tested in HUH7 cells, none of the compounds synthesised reached the threshold of 
50% protection at 10M. The lead compound was again FIAU (1.66). Ribavirin (Riba) 
was again used as control at a concentration of 100M (Figure 5.10). 
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Figure 5.10: Antiviral effect of Zika virus  at 10µm on HUH7 cells (n=3) 
 
 
Cytotoxicity essays have also been performed on both cell lines. When the toxic 
effect was tested at 10M in HUH7cells, none of the compounds showed toxicity 
(Figure 5.11) but, when tested on DBGRT at 10µM, some of the compounds showed 
toxicity although the CC50 was >10M (Figure5.12). 
 
Figure 5.11: Cytotoxicity at 10µm on HUH7 cells (n=3) 
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Figure 5.12: Cytotoxicity at 10µm on DBGRT cells (n=3) 
 
 
5.4 Conclusion 
In conclusion a novel class of 2’-deoxy-2’-fluoro-5-iodouridine ProTides has 
been synthesised. The yields of the final ProTides were low because of purification 
issues associated with the intermediates and because of the presence of the hydroxyl 
group in the 3’-position of the sugar that can compete with the hydroxyl in the 5’-
position when reacting with the phosphorochloridates leading to the formation of by-
products. 
Initial antiviral tests show no activity against Zika virus when compared to the 
antiviral agent Ribavirin. No particular difference in activity has been noticed between 
the α- and β-anomers showing that position of fluorine in this particular case does not 
influence either the cytotoxicity or the antiviral activity of these compounds and 
interestingly, no increase in activity has been observed in the ProTides when compared 
to the parent lead nucleosides. Future plans will consist of performing antiviral tests 
against HSV and Dengue viruses that could be other potential targets of these novel 
fluorinated uridine based pro-nucleotides.189 
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6. Synthesis of novel FLT chimeric ProTides with 
fluorescent probes 
 
6.1 Introduction 
The scientific importance of ProTide technology in the anticancer and antiviral 
drug discovery setting has already been discussed in Chapter 1.82 Nevertheless 
questions remain surrounding the mechanism of in vivo ProTide activation, 
biodistribution and the potential toxicity of their metabolites. Although PET would be 
the most sophisticated and sensitive imaging tool to answer these questions, other 
imaging techniques could be used as a short-term approach that would give a first 
insight of the ProTide activation pathway and metabolism within in vivo models.190–192 
Fluorescence spectroscopy is a widely used technique that analyzes the 
fluorescence of molecules by using a beam of light, typically ultraviolet light, to excite 
the electrons in molecules and cause them to emit light. Measurement of fluorescence 
is taken by devices called fluorimeters.193 With the rapid development of fluorescence 
analysis technology, small-molecule fluorescent probes have been widely applied to 
track biological changes with many advantages such as high sensitivity and selectivity 
compared to other imaging tools.193,194 
The aim of this project is indeed to synthesise a small series of ProTides as 
fluorescent probes by replacing the normally used and potentially toxic phenyl and 
naphtyl groups with aromatic moieties known to have characteristic fluorescent as 
well as therapeutic properties. In particular the fluorescent probes chosen as targets 
for this project were the coumarin derivatives of FLT ProTides (Figure 6.1). 
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Figure 6.1: Structure of hybrid coumarin derivatives of FLT ProTides 
 
Coumarins, naturally occurring fluorophores from the benzopyrone family,195 have 
been chosen for this co-drug approach196 for several reasons: 
- They are non-polar cell permeable molecules with drug-like properties.197,198 
- The coumarin backbone is particularly advantageous because of its stability, 
synthetic accessibility and light emitting properties. When substituted in 
position 7 with electron-donating groups the intensity of blue fluorescence 
emitted increases remarkably197,199 (Figure 6.2). 
 
Figure 6.2: Structure of coumarin backbone 
 
 
- The 4-hydroxycoumarin pharmacophore has been shown to be a potent 
inhibitor of HIV protease leading to the approval of tipranavir (6.1),198 an anti-
HIV agent. 198,200,201 Synthetic (+)-calanolide (6.2), a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) of HIV-1, has also completed phase I/II clinical 
trials as combination therapy for HIV infection (Figure 6.3).202,203 Many other 
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coumarin derivatives are currently under clinical investigation as anti-HIV 
agents.204,205 
 
Figure 6.3: Structures of the coumarin derivatives tipranavir (6.1) and  
(+)-calanolide (6.2) 
 
 
FLT (1.29) has been selected as the nucleoside to be incorporated into this 
novel hybrid ProTide for the following reasons: 
- It was one of the first fluorinated nucleosides synthesised that showed a potent 
inhibition of reverse transcriptase in HIV strains. However it did not progress 
further in clinical trial because of dose-dependent safety concerns.53 
- ProTides of FLT have been synthesised showing also potent inhibition of HIV-1 
and HIV-2 replication.114 
- The absence of hydroxyl groups on the 2’ and 3’ position of the ribose sugar 
ensures a selective 5’- O-phosphorylation thus preventing the formation of side 
products.128 
 
This co-drug approach could represent an exciting opportunity to boost the 
antiviral activity of FLT and its ProTides by working synergistically with the coumarin 
derivative, as well as providing a novel class of fluorescent ProTide probes. It is 
proposed that coumarin-containing FLT ProTides will be characterised by an absence 
of toxicity and will have potentially a better anti-HIV activity compared to the parent 
nucleoside overcoming their resistance mechanisms. 
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6.2 Synthesis of FLT chimeric ProTides with fluorescent 
probes 
The synthesis of coumarin-derivatives of FLT ProTides was accomplished 
according to the general scheme shown in Figure 6.4. 
 
Figure 6.4: General synthetic scheme for FLT-coumarin derivative ProTides 
 
Reagents and conditions: a) POCl3, Et3N, -78°C to rt, 1h, 86-86%; b) L-alanine ester salt, anh. CH2Cl2, 
Et3N,  -78°C to rt, 2h, 71-81%; c) Phosphorochloridate, tBuMgCl, anh. THF, 0°C to rt, 16 h, 5-11%. 
 
Two coumarin derivatives have been chosen as starting materials to form the 
phosphorochloridate, the 4-methylumbelliferone (4-MU) (6.3a, R = Me) and the 7-
hydroxy-4-(trifluoromethyl)coumarin (4-TF) (6.3b, R = CF3).  
4-MU (6.3a), besides being a pH-sensitive fluorescent indicator, is also currently 
used for the treatment of biliary spasm. It inhibits hyaluronic acid synthesis that is a 
factor often associated with diseases such as tumour progression.205–207 4-MU is 
indeed under investigation as an anticancer agent because of its ability to inhibit 
proliferation, migration and invasion of cancer cells.207,208 It also showed activity 
against chronic hepatitis C and B and is currently in Phase II clinical trials under the 
registered name of Heparvit.209 Recent studies also suggest its potential for future HIV-
1 reservoir eradication strategies.210 
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4-TF (6.3b) is used as fluorescent probe for the imaging of enzymes such as 
endoplasmic reticulum carboxylesterases, enzymes involved in the cleavage of ester-
containing prodrugs.211,212 Although 4-TF has not shown any therapeutic activity, its 
application to ProTide strategy could be useful for in vivo imaging of the ProTide 
activation pathway into cells. 
The first step consisted of the synthesis of phosphorochloridates according to 
the standard procedure shown in Chapter 3 and 5.128 In this case the appropriate 
coumarin derivative was coupled with phosphorus oxychloride using triethylamine as 
the base, and HCl scavenger. Anhydrous conditions were again essential for the 
successful outcome of the reaction therefore all the synthetic procedures have been 
conducted under nitrogen atmosphere. Compounds were obtained in good yields and 
were used for the next step without further purification (Figure 6.5). 
 
Figure 6.5: Synthesis of the phosphorodichloridates 
 
Reagents and conditions: a) POCl3, Et3N, -78°C to rt, 1h, 86-88%. 
 
Step b consisted of the formation of the phosphorochloridates by reacting the 
phosphorodichloridates with the appropriate L-alanine esters using TEA as the base 
and anhydrous conditions as per the previously reported standard procedure.128 The 
reaction mixture was monitored by 31P NMR and after 1h at rt the conversion of the 
starting material into the product was complete, therefore the reaction was stopped, 
reduced under vacuum and stored in the freezer under a strict nitrogen atmosphere 
(Figure 6.6). 
 
 
 
 6. Synthesis of novel FLT chimeric ProTides with fluorescent probes 
122 
 
Figure 6.6: Synthesis of the phosphorochloridate 
 
Reagents and conditions: b) L-alanine ester salt, CH2Cl2, Et3N, -78°C to rt, 2h, 71-81%. 
 
Step c consisted of the coupling between the commercially available FLT with 
the freshly synthesised phosphorochloridate. Tert-butyl magnesium chloride (tBuMgCl) 
was used as base following the standard procedure showed in Chapter 3.22 The 
reaction mixture was dried under vacuum and purified using silica gel column 
chromatography. (Figure 6.7) 
 
Figure 6.7: Synthesis of the phosphoramidates 
 
Reagents and conditions: c) Phosphorochloridate, tBuMgCl, anhydrous THF, 0°C to rt, 16 h, 5-11%. 
 
Attempts to synthesise other coumarin derivatives of FLT ProTides bearing a 
benzyl, isopropyl or neopentyl L-alanine ester where performed but all intermediate 
reactions (step a and b) led to the formation of numerous by-products. Attempts at 
purification using silica gel column chromatography were performed leading to further 
decomposition of the intermediates because of their instability and sensitivity to air. 
Attempts to synthesise their equivalent ProTides by using the non-purified 
reaction mixtures led to formation of ProTides in very poor yield (0.1-0.3%) so that the 
isolation by gradient flash column chromatography was not successful due to the 
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formation of side products with similar Rf values. Despite many attempts at further 
purification via preparative TLC, no successful isolation of these compounds was 
achieved.  
ProTides 6.6a and 6.6b were instead isolated as diastereisomeric mixtures in 
the ratio of roughly 1:1 as yellowish solids with yield ranging from 5-11%. All ProTides 
and intermediates were characterised by MS, 31P-NMR, 1H-NMR,19F-NMR, COSY-NMR, 
13C-NMR and HSQC-NMR. 
As mentioned before, 31P-NMR was used to monitor formation of most 
products and intermediates. Despite using stringent anhydrous and inert conditions, 
31P-NMR revealed the presence of side products in most of the crude mixtures of 
intermediates that were synthesised. 
The use of non-purified mixtures has probably contributed to the formation of 
many side products. To increase the yield and prevent the formation of too many by-
products, it is suggested for the future to purify the crude phosphorochloridate 
mixtures by preparative HPLC. 
 
6.3 Fluorescence data  
Measures of fluorescence emission of the Protides synthesised has been taken 
to compare them with the parent coumarin derivatives.213 Compound 6.6a emitted no 
fluorescence, however the 4-MU (6.3a) emitted at short wavelengths. Compound 6.6b 
showed a weak fluorescence emission at the same wavelength as the parent 4-FT 
(6.3.b) (500 nm). 
 
Figure 6.8: Fluorescence emission spectrum of compound 6.3a, 6.3b and 6.6b 
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These preliminary data suggest that these ProTides could be used as 
fluorescent Probes as they possess different UV absorption fluorescence wavelengths 
and intensity compared to their parent coumarin derivatives. Therefore, a change in 
UV fluorescence could be observed during metabolism in vivo when the coumarin is 
cleaved off the ProTide. This change could be useful to visualise ProTide uptake in vivo, 
and thus confirm whether ProTides are activated inside the cells as speculated. 
 
6.4 Conclusion 
In conclusion two novel ProTides of FLT containing coumarin derivatives and L-
alanine esters as masking groups (6.6a, 6.6b), have been synthesised as models of a 
new class of ProTide fluorescent probes. These novel compounds are characterised by 
fluorescence properties that may allow the visualisation of their uptake thus 
demonstrating their activation mechanism. This co-drug approach with coumarin 
derivatives could also boost the anti-HIV properties of the parent NA FLT. Another six 
ProTides were synthesised but couldn’t be isolated because of the formation of 
numerous side products, instability issues, poor yield and difficult purification process. 
All ProTides and by-products have been characterised by MS and NMR spectroscopy. 
It is recommended for the future to test these compounds in in vitro models to 
assess their efficacy and potency as anti-HIV and more generally as antiviral agents. If 
efficacious, they could be optimised by altering the coumarin moiety with other 
coumarins known to have anti-HIV activity or simply by increasing the lipophilicity of 
the parent coumarin to facilitate their cell permeability. This could increase the anti-
HIV efficacy of FLT ProTides even further. The drawback of this co-drug approach, as 
for any other co-drug approaches, could be the issue with dosing.196,214 Therapeutic 
doses for FLT and for the coumarin derivative could be different so that the 
administration of both drugs as one co-drug may not be feasible. Nevertheless, UV 
absorbance and fluorescence data could still be used to visualise uptake and activation 
mechanism of this class of novel FLT chimeric ProTides with fluorescent probes in in 
vivo models. 
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7. Conclusions and future work 
 
7.1 General conclusions and future perspective 
The phosphoramidate (ProTide) technology developed by McGuigan and co-
workers from 1995 onwards is considered to be the most effective pro-nucleotide 
approach currently used in the clinic.17 Fluorinated nucleosides and ProTides represent 
a significant class of anticancer and antiviral agents used in the clinic and in clinical 
development. Fluorine plays a crucial rule in the optimization of these clinical agents 
and candidates by improving their selectivity, toxicity, potency, and pharmacokinetic 
and pharmacodynamic properties.34 
In order to visualize pharmaceutical and biological effects of fluorinated 
ProTides directly in vivo, [18F]-radiolabelled ProTides have been synthesised for the 
first time as PET imaging probes. These imaging biomarkers represent a proof of 
concept for the ProTide strategy and a model system to visualize their pharmaceutical 
and biological effects directly in vivo. Two [18F]-radiolabelled ProTides have been 
synthesised as model standards for two classes, the 2’- and the 3’-fluorinated ProTides. 
The 3’-[18F]FLT ProTide (2.1) was synthesised via a convenient late stage 
[18F]fluorination of ad hoc designed precursor molecules. Among the five precursor 
molecules synthesised, the nosyl derivative furnished the desired product in poor 
yields therefore protection of the NH moieties of the molecule with BOC protecting 
groups was performed to minimize the formation of undesired by-products. This 
protection increased remarkably the yield of the reaction furnishing the desired 
radiolabelled BOC protected compound that was then deprotected to finally furnish 
the desired target compound 2.1 in good radiochemical yield and radiochemical purity. 
The 2’-[18F]FIAU ProTide (2.2) was synthesised following a different synthetic 
approach involving an early stage [18F]-fluorination of the sugar moiety with an overall 
synthetic time of 4h.   
This was the first time that [18F]-radiolabelled ProTides have ever been 
synthesised. Although these results have to be regarded as first trials of their synthesis, 
these radiolabelled probes could provide evidence for the in vivo behaviour of this 
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class of compounds answering key questions about their metabolism and uptake 
directly. 
For the future it is recommended to investigate different set-ups such as the 
use of different automated synthetic modules, microwave-assisted synthesis and 
microfluidic systems in order to validate the potential clinical application of these 
radiosyntheses. These radiolabelled ProTides not only could represent a first step 
towards ProTide personalised medicine but, on the other hand, could also represent a 
novel class of PET imaging diagnostic probes. 
Other imaging techniques could also be used to provide insight into ProTide 
activation pathways in vivo.215 For this reason novel ProTides of FLT containing 
coumarin derivatives (6.6a, 6.6b), have been synthesised as new potential fluorescent 
probes and therapeutic agents. By incorporating the coumarin moiety, these new FLT 
ProTides are characterised by fluorescence properties, which should allow the 
visualisation of their uptake thus demonstrating their activation mechanism. As some 
coumarin derivatives are also characterised by interesting antiviral therapeutic 
properties, this could also be considered as a co-drug approach that could boost the 
anti HIV properties of the parent NA FLT. Future work will investigate their efficacy and 
potency as anti-HIV and more generally as antiviral agents. Where efficacious, 
optimization of the coumarin moiety with respect to anti-HIV properties could be 
performed in order to boost their therapeutic activity. UV absorbance and 
fluorescence data will be used to visualise uptake and the activation mechanism of this 
class of novel FLT chimeric ProTides with fluorescent probes within in vivo models. 
Besides the use of imaging techniques to study the mechanism of action of 
ProTides, a novel class of cold, non-fluorescent 2’-deoxy-2’-fluoro-5-iodouridine 
ProTides (2.9, 4.3, 5.8a-l) have been synthesised and tested as antiviral agents in 
response to the high demand of novel antiviral agents against the outbreak of new 
viral diseases or against novel strains of well-known viruses.178 Initial antiviral tests 
against Zika virus did not show any activity of these fluorinated uridine based ProTides 
when compared to Ribavirin, but further investigation on other viruses such as Dengue 
and HSV are currently ongoing. 
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8. Experimental 
 
8.1 General information 
8.1.1 Analytics 
1H NMR spectra were measured on a Bruker Avance Ultra Shield spectrometer 
(500 MHz) at ambient temperature. Data were recorded as follows: chemical shift in 
δppm from internal standard tetramethylsilane; multiplicity (s =singlet; d = doublet; t = 
triplet; m = multiplet); coupling constant (Hz), integration and assignment. 13C NMR 
spectra were measured on a Bruker Avance Ultra Shield spectrometer (125 MHz) at 
ambient temperature. Chemical shifts were recorded in ppm from the solvent 
resonance employed as the internal standard (e.g. CDCl3 at 77.00 ppm). 
31P NMR 
spectra were recorded on a Bruker Avance Ultra Shield spectrometer (202 MHz) at 
ambient temperature. 19F NMR spectra were recorded on a Bruker Avance Ultra Shield 
(474 MHz) spectrometer at ambient temperature. Highperformance liquid 
chromatography (HPLC) analysis was conducted on an Agilent Technology 1200 Series 
System with an analytical reversed phase column (Phenomenex Synergi 4μ Hydro- RP 
80, C-18, 4.6×250 mm) and with a semi-preparative reversed phase column 
(Phenomenex Synergi 4μ Hydro-RP 80, C-18, 10×250 mm) both coupled with a RAM/ 
RAM Model 4 detector (Lablogic System, Ltd.) for radio-HPLC purposes. Thin-layer 
chromatography (TLC) was conducted on pre-coated silica gel 60 GF254 plates. 
Preparative TLC plates (20x20 cm, 500-2000 silica) were purchased from Merck. Radio-
TLC was performed on a Canberra UNISPEC 125. Mass spectrometry analysis (LC-ESI-
MS) was performed on a Bruker micro-TOF or on an Agilent 6430 T-Quadrupole 
spectrometer. High-resolution mass spectrometry (ESI-HRMS was performed at the 
EPSRC National Mass Spectrometry facility at Swansea University. 
 
8.1.2 Solvents and chemicals 
All the anhydrous solvents and reagents were purchased from Sigma-Aldrich 
and they were used without further purification. Some nucleosides used as starting 
materials were purchased from Carbosynth Ltd. UK. Fluka silica gel (35-70 mm) was 
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used as stationary phase for column chromatography. Radioactive material was 
purified with QMA and Al cartridges (Waters corp., Milford, MA, USA). 
 
8.1.3 Radioactive source and equipment 
18F-Fluoride was produced in an IBA Cyclon 18/9 cyclotron using the 18O(p,n)18F 
nuclear reaction. 18O-Enriched water (enrichment grade 98%, 2.2 mL, Nukem GmbH 
Germany) was irradiated with 18MeV protons. An Eckert & Ziegler module system was 
used to perform the radiofluorinations. A vacuum pump N820 (Neuberger, Freiburg, 
Germany) was used for the drying process. Smartline pump 100 126 was used for the 
semi-preparative HPLC attached to the Eckert & Ziegler module system. 
 
8.2 Procedures  
Described below are the standard procedures followed in the synthesis of L-
alanine ester salts, phosphorochloridates and the ProTides.128 
 
8.2.1 Standard procedure A1: synthesis of L-alanine ester 
hydrochloride salts 
Thionyl chloride (2.0 mol/eq) was added dropwise to a stirring solution of the 
appropriate alcohol (15.0 mol/eq) at 0°C under nitrogen atmosphere. The reaction was 
allowed to stir at 0°C for 0.5 hr then slowly allowed to warm to room temperature (r.t). 
L-alanine (1.0 mol/eq) was added dropwise and the mixture was heated under reflux 
overnight. The reaction was monitored by TLC using 2-propanol/water (7:3) and 
ninhydrin solution. The solvent was removed in vacuo with last traces of solvent 
removed by azeotropic co-evaporation to give a solid crude product. 
 
8.2.2 Standard procedure A2: synthesis of L-alanine ester 
sulfonate salts 
A mixture of L-alanine (1.0 mol/eq), the appropriate alcohol (15.0 mol/eq) and 
para-toluene sulfonic acid (p-TSA) monohydrate (1.1 mol/eq) in toluene was heated 
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under reflux overnight using the Dean-Stark apparatus. The reaction was monitored by 
TLC using 2-propanol/water (7:3) and ninhydrin solution. The solvent was then 
removed in vacuo with last traces of solvent removed by azeotropic co-evaporation to 
give a solid crude product. 
 
8.2.3 Standard procedure B: synthesis of aryloxy 
phosphorochloridates 
To a solution of an appropriate amino acid ester salt (1.0molequivalent) and 
phenyl dichlorophosphate (1.0 mol/eq) in anhydrous CH2Cl2, anhydrous triethylamine 
(TEA) (2.0 mol/eq) was added dropwise at -78°C under a nitrogen atmosphere. The 
reaction mixture was then stirred at -78°C for 1h, then at r.t for 3h. The reaction was 
monitored by 31P-NMR. The solvent was removed under reduced pressure and the 
residue triturated with anhydrous diethyl ether. The precipitate was filtered under 
nitrogen and the filtrate was concentrated to produce the product as an oil. 
 
8.2.4 Standard procedure C: synthesis of phosphoramidates  via 
NMI 
To a stirring solution of an appropriate nucleoside (1.0 mol equivalent) in 
anhydrous tetrahydrofuran (THF) at 0°C under nitrogen atmosphere, N-
methylimidazole (NMI) (5.0mol equivalent) was added and the reaction was stirred for 
30 min. A solution of an appropriate phosphorochloridate (3.0mol equivalent) 
dissolved in THF was then added dropwise and the reaction was stirred at r.t for 18h. 
The reaction was monitored by TLC with CH2Cl2/CH3OH (9:1). The solvent was then 
removed in vacuo to give a residue that was re-dissolved in CH2Cl2 and washed twice 
with 0.5N HCl. The organic phase was dried over MgSO4, filtered and reduced to 
dryness to give a crude product that was purified by flash column chromatography 
eluting with CH2Cl2/CH3OH in different proportions depending on the specific analogue 
being synthesised. 
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8.2.5 Standard procedure D: synthesis of phosphoramidates via 
tBuMgCl 
To a stirring solution of the appropriate nucleoside (1 mol/eq) in anhydrous 
THF under a nitrogen atmosphere, tBuMgCl (1.1 mol/eq) was added, and stirred for 10 
min. The appropriate phosphorochloridate (1.2 mol/eq) dissolved in anhydrous THF 
was added to the reaction mixture dropwise. The reaction mixture was left stirring at 
rt for 24 h, then anhydrous THF solvent removed by evaporation in vacuo at rt. The 
crude product was purified by flash column chromatography eluting with 
CH2Cl2/CH3OH in different proportions depending on the specific analogue being 
synthesised. 
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8.3 Spectroscopic data 
8.3.1Experimental section from Chapter 3 
 
(3R,5R)-3-(hydroxymethyl)-8-methyl-2,3-dihydro-5H,9H-2,5-methanopyrimido[2,1-
b][1,5,3]dioxazepin-9-one. (3.5) 
 
MF: C10H12N2O4 
MW: 224.22 
 
A  mixture  of  thymidine (1.28)(1eq, 0.250g,  1.032mmol)  and  triphenylphosphine 
(Ph3P)  (2eq, 0.541g, 2.064mmol) was suspended in anhydrous acetonitrile (20mL) and 
cooled down to -15°C. To this mixture diisoproprylazadicarboxylate (DIAD) (2eq, 
0.406mL, 0.417g, 2.64 mmol) was added dropwise maintaining the temperature 
below -5°C with vigorous stirring. After the addition the reaction was left to stir for 5h 
at 0°C. Following this, the mixture was again cooled down to -20°C and ethyl acetate 
(20mL) was added at the same temperature and stirred for other 15min. The white 
precipitate formed, was collected by Buchner filtration and washed with cold ethyl 
acetate. The filtrate solution was reduced to dryness and the resulting compound was 
purified by silica g e l  column chromatography using 9 0 % CH2Cl2-10%CH3OH as 
eluent to obtain the product 3.5 as a white solid. Yield: 52%. Rf: 0.5. 
 
1H-NMR (500 MHz, DMSO-d6): δppm 7.55 (d, J=1.2Hz, 1H, ArH), 5.80 (d, J=3.9Hz, 1H, 
H-1’), 5.23 (brs, 1H, H-3’), 5.01 (t, 1H, C-5’OH), 4.20 (m, 1H, H-4’), 3.51 (m, 2H,  H-5’, H-
5”), 2.55 (d, J=1.2Hz, H-2’,1H), 2.47 (ddd, J1,8=19Hz, J1,4=6.7Hz, J1,2=3Hz, 1H,  H-2”), 1.76 
(d, J=1.1Hz, 3H, CH3). , . 
Note: Data agrees with previously published papers.216 
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(2S)-ethyl-2-((chloro(phenyl)phosphoryl)amino)propanoate. (3.10) 
 
 
MF: C11H15ClNO4P 
MW: 291.6 
 
Compound 3.10 was prepared according to standard procedure B. Anhydrous 
triethylamine (2eq; 0.662mL; 0.480g; 4.74mmol), phenyldichlorophosphate (3.9) (1eq; 
0.354 mL; 0.500 g; 2.37 mmol) and L-alanine ethyl ester hydrochloride salt (1eq; 
0.364g; 2.37mmol) in anhydrous CH2Cl2 (5mL) were used to obtain the final compound 
(3.10) as a yellowish oil which wasn’t further purified. Yield: 92%. 
 
1H-NMR (500 MHz, CDCl3): δ ppm 7.35-7.41 (m, 2H, Ar-H), 7.21-7.30 (m, 3H, Ar-H), 4.53 
(m, 1H, NH),  4.21 (m, 1H, CH), , 3.95 (m, 2H, CH2), 1.51 (m, 3H, CH3), 1.23 (m, 3H, CH3). 
31P-NMR (202 MHz, CDCl3): δppm 7.71, 8.05. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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Ethyl((((3R,5R)-8-methyl-9-oxo-2,3-dihydro-5H,9H-2,5-methanopyrimido[2,1- 
b][1,5,3]dioxazepin-3-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (3.8) 
 
 
 
MF: C21H26N3O8P 
MW: 691.3 
 
Compound 3.8 was synthesised according to standard procedure C. 2’-3’-
anhydrothymidine (3.5) (1eq; 0.175g; 0.780mmol), NMI (5eq; 0.331mL; 0.320g; 
3.9mmol) and ethyl(2chloro(phenyl)phosphorylamino)propanoate (3.10) (3 eq; 
0.684g; 2.34mmol) were reacted to obtain a residue that was purified by silica gel 
column chromatography (CH2Cl2/ CH3OH gradient from 100%CH2Cl2  to 95%CH2Cl2) 
to furnish the desired product (3.8) as a yellowish oil. Yield: 0.6%. 
 
1H-NMR (500 MHz, CDCl3): δppm7.40 (d, J=3.9Hz, 1H, H6), 7.23 (td, J=7.8, 2.8Hz, 2H, 
CH-phenyl), 7.13 (d, J=7.6Hz, 2H, CH-phenyl), 7.09 (t, J=7.6Hz, 1H, CH-phenyl), 5.89 
(ddd, J = 31.8, 16.5, 1.9 Hz, 1H, 1'-CH), 4.39 (d, J= 7.0 Hz, 2H, 5'-CH2), 4.22 (m, 1H,2'-
CH), 4.1 (m, 1H, 3'-CH), 4.09 (m, 1H, 4'-CH), 3.86 (d, J=10.7Hz, 1H, NH-ala), 3.76 (m, 2H, 
CH2-ester), 3.29 (dd, J=7.0, 4.9Hz, 1H, CH-ala), 1.21 (dd, J=10.3, 6.4Hz, 3H, CH3-ala), 
1.15 (t, J=7.0Hz, 3H, CH3-ester).  
13C-NMR (125 MHz, CDCl3): δppm174.70 (C=O, ala), 
171.41 (C-4), 169.00 (C-2), 151.51 (C-6), 139.86, 128.13 (Ar-C and Ar-CH), 100.87, 94.73 
(C-5), 91.20, 90.21 (C-4'), 89.12, 88.41 (C-3'), 85.7, 84.31 (C-1'), 63.41(C-5'),62.17, 62.12 
(CH3-ester), 59.21 (CH-ala), 55.75 (C-3’), 43.12 (C-2’), 30.01, 28.76 (CH3-ala). 
31P-NMR 
(202 MHz, CDCl3): δppm3.71, 3.43. MS (ESI)+: 692.3 [M+H+]. HPLC: Rt: 10.03 min 
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(95%). *Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% 
H2O/50% CH3CN- (20’) 95% H2O/5% CH3CN]. 
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1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-
methylpyrimidine- 2,4(1H,3H)-dione. (3.6) 
 
 
 
MF: C10H14N2O5 
MW: 242.2 
 
A mixture of 2’-3’-anhydrothymidine (3.5) (0.200g; 0.892mmol) and aq. 1.5M NaOH 
(3.33mL) was stirred in methanol (30mL) under reflux for 3h. The clear solution 
changed colour to gold brown upon heating. The reaction was monitored by TLC 
analysis. Once the reaction was complete, the solvent was removed by evaporating 
under reduced pressure. The crude compound was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from100% to 90% of CH2Cl2) to obtain the 
product (3.6) as a white powder. Yield: 64%. (Rf: 0.4 in 90%CH2Cl2/10%CH3OH TLC 
system). 
 
1H-NMR (500 MHz, DMSO-d6): δppm 11.24 (s, 1H, NH), 7.78 (s, 1H, H-6), 6.07 (dd, J = 
8.5, 2.44 Hz, 1H, H-1’), 5.25 (d, J=3.35Hz, 1H, 3’-OH), 4.67 (t, J= 5.49Hz, 1H, 5’-OH), 4.23 
(m, 1H, H-3’), 3.60-3.84 (m, 3H, H-4’, H-5’ and H-5”), 2.55-2.59 (m, 1H, H-2”), 1.84 (dd, 
J=14.95Hz, J=2.14Hz, 1H, H-2’), 1.76 (s, 3H, CH3). 
 
 
Note: Data agrees with previously published papers. 216 
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(2S)-methyl2-(((((2R,3R,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)- yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. 
(3.7b) 
 
 
MF: C20H26N3O9P 
MW: 483.4 
 
Compound 3.7b was synthesised according to the standard procedure C. 1-(2-deoxy-β-
lyxofuranoxyl thymidine) (3.6) (1eq; 0.109g; 0.45mmol), NMI (5eq; 0.177mL; 0.183g, 
2.23mmol) and methyl-(2-chloro(phenyl)phosphorylamino)propanoate (5.7a) (3eq; 
0.350g; 1.34mmol) were reacted to obtain a residue that was purified by silica gel 
column chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to 
afford the product 3.7b  as a white solid. Yield: 9.3%. 
 
1H NMR(500 MHz, CDCl3): δppm 7.56 (d, J = 7 Hz, 1H, H-6), 7.33-7.41 (m, 2H, Ar- H), 
7.22-7.31 (m, 3H, Ar-H), 6.24-6.31 (m, 1H, H-1’), 5.25 (m, 1H, 3’-OH), 4.98 (m, 1H, H-
3’), 4.30-4.51 (m, 2H, NH, H-4’), 3.94-4.02 (m, 1H, CH), 3.67 (s, 3H, OCH3), 3.38 (d, J = 
16 Hz, 2H, H-5’, H-5”), 2.45-2.47 (m, 1H, H-2”), 2.07-2.23 (m, 1H, H-2’), 1.850 (d, J = 10 
Hz, 3H, CH3 -Thy), 1.15-1.38 (m, 3H, CH3 -Ala). 
31P NMR: (202 MHz, CDCl3): δppm 5.34, 
4.89 
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(2S)-ethyl2-(((((2R,3R,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)- yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 
 
 
MF: C21H28N3O9P 
MW: 497.4 
 
Compound 3.7 was prepared according to standard procedure C. 1-(2-deoxy-β-
lyxofuranoxyl thymidine) (3.6) (1eq; 0.175g; 0.721mmol), NMI (5eq; 0.287mL; 0.297g, 
3.62mmol) and ethyl-(2-chloro(phenyl)phosphorylamino)propanoate (3.10) (3eq; 
0.633g; 2.17mmol) were reacted to obtain a residue that was purified by silica gel 
column chromatography (97% CH2Cl2/3% CH3OH) to afford the product as a white solid. 
Yield: 18.4 %. Rf: 0.4 
 
1H-NMR (500 MHz, CDCl3): δppm7.58 (d, J=7 Hz , 1H, H-6), 7.35-7.43 (m, 2H, Ar-H), 
7.20-7.29 (m, 3H, Ar-H), 6.25-6.32 (m, 1H, H-1’), 5.22 (m, 1H, 3’-OH), 4.94 (m, 1H, H-
3’), 4.31-4.52 (m, 2H, NH, H-4’), 3.95-4.03 (m, 1H, CH), 3.68 (d, J=7Hz,2H, CH2-ester), 
3.35 (d, J=16Hz, 2H, H-5’, H-5”), 2.48-2.51 (m, 1H, H-2”), 2.09-2.25 (m, 1H, H-2’), 1.85 
(d, J=10Hz, 3H, CH3-thy), 1.16-1.23 (m, 6H, CH3-ester). 
31P-NMR (200 MHz, CDCl3): 
δppm5.34, 4.98. 
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(2S)-ethyl2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3- 
((methylsulfonyl)oxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino) 
propanoate. (3.1) 
 
 
 
MF: C22H30N3O11PS  
MW: 575.5 
 
Triethylamine (10eq; 1.06mL; 0.769g; 7.6mmol) and mesyl chloride (4 eq; 0.235mL; 
0.348g; 3.04mmol) were added to a solution of the compound 3.7 (1eq; 0.378g; 
0.76mmol) in dry CH2Cl2 (20mL) at 0°C. The mixture was stirred at this temperature for 
additional 10 minutes before it was allowed to warm up to rt and it was stirred for 1.5 h. 
After full conversion of the starting material, the mixture was diluted with sat. NaHCO3-
solution and extracted with CH2Cl2 (2x 20mL). After drying over Na2SO4, the solution 
was reduced in vacuo and the resulting compound was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to afford 
the product (3.1) as a white solid. Yield: 29.5%. Rf: 0.45 in 90%CH2Cl2/10%CH3OH TLC 
system.  
 
1H NMR (500 MHz, CDCl3): δppm 8.93-8.96(s, 1H, NH, thy), 7.33-7.32 (d, J=7 Hz, 1H, 
H-6), 7.24-7.28 (m, 2H, Ar-H), 7.10-7.15 (m, 3H, Ar-H), 6.23-6.21 (m, 2H, H-1’), 5.19-5.15 
(s, 1H, NH-ala), 3.84-4.37 (m, 1H, H-3’; 1H, H-4’; 1H, CH; 2H, H-5’, H-5”; 4H, CH2-ala), 
2.96-3.01 (s, 3H, SO2CH3), 2.72-2.75 (m, 1H, H-2”), 2.38-2.42 (m, 2H, H-2’), 1.87 (d, 
J=1Hz, 3H, CH3-thy), 1.28-1.33 (m, 3H , CH3-ala), 1.19-1.16 (m, 3H, CH3-ala).  
13C NMR 
(125 MHz, CDCl3) δppm 173.7-173.4 (C=O, acetyl), 163.6 (C-2), 150.42 (C-1), 135.1 (C-4), 
129.8 (C-2; C-6Ar), 125.2 (C-4Ar), 120.2 (C-3; C-5Ar), 111.6 (C-3), 83.5 (C-1’), 79.9(C-
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3’), 77.3 (C-4’), 63.7 (C-5’), 61.7 (CH2-Ala), 50.8 (CH-ala), 39.2 (C-2’), 38.8 (CH3-mesyl), 
21.34 (CH3-ethyl), 14.04 (CH3-ala), 12.76 (CH3-thy).
 31P NMR (202MHz, CDCl3): δppm 
2.92, 2.63. MS(ESI+): 576.2 [M+H+]. HPLC: Rt: 13.2 min (98%). *Gradient: (0’) 
95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% 
H2O/5% CH3CN].   
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(2S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3- 
(tosyloxy)        tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. 
(3.2) 
 
 
MF: C28H34N3O11PS 
MW: 651.6 
 
The ProTide 3.7  (1 eq; 0.181g; 0.364mmol) was dissolved in pyridine (5mL) at 0°C 
and tosylchloride (2eq; 0.138g; 0.727mmol) and silvertrifluoromethansulfonate (AgOTf) 
(2eq; 0.186g; 0.727mmol) were added. The reaction mixture was stirred for 1h at 
0°C and then it was allowed to slowly warm down to rt. It was then stirred at rt for 
other 2h. After, the reaction mixture was diluted with EtOAc, it was filtered, and the 
filtrate was washed with H2O and brine. The organic layer was dried over Na2SO4 
anhydrous and the solvent was evaporated under reduced pressure. The residue was 
purified by silica gel column chromatography (95% CH2Cl2/5% CH3OH) to give the 
product 3.2 as a yellowish solid. Yield: 35%; Rf: 0.55. 
 
1H NMR (500 MHz, CDCl3) δppm7.76-7.75 (d, J=1.9Hz, 1H, H6 Ar), 7.34 (dd, J=15.7, 
8.6Hz, 4H, Ar-H tosyl), 7.27–7.17 (m, 5H, Ar), 6.19-5.20 (td, J=7.8, 2.9Hz, 1H, H-1’) , 
4.45-3.74 (m, 12H), 2.72–2.61 (m, 1H, CH-ala), 2.46 (s, 3H, CH3, tosyl), 1.85 (s, 3H, CH3, 
thym), 1.39 (t, J=7.2 Hz, CH3, ethyl), 1.31 (m, 3H, CH3-ala). 13C NMR (126 MHz, CDCl3) 
δppm 173.65, 173.59 (C-ala), 163.52 (C1-t hy), 150.58, 150.53 (C3-thy), 150.25, 
150.19(C1-tosyl), 145.99, 145.98 (C1-phenyl), 135.04, 134.95 (CH- thy), 133.05, 
132.90 (C4-tosyl), 130.27, 130.21(CH, C2, C6-tosyl), 129.75, 129.70 (CH, C2, C6- 
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phenyl), 127.64, 127.58 (CH,C4-phenyl), 125.10, 120.35 (CH, C3, C5-phenyl), 120.31, 
120.21 (CH,  C3, C5- tosyl), 111.15, 110.98 (C3-thy), 84.22, 83.99 (CH, C1’), 80.96, 
80.90 (CH, C3’), 80.72, 80.66 (CH, C4’), 63.89, 63.85 (CH2, C6’), 63.33, 63.29(CH2, ethyl), 
50.39, 50.38(CH, ala), 39.03 (CH2, C3’), 21.69, 21.00 (CH3-ethyl), 20.96, 20.95 (CH3-
tosyl), 14.12 (CH3, ala), 12.49, 12.44 (CH3-thy). 
31P NMR (202 MHz, CDCl3) δppm 2.78, 
2.66. MS (ESI)+: 652.2 [M +H+]; 674.1 [M + Na+]. HPLC: Rt: 16.03 min (98%). [Gradient: 
(0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 
95% H2O/5% CH3CN]. 
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2S)-ethyl2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-(((4- 
nitrophenyl)sulfonyl)oxy)tetrahydrofuran-2yl)methoxy)(phenoxy)phosphoryl)amino) 
propanoate. (3.3) 
 
 
 
MF: C27H31N4O13PS 
MW: 682.5 
 
The ProTide 3.7 (1eq; 1.16g; 2.34 mmol) was dissolved in pyridine (20mL) at 0°C and 4-
nitrobenzenesulfonylchloride (nosyl chloride) (2eq; 1.06g; 4.79mmol) and 
silvertrifluoromethansulfonate (AgOTf) (2eq; 1.23g; 4.79 mmol) were added. The 
reaction mixture was stirred for 1h at 0°C and then it was allowed to slowly warm down 
to rt. It was then stirred at rt for other 2h. After the reaction mixture was diluted 
with EtOAc, it was filtered, and the filtrate was washed with H2O and brine. The organic 
layer was dried over Na2SO4 anhydrous and the solvent was evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography (95% 
CH2Cl2/5% CH3OH) to give compound 3.3 as  yellowish solid. Yield: 60%. Rf: 0.6. 
 
1H NMR (500 MHz, CDCl3) δppm8.77-8.67 (s, 1H, NH, thy), 8.41-8.39 (d, J=2.2Hz, 2H-Ar, 
nosyl), 8.14–8.08 (m, 2H-Ar, nosyl), 7.71(ddd, J=7.6, 4.7, 1.7 Hz, 1H, H6-Ar), 7.42–7.30 
(m, 5H-Ar), 6.28–5.28 (m, 1H-H-1’) , 4.51–3.75 (m, 6H), 2.79-2.46 (m, 1H, CH-ala), 1.96–
1.86 (m, 2H, H2’), 1.37 (t, J=7.6 Hz, 3H, CH3 ester), 1.31–1.25 (m, 6H, CH3-thy, CH3-ala). 
13C NMR (126 MHz, CDCl3) δppm173.66, 173.36 (C-ala), 163.48(C2, thy), 151.13, 151.10 
(C1, thy), 150.29, 150.25 (C1,nosyl), 141.45, 141.35 (C1, phenyl), 134.73, 134.67 (CH, 
thy), 129.86, 129.81 (CH, C2-6, nosyl), 129.15, 129.13 (CH, C2, C6, phenyl), 125.28 (CH, 
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C4, phe), 124.84, 124.77 (CH, C3, C5, phenyl), 120.15, 120.11 (CH, C3, C5, nosyl), 
120.06, 120.02, 111.36, 111.23 (C, C3, thy), 84.14, 84.00 (CH, C1’), 80.58, 80.52 (CH, 
C3’), 80.25, 80.18 (CH, C4’), 63.17, 63.14 (CH2, C5’), 62.82, 62.79(CH2, ethyl), 50.41, 
50.20 (CH,ala), 39.18, 39.16 (CH2, C2’), 20.94, 20.90 (CH3, ethyl), 14.12, 14.11 (CH3, ala), 
12.58, 12.56 (CH3, thy). 
31P NMR (202 MHz, CDCl3) δppm2.75, 2.48. MS (ESI)
+: 705.1 [M 
+ Na+]. HPLC: Rt: 15.88 min (99%). *Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% 
H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% H2O/5% CH3CN]. 
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Tert-butyl 3-((2R,4R,5R)-5-(((((tert-butoxycarbonyl)((S)-1-ethoxy-1-oxopropan-2-
yl)amino)(phenoxy)phosphoryl)oxy)methyl)-4-(((4-
nitrophenyl)sulfonyl)oxy)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-3,6-
dihydropyrimidine-1(2H)-carboxylate. (3.4) 
 
 
MF: C37H47N4O17PS 
MW: 882.83 
 
The nosylate precursor (3.3) (1eq, 0.050g, 0.073mmol) was dissolved in pyridine (6mL) 
at rt under nitrogen atmosphere. Diterbutyl dicarbonate (BOC2O) (1.3eq, 0.021ml, 
0.020g, 0.095mmol) was added dropwise and the reaction was allowed to stir for 3 
days. The crude product was then evaporated in vacuo and was purified by silica gel 
column chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2to 95% CH2Cl2) to 
obtain the product 3.4 as a yellowish oil. Yield: 56%. Rf: 0.67 in 90% CH2Cl2/10% 
CH3OH as TLC system. 
 
1H NMR (500 MHz, CDCl3) δppm8.47–8.36 (d, 2H, J=2.2Hz, Ar, nosyl), 8.17–8.08 (m, 
2H, Ar, nosyl), 7.38 (m, 1H, Ar), 7.32–7.24 (m, 4H), 7.17 (s, 1H, Ar), 6.31–6.24 (m, 1H-H-
1’), 4.51–3.75 (m, 7H), 2.78-2.43 (m, 1H, CH-Ala), 2.31–2.23 (m, 1H-H-2’), 2.01 (m, 3H, 
CH3,thy), 1.53–1.49 (m, 9H, CH3, tert-butyl), 1.44 (m, 9H, CH3, tert-butyl), 1.38 (t, 
J=7.6Hz, 3H, CH3, ester), 1.31 (m, 3H, CH3,ala). 13C NMR (126 MHz,  CDCl3) 
δppm175.50, 174.29 (C,ala), 161.32 (C2, thy), 150.13, 150.08 (C1, thy), 150.02, 150.00 
(C1, nosyl) 143.51, 142.21 (C1,  phenyl), 132.71, 132.23 (CH, thy), 130.68, 129.99 (CH, 
C2-C6, nosyl), 129.34, 129.5 (CH, C2,C6, phenyl), 126.28 (CH, C4, phe), 125.79, 
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124.85 (CH, C3, C5, phe), 120.15, 120.13 (CH, C3,C5, nosyl), 120.06, 120.02, 111.36, 
111.23 (C, C3, thy), 84.13, 84.10 (CH, C1’), 80.78-80.77 (C-tert-butyl), 80.58, 80.52 
(CH, C3’), 80.25, 80.18 (CH, C4’), 63.21, 63.20 (CH2, C5’), 62.79, 62.77 (CH2, ethyl), 
50.39,  50.30 (CH, ala), 39.18, 39.15 (CH2, C2’), 28.41-28.23 (CH3, tert-butyl), 20.94, 
20.90 (CH3, Ethyl), 14.12, 14.11 (CH3, ala), 12.58, 12.56 (CH3, thy). 
31PNMR: (202 MHz, 
CDCl3): δppm2.61-2.53. MS (ESI
+): 905.83 [M + Na+]. HPLC: Rt: 17.1 min (99%). 
*Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% 
CH3CN- (20’) 95% H2O/5% CH3CN]. 
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2S)-ethyl2-(((((2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- 
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. (3.11) 
 
 
 
MF: C21H27FN3O8P 
 MW: 499.4 
 
To a stirring solution of FLT (1.29) (1eq; 0.100g; 0.41mmol) in anhydrous THF, was 
added under nitrogen atmosphere tButMgCl (1.5eq; 0.08mL) and the reaction mixture 
was stirred at rt for 30min. Then a solution of the phosphorochloridate 3.10 (2eq; 
0.239g; 0.82mmol) in anhydrous THF was added dropwise to the reaction mixture and 
was left to stir overnight. The solvent was evaporated under reduced pressure and the 
resulting residue was purified by silica gel column chromatography (CH2Cl2/CH3OH 
from 100% CH2Cl2 to 95% CH2Cl2) to afford the product 3.7 as a yellowish oil. Yield: 
23.5 %. (Rf: 0.44 in 90%CH2Cl2-10%CH3OH TLC system). 
 
1H NMR (500 MHz, CDCl3): δppm8.60 (br s, 1H, NH), 7.55 (s, 1H, H-6), 7.33-7.41 (m, 2H, 
Ar-H), 7.20-7.29 (m, 3H, Ar-H), 6.23-6.30 (m, 1H, H-1’), 5.33 (m, 1H, H-3’), 4.43-4.53 
(m, 1H, NH, H-4’), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 3.35-3.51 (m, 2H, H-5’, H-5”), 
2.48-2.51 (m, 1H, H-2”), 2.55–2.33 (m, 2H, H2’), 1.93–1.74 (m, 3H, CH3, thy), 1.30-1.18 
(d, J=6.9Hz, CH3-ala). 
19F-NMR (479 MHz, CDCl3): δppm-173.70, -175.20. 
31P NMR (202 
MHz, CDCl3): δppm4.34, 4.12. MS (ESI
+): 498.1 [M + H+]. HPLC: Rt: 10.8 min (96%). 
*Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% 
CH3CN- (20’) 95% H2O/5% CH3CN]. 
 
Note: Data agrees with previously published papers.114   
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Tert-butyl-3-((2R,4S,5R)-5-((((N-((S)-1-ethoxy-1-oxopropan-2-yl)-3,3-
dimethylbutanamido)(phenoxy)phosphoryl)oxy)methyl)-4-(fluoro-
18F)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-
carboxylate. (3.12) 
 
 
 
MF: C32H45
18FN3O11P 
MW: 696.70 
Aqueous 18F (2.5 GBq), produced by the cyclotron by the nuclear reaction, was 
trapped in a QMA cartridge before it was eluted with an aqueous solution of KHCO3 and 
Kryptofix in CH3CN. The resulting 
18F/KHCO3/Kryptofix complex was dried by co-
evaporation with CH3CN anhydrous (2x 1 mL) under reduced pressure and a stream of 
nitrogen. A solution of the precursor 3.4 (20mg) in CH3CN anhydrous (1mL) was added 
ad the reaction was stirred for 30 mins at 95°C. The resulting mixture was passed 
through an alumina cartridge to finally obtain the radiolabelled product 3.12. The 
reaction mixture was analyzed by analytical HPLC and radio TLC. (Analytical HPLC: (0’) 
95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50%CH3CN- (20’) 
95%H2O/5%CH3CN); Rt: 15 min. 
 
 
CH3CNDMSO
Bkg 1
Region 1
Bkg 2
Region 2
Bkg 3
0:00 5:00 10:00 15:00 mm:ss
0.0
10000.0
20000.0
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Ethyl ((((2R,3S,5R)-3-(fluoro-18F)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (2.1) 
 
 
MF: C21H27
18FN3O8P 
MW: 498.43 
 
The BOC protected [18F]-radiolabelled ProTide (3.12) was transferred into a V-vial. A 
solution of 2N HCl (1mL) was added and it was allowed to stir for 10 mins. It was then 
neutralised with NaOH 2N. The compound was then purified by semi-preparative HPLC 
and was eluted after 35 minutes at a flow rate of 3.5 mL/min using 70% H2O/30% 
MeCN as the mobile phase. The HPLC solvent was then removed from the mixture 
under a stream of nitrogen. The radioactive product was taken up in saline and 
subsequently flushed through a sterility filter to obtain a sterile and clean aqueous 
solution of [18F]FLT ProTide (2.1). RCY of 15-30% (n=5, decay-corrected from end of 
bombardment (EoB)), with high radiochemical purities (97%) and specific activities of 
1800 mCi/μmol. The total synthesis time was 130 min after the end of bombardment 
(EoB). The reaction mixture was analyzed by analytical HPLC and radio TLC. 
(Analytical HPLC: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% 
H2O/50%CH3CN- (20’) 95%H2O/5%CH3CN); Rt: 10.8 min).  
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8.3.2 Experimental section from chapter 4 
 
2’deoxy-2’-α-F-5-iodouridine. (1.66) 
 
MW: 372.1 
MF: C9H10FIN2O4 
 
To a solution of 2’-β -fluoro-2’-deoxyuridine (4.4) (2eq; 2g; 8.12mmol) in anhydrous 
acetonitrile (50mL), iodine (1.2eq; 1.24g; 4.87mmol) and ceric ammonium nitrate 
(CAN) (1eq; 2.23g; 4.062mmol) were added. The reaction mixture was stirred at 75°C 
for 1h and it was then quenched with a saturated solution of Na2S2O3 and 
concentrated. The residue was re-dissolved in ethyl acetate and washed twice with 
brine. The organic layer was dried under MgSO4, filtered and concentrated in vacuo to 
give compound 1.66 as a pale yellow solid. Yield: 60%. HPLC: Rt: 2.3 min (95%). 
98%H2O/2%CH3CN. 
 
 
1H-NMR (500 MHz, DMSO-d6): δppm11.69 (s, 1H, NH), 8.53 (s, 1H, 6-CH), 5.86 (d, 
J=15.8Hz, 1H, 1'-CH), 5.60 (d, J=6.4Hz, 1H, 3'-OH), 5.39 (t, J=4.5Hz, 1H, 3'-CH), 5.04 (dd, 
J=53.2, 4.1Hz, 1H, 2'-CH), 4.18 (ddd, J=23.4, 11.4, 7.2Hz, 1H, 4'-CH), 3.90 (d, J=8.2Hz, 
1H, 5'-OH), 3.85–3.79 (m, 1H, 5'-CH), 3.63–3.58 (m, 1H, 5'-CH). 13C-NMR (125 MHz, 
DMSO-d6): δppm167.88 (C=O), 165.01 (C=O), 145.02 (C-6), 125.19 (C-2'), 121.26 (C-1'), 
115.81 (C-4'), 61.11 (C-5), 57.30 (C-3'), 45.87 (C-5'). 19F-NMR (470 MHz, DMSO-d6): 
δppm-202.09. 
 
Note: Data agrees with previously published papers.155 
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Benzyl (chloro(phenoxy)phosphoryl)-L-alaninate. (4.5) 
 
 
MW: 353.73 
MF: C16H17ClNO4P 
 
 
Compound 4.5 was prepared according to the standard procedure B. Anhydrous 
triethylamine (2eq; 1.26mL; 0.918g; 9.08mmol), phenyl dichlorophosphate (3.9)(1eq; 
0.678mL; 0.958 g; 4.54 mmol) and L-alanine benzyl ester hydrochloride salt ( 1eq; 
1.50g; 4.54mmol) were reacted to afford compound 4.5 as a yellowish oil which wasn’t 
further purified. Yield: 88%. 
 
1H NMR (500MHz, CDCl3): δppm7.54–7.47 (m, 7H, Ar-H), 7.46–7.40 (m, 3H, Ar-H), 5.27 
(d, J=8.4Hz, 2H, CH2-ester), 4.69 (d, J=9.9Hz, 1H, NH), 4.13 (dd, J=34.4, 29.8 Hz, 1H, CH-
ala), 1.52 (m, 3H, CH3-ala). 
31P NMR (202 MHz, CDCl3): δppm8.03-7.75. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
 
  
 
 8. Experimental 
151 
 
Benzyl ((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin- 
1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (4.3) 
 
 
MF: C25H26FIN3O9P 
MW: 689.3 
 
Compound 4.3 was prepared according to the standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(1.66) (1eq; 0.400g; 1.07mmol), NMI (5eq; 0.424mL; 0.439g; 5.35mmol), benzyl-2-
(chloro(phenoxy)phosphorylamino)propanoate (4.5)(3eq; 1.05g; 3.22mmol) were 
reacted to obtain a residue that was purified by silica gel column chromatography 
(CH2Cl2/CH3OH from 100% CH2Cl2 to 95% CH2Cl2) to obtain the product 4.3 as a yellowish 
oil. Yield: 10%. 
 
1H NMR (500 MHz, CDCl3): δppm10.59 (s, 1H, 3-NH), 7.89 (s, 1H, 6-CH), 7.53–7.48 (m, 
2H, CH-phenyl), 7.45 (t, J=8Hz, 2H, CH-phenyl), 7.41-7.38 (m, 2H, CH-benz), 7,17-7.15 
(m, 2H, CH-benz), 7.13 (t, 8Hz, 1H, CH-benzyl), 7.12 (t, J=7.4 Hz, 1H, CH-phenyl), 5.99 
(m, 1H, 1'-CH), 5.79 (dd, J=47.6, 4.6 Hz, 1H, 2'-CH), 5.14 (m, 2H, CH2-benz), 4.90 (m, 2H, 
5'-CH2), 4.39 (m, 1H, 4'-CH), 4.27 (m, 1H, 3'-CH), 4.19 (m, 1H, 3'-OH), 4.02 (m, 1H, NH-
ala), 3.99 (m, 1H, CH-ala), 1.29 (d, J=7.0Hz, 3H, CH3-ala). 
13C NMR (125 MHz, CDCl3): 
δppm 171.9 (C=O, ala), 168.12 (C-4), 144.18 (C-2), 149.0 (C-phenyl), 147.91 (C-
benzyl), 145.5, 145.1 (C-6), 128.31-121.48 (Ar-C), 94.3 (C-5), 92.10 (C-4'), 89.13 (C-2'), 
83.6, 82.97 (C-1'), 81.08, 80.97 (C-ester), 69.61, 68.14 (C-3'), 67.23 (C-5'), 52.8 (CH-ala), 
21.98 (CH3-ala). 
19F NMR (470 MHz, CDCl3): δ-200.91, -201.15. 
31P NMR (202 MHz, 
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CDCl3): δppm3.90, 3.86. MS (ESI)
+: 690.3 [M + H+]. HPLC: Rt: 13.4 min (97%). [Gradient: 
(0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 
95% H2O/5% CH3CN]. 
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(2R,3S,4R,5R)-5-((benzoyloxy)methyl)-3-(fluoro-18F)tetrahydrofuran-2,4-diyl 
dibenzoate. (4.2) 
 
 
MF: C26H21
18FO7 
MW: 463.4 
 
Aqueous 18F (4.11 GBq), produced by the cyclotron by the nuclear reaction, was 
trapped in a QMA cartridge before it was eluted with an aqueous solution of KHCO3 and 
Kryptofix in CH3CN. The resulting 
18F/KHCO3/Kryptofix complex was dried by co-
evaporation with CH3CN anhydrous (2x 1mL) under reduced pressure and a stream of 
nitrogen. A solution of the triflate precursor of the sugar (4.1) (20 mg) in CH3CN 
anhydrous (1 mL) was added and the reaction was stirred for 30 mins at 95°C. The 
resulting mixture was passed through an alumina cartridge to finally obtain the 
radiolabelled product that was used for next step without any further purification. The 
reaction mixture was analyzed by analytical HPLC and radio TLC. (Analytical HPLC: 
100% CH3CN; Rt: 8.3 min). 
 
 
 
 
Note: Data agrees with previously published papers.155 
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5-iodo-2,4-bis((trimethylsilyl)oxy)pyrimidine. (4.7) 
 
 
MF: C10H19IN2O2Si2 
MW: 382.3 
 
To a solution of 5-iodouracil (4.6) (1eq; 10mg; 0.042mmol) in dichloroethane 
(500μL), hexamethyldisilazane (11.4eq; 100μL; 0.0774mg; 0.479mmol) and TMSOTf 
(13.1eq; 100μl, 0.123mg; 0.549mmol) were added into a 4mL vial on a hot plate 
placed into a hot cell. The mixture was stirred for 2h at 85°C. The crude mixture was 
used directly for next step without further purification. The purity of the compound 
was proved by analytical HPLC (88% H2O/12% CH3CN, Rt= 6.9 min) and LC-MS ([M+H
+]: 
383.2). 
 
 
 
Note: Data agrees with previously published papers.155 
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18FIAU 
1-((2R,3S,4R,5R)-3-(fluoro-18F)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5- 
iodopyrimidine-2,4(1H,3H)-dione. (1.16) 
 
 
MF: C9H10
18FN2O5 
MW: 371.0 
 
Compound synthesised with the E&Z modular lab (4.2), was delivered directly from 
the unit to the vial containing 2-4-bis(trimethyl silyl)-5-iodo uracil (4.7). The mixture 
was then heated at 85°C for 60 min. To this mixture, 0.5M of NaOMe in CH3OH (1mL) 
was added and the reaction was stirred at 85°C for other 5 min. The precipitate was 
reconstituted in water (1mL) and neutralized with 6N HCl. The reaction mixture was 
then analyzed by analytical HPLC showing the formation of the 2 anomers α and β of 
the 2’-deoxy-2’-fluoro-5-iodouridine. (Analytical HPLC: 98% H2O/2% CH3CN; Rt : α 
anomer 2.1 min; β anomer 2.9 min). The anomeric mixture was then purified by semi-
preparative HPLC and the target compound (1.16) was eluted after 7.3mins at a flow 
rate of 3.5mL/min using 20% CH3CN/ 80% H2O as the mobile phase to obtain the final 
compound which was analysed by analytical HPLC. (Analytical HPLC: 98% H2O/2% 
CH3CN; Rt: 2.1min). 
 
 
Note: Data agrees with previously published papers.155  
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[18F]FIAU ProTide. (2.2) 
 
 
MF: C25H26
18FIN3O9P 
MW: 688.3 
 
To the vial containing [18F]FIAU (1.16) under nitrogen atmosphere, NMI (0.1mL) was 
added dropwise and the solution of benzyl-2-
(chloro(naphtoxy)phosphorylamino)propanoate (4.5) (0.050g) dissolved in anhydrous 
THF (0.5ml) was added dropwise. The reaction mixture was stirred at 50°C for 20 
mins  and then dried under a flow of nitrogen, re-dissolved in CH3CN  and then was 
indeed isolated via semi preparative HPLC and was eluted after 23 minutes at a flow 
rate of 3.5mL/min using 50% MeCN/ 50% H2O as the mobile phase. The HPLC solvent 
was removed from the mixture under a stream of nitrogen. The radioactive product 
was taken up in saline and subsequently flushed through a sterility filter to obtain a 
sterile and clean aqueous solution of [18F]FIAUProTide (2.2). Radiochemical reactions 
were carried out using starting activities between 4-15 GBq, leading to RCY of 1-5% 
(n=7, decay-corrected from end of bombardment (EoB)), with high radiochemical 
purities (98%) and specific activities of 1800 mCi/μmol. The total synthesis time was 
240 min after the end of bombardment (EoB). (Analytical HPLC: (0’) 95%H2O/5%ACN - 
(5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50%CH3CN- (20’) 95%H2O/5%CH3CN); Rt: 12.3 
min. 
 
 8. Experimental 
157 
 
 
  
0:00 5:00 10:00 15:00 mm:ss
0.0
100.0
200.0
300.0
400.0
Counts
 
 8. Experimental 
158 
 
8.3.3 Experimental section from chapter 5 
 
2’-deoxy- 2’α-fluoro-5-iodouridine 
 
 
MW: 372.1 
MF: C9H10 FIN2O4 
 
 
To a solution of 2’-α-fluoro-2’-deoxyuridine(2eq; 2g; 8.12mmol) in anhydrous 
acetonitrile (50 ml), iodine (1.2eq; 1.24g; 4.87mmol) and ceric ammonium nitrate (CAN) 
(1eq; 2.23g; 4.062mmol) were added. The reaction mixture was stirred at 75°C for 1h 
and it was then quenched with a saturated solution of Na2S2O3 and then 
concentrated. The residue was re-dissolved in ethyl acetate and washed twice with 
brine. The organic layer was dried under MgSO4, filtered and concentrated in vacuo to 
give a pale yellow solid. Yield: 60%. 
 
1H NMR (500 MHz, DMSO-d6): δppm11.69 (s, 1H, NH), 8.53 (s, 1H, 6-CH), 5.86 (d, 
J=15.8 Hz, 1H, 1'-CH), 5.60 (d, J=6.4Hz, 1H, 3'-OH), 5.39 (t, J=4.5Hz, 1H, 3'-CH), 5.04 (dd, 
J=53.2, 4.1Hz, 1H, 2'-CH), 4.18 (ddd, J=23.4, 11.4, 7.2 Hz, 1H, 4'-CH), 3.90 (d, J=8.2Hz, 
1H, 5'-OH), 3.85–3.79 (m, 1H, 5'-CH), 3.63–3.58 (m, 1H, 5'-CH). 13C NMR (125 MHz, 
DMSO-d6): δ 167.88 (C=O), 165.01 (C=O), 145.02 (C-6), 125.19 (C-2'), 121.26 (C-1'), 
115.81 (C-4'), 61.11 (C-5), 57.30 (C-3'), 45.87 (C-5'). 19F NMR (470 MHz, DMSO-d6): 
δppm-202.09. HPLC: Rt: 2.0 min (97%). 98%H2O/2%CH3CN.  
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Naphthalen-1-yl phosphorodichloridate(5.4) 
 
 
MF: C10H7Cl2O2P 
MW: 261.03 
 
Phosphorus oxychloride (1eq; 0.912mL; 1.5g; 9.78mmol) and 1-naphtol (1eq; 1.41g; 
9.78mmole) were stirred in anhydrous Et2O under nitrogen atmosphere. Anhydrous 
TEA (1eq; 1.36 ml; 0.990 g; 9.78mmoles) was added dropwise at -78°C. The reaction 
mixture was then allowed to stir for 1h and then to slowly warm to rt and stirred for 
other 3h. The reaction was monitored by 31P NMR. The crude mixture was then filtered 
under nitrogen atmosphere and reduced under pressure to furnish a yellowish oil 
which wasn’t further purified. Yield: 98%. 
 
1H NMR (CDCl3, 500MHz): δppm 8.01-8.00 (m, 1H, H-8), 7.81-7.79 (m, 1H, H-5), 7.70-
7.68 (m, 1H, H-4), 7.63-7.52 (m, 4H, H-2, H-3, H-6, H-7). 31P NMR (CDCl3, 202 MHz): 
δppm 3.88. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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(S)-1-(neopentyloxy)-1-oxopropan-2-aminium – chloride. (5.6a) 
 
 
MF: C8H18 Cl NO2 
MW: 195.6 
 
Compound 5.6a was prepared according to standard procedure A1. Thionyl chloride 
(2eq; 1.63mL, 2.66g, 22.44mmol), neopentyl alcohol (15eq; 12.88mL; 10.11g; 
0.168mol), L-alanine (1eq; 1g; 0.0112mol) were reacted to give the product 5.6a a 
yellowish oil which wasn’t further purified. Yield: 57%. 
 
1H NMR (500 MHz, CDCl3): δppm8.56 (s, 3H, NH3
+), 4.92 (s, 2H, CH2-neopentyl), 3.92 
(m, 1H, CH-ala), 1.39 (d, J=7.5 Hz, 3H, CH3-ala), 1.21 (d, J=6.0Hz, 9H, 3xCH3-neopentyl). 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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(S)-1-(neopentyloxy)-1-oxopropan-2-aminium - 4-methylbenzenesulfonate. (5.6b) 
 
 
MF: C15H25NO5S 
MW: 331.4 
 
Compound 5.6b was prepared according to standard procedure A2. L-alanine (1eq; 
0.500g; 5.61mol), 2,2-dimethyl-1-propanol (15eq; 9.07mL; 7.41g; 0.084mol) and p-
toluenesulfonic acid (1.1eq; 1.17g; 6.17mmol) were reacted to give as a product a 
white solid (5.6b) which wasn’t further purified. Yield: 83%. 
 
1H NMR (500 MHz, CDCl3): δppm8.29 (s, 3H, NH3
+), 7.49 (d, J=7.9Hz, 2H, CH-tosylate), 
7.13 (d, J=7.7Hz, 2H, CH-tosylate), 3.89 (m, 1H, CH-ala), 3.06 (s, 2H, CH2-ester), 2.30 (s, 
3H, CH3-tosylate), 0.94 (s, 3H, CH3-ala), 0.86–0.79 (m, 9H, 3xCH3-ester). 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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(S)-1-isopropoxy-1-oxopropan-2-aminium chloride. (5.6c) 
 
 
MF: C6H14ClNO2 
MW: 167.6 
 
Compound 5.6c was prepared according to standard procedure A1. Thionyl chloride 
(2eq; 1.63mL, 2.66g, 22.44mmol), 2-propanol (isopropanol) (15eq; 12.88mL; 10.11g; 
0.168mol) were reacted to give 5.6c as a white solid. Yield: 89%. 
 
1H NMR (500 MHz, CDCl3): δppm8.66 (s, 3H, NH3
+), 4.98 (dt, J=12.5, 6.2Hz, 1H, CH-
ester), 3.96 (m, 1H, CH-ala), 1.41 (d, J=7.2Hz, 3H, CH3-ala), 1.24 (d, J = 6 Hz, 6H, 2xCH3, i-
propyl). 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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S)-1-(tert-butoxy)-1-oxopropan-2-aminium chloride. (5.6e) 
 
 
MF: C7H16ClNO2 
MW: 146.21 
 
Compound 5.6e was prepared according to standard procedure A1. Thionyl chloride 
(2eq; 1.63mL, 2.66g, 22.44mmol), tert-butanol  (15eq; 12.88mL; 10.11g; 0.168mol) and 
L-alanine (1eq; 1g; 0.0112mol) were reacted  to furnish compound 5.6e as yellowish 
solid. Yield: 84%. 
 
1H NMR (500 MHz, CDCl3): δ 8.56 (s, 3H, NH3
+), 3.99 (m, 1H, CH-ala), 1.36 (d, J=7.1Hz, 
3H, CH3-ala), 1.19 (s, 9H, 3xCH3, tert-butyl). 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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(S)-1-isopropoxy-1-oxopropan-2-aminium 4-methylbenzenesulfonate. (5.6d) 
 
 
MF: C13H24O5S 
MW: 171.19 
 
Compound 5.6d was prepared according to standard procedure A2. L-alanine (1eq; 
0.500g; 5.61mol), isopropanol (15eq; 9.01mL; 7.39g; 0.081mol) and p-toluenesulfonic 
acid (1.1eq; 1.17g; 6.17mmol) were used as reagents to give 5.6d as a white solid 
which wasn’t further purified. Yield: 78%. 
 
1H NMR (500 MHz, CDCl3): δppm8.34 (s, 3H, NH3
+), 7.51 (d, J=7.8Hz, 2H, CH-tosylate), 
7.09 (d, J=7.5Hz, 2H, CH-tosylate), 3.90 (m, 1H, CH-ala), 3.06 (m, 1H, CH-ester), 2.11 (s, 
3H, CH3-tosylate), 1.11 (s, 3H, CH3-ala), 0.86–0.79 (d, J=7.2 Hz 2xCH3-ester). 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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(2S)-methyl 2-((chloro(phenyl)phosphoryl)amino)propanoate. (5.7a) 
 
 
MF: C10H13ClNO4P 
MW: 277.6 
 
Compound 5.7a was prepared according to standard procedure B. Phenyl 
dichlorophosphate (3.9) (1eq; 0.250g; 1.18mmol), L-alanine methyl ester 
hydrochloridate salt (1eq; 0.165g; 1.18mmol), triethylamine (2eq; 0.239g; 0.329mL; 
2.36mmol) were used as reagents to furnish 5.7a as a yellowish oil. Yield: 80%. 
 
1H NMR (500 MHz, CDCl3): δppm 7.25-7.39 (m, 2H, Ar-H), 7.21-7.37 (m, 3H, Ar-H), 4.30 
(m, 1H, NH), 4.19 (m, 1H,CH-ala), 3.50 (s, 3H, CH3-ester), 1.21 (m, 3H, CH3-ala). 
31P 
NMR: (202 MHz, CDCl3): δppm 7.96, 7.64. 
 
 
Note: Data agrees with previously published papers.85,103,156 
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Ethyl (chloro(phenoxy)phosphoryl)-L-alaninate. (3.10) 
 
 
MF: C11H15ClNO4P 
MW: 291.6 
 
Compound 3.10 was synthesised according to standard procedure B. Anhydrous 
triethylamine (2eq; 0.662mL; 0.480g; 4.74mmol), phenyl dichlorophosphate (3.9) (1 
eq; 0.354mL; 0.500g; 2.37mmol) and L-alanine ethyl ester hydrochloride salt (1eq; 
0.364g; 2.37mmol) were reacted to afford the  product 3.10 as a yellowish oil. Yield: 
95%. 
 
1H NMR (500MHz, CDCl3): δppm 7.35-7.41 (m, 2H, Ar-H), 7.21-7.30 (m, 3H, Ar-H), 4.53 
(m, 1H, NH), 4.21 (m, 1H,CH), 3.95 (m, 2H, CH2), 1.51 (m, 3H, CH3-ala), 1.23 (m, 3H, 
CH3-ester). 
31P NMR (202 MHz, CDCl3): δppm 8.05, 7.71. 
 
 
Note: Data agrees with previously published papers.85,103,156 
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Isopropyl(chloro(phenoxy)phosphoryl)-L-alaninate (5.7b) 
 
 
MF: C12H17ClNO4P 
MW: 305.69 
 
Compound 5.7b was synthesised according to standard procedure B. Anhydrous 
triethylamine (2eq; 1.08mL; 0.78g; 7.74mmol), phenyl dichlorophosphate (3.9) (1eq; 
0.579 ml; 0.818 g; 3.87mmol) and L-alanine isopropyl ester hydrochloride salt (1eq; 
0.650g; 3.87mmol) were reacted to afford 5.7b as a yellowish oil which wasn’t further 
purified. Yield: 83%. 
 
1H NMR (500 MHz, CDCl3): δppm 7.28 (m, 2H, CH-phenyl), 7.23 (m, 2H, CH-phenyl), 
7.08 (m, 1H, CH-phenyl), 4.98 (m, 1H, CH-i-propyl), 4.37 (s, 1H, NH), 4.04 (m, 1H, CH-
ala), 1.30 (d, J=7.5, 3H, CH3- ala), 1.16 (dd, J=9.7, 3.5Hz, 6H, 2xCH3-ester). 
31P NMR 
(202MHz, CDCl3): δppm 8.18, 7.84. 
 
 
Note: Data agrees with previously published papers. 85,103,156  
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Tert-butyl (chloro(phenoxy)phosphoryl)-L-alaninate. (5.7c) 
 
 
MW: 319.72 
MF:C13H19ClNO4P 
 
Compound 5.7c was prepared according to the standard procedure B.  Anhydrous 
triethylamine (2eq; 0.661ml; 0.48g; 4.74mmol), phenyl dichlorophosphate (3.9) (1eq; 
0.354mL; 0.500g; 2.37mmol) and L-alanine tert-butyl ester hydrochloride salt (5.6e) 
(1eq; 0.430g; 2.37mmol) were reacted to afford 5.7c as a yellowish oil which wasn’t 
further purified. Yield: 91%. 
 
1H NMR (500 MHz, CDCl3): δppm 7.28 (ddd, J=14.7, 9.4, 4.0Hz, 2H, CH-phenyl), 7.10–
7.00 (m, 3H, CH-phenyl), 4.31 (m, 1H, NH), 3.98 (m, 1H, CH-ala), 1.60 (d, J=7,1Hz, CH3-
ala), 1.53 (s, 9H, 3xCH3). 31P NMR (202 MHz, CDCl3): δppm 8.24, 7.82. 
 
 
Note: Data agrees with previously published papers. 85,103,156  
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Neopentyl(chloro(phenoxy)phosphoryl)-L-alaninate. (5.7d) 
 
 
MW: 333.74 
MF: C14H21ClNO4P 
 
 
Compound 5.7d was synthesised according to the standard procedure B. Anhydrous 
triethylamine (2eq; 1.26mL; 0.918g; 9.08mmol), phenyl dichlorophosphate (3.9) (1eq; 
0.678mL; 0.958g; 4.54 mmol) and L-alanine neopenthyl ester sulfonate salt (5.6b) (1eq; 
1.50g; 4.54mmol) were reacted  to afford compound 5.7d as a yellowish oil which 
wasn’t further purified. Yield: 82%. 
 
1H NMR (500MHz, CDCl3): δppm 7.33–7.21 (m, 2H, H-Ar), 7.11 (m, 3H, H-Ar), 3.97–3.83 
(m, 1H, NH), 3.82–3.70 (m, 2H, CH2-ester), 3.68 (m, 1H, CH-ala), 0.90–0.84 (s, 9H, 3x 
CH3-ester), 0.82 (d, J=3.5Hz, 3H, CH3-ala). 
31P NMR (202 MHz, CDCl3): δppm 8.12, 7.80. 
 
 
Note: Data agrees with previously published papers. 85,103,156   
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Methyl(chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (5.7e) 
 
 
MW: 327.70 
MF: C14H15ClNO4P 
 
 
Compound 5.7e was prepared according to standard procedure B. Anhydrous 
triethylamine (2eq; 1.61mL; 1.17g; 11.54mmol), naphtyl dichlorophosphate (5.4) (1eq; 
1.50g; 5.77mmol) and L- alanine methyl ester hydrochloride salt (1eq; 0.805g; 
5.77mmol) were used as reagents to afford  the compound 5.7e as a yellowish oil 
which wasn’t further purified. Yield: 85%. 
 
1H NMR (CDCl3, 500 MHz): δppm 7.89-7.15 (m, 7H, Naph), 4.29-4.25 (m, 1H, NH), 4.31-
4.20 (m, 1H, CH- ala), 3.81-3.64 (s, 3H, CH3-ester), 1.34 (d, J=3.5Hz, 3H, CH3-ala). 
31P 
NMR (CDCl3, 202 MHz): δppm 7.99, 7.87. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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Ethyl(chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate. (5.7f) 
 
 
MF: C15H17ClNO4P 
MW: 341.72 
 
 
Compound 5.7f was prepared according to standard procedure B. Anhydrous 
triethylamine (2eq; 1.61mL; 1.17g; 11.54mmol), naphtyl dichlorophosphate (5.3) 
(1eq; 1.50g; 5.77mmol) and L-alanine ethyl ester hydrochloride salt (1eq; 0.886g; 
5.77mmol) were reacted to afford the product 5.7f as a yellowish oil which wasn’t 
further purified. Yield: 94%. 
 
1H NMR (CDCl3, 500 MHz): δppm 8.31-8.26 (m, 1H, H-8, naph), 7.63-751 (m, 1H, H-6, 
naph), 7.74-7.71 (m, 1H, H-2, naph), 7.52-7.43 (m, 4H, naph), 4.39 (m, 1H, CH-ala), 
4.21 (q, 2H,  CH2-ester), 1.58-1.54 (m, 3H, CH3-ala), 1.41-1.29 (d, J=6.3Hz 3H, CH3-
ester). 
31P NMR (CDCl3, 202 MHz): δ 8.13, 7.89. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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Isopropyl(chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate. (5.7g) 
 
 
MF: C16H19ClNO4 
MW: 355.75 
 
Compound 5.7g was prepared according to standard procedure B. Anhydrous 
triethylamine (2eq; 0.749mL; 0.54g; 5.38mmol), naphtyl dichlorophosphate (5.4) (1eq; 
0.7g; 2.69mmol) and L-alanine isopropyl ester hydrochloride salt (5.6c) (1eq; 0.45g; 
2.69mmol) were reacted to afford product 5.7g as a yellowish oil which wasn’t further 
purified. Yield: 82%. 
1H NMR (CDCl3, 500MHz): δppm 8.09 (m, 1H, H-8, naph), 7.89-7.86 (m, 1H, H-6, naph), 
7.76-7.73 (m, 1H, H-2, naph), 7.59-7.44 (m, 4H, naph), 5.12-5.05 (m, 1H, CH, i-propyl), 
4.43-4.20 (m, 1H, CH-ala),  1.56-1.51  (d, J=3.1Hz, 3H, CH3-ala),  1.31-1.23  (d, J=4.5Hz, 
6H, 2x CH3, i-propyl). 
31P-NMR (CDCl3, 202 MHz): δ 8.15, 7.99. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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Benzyl(chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (5.7h) 
 
 
MF: C20H19ClNO4P 
MW: 403.79 
 
Compound 5.7h was prepared according to standard procedure B. Anhydrous 
triethylamine (2eq; 0.749mL; 0.54g; 5.38mmol), naphtyl dichlorophosphate (5.3) 
(1eq; 0.7g; 2.69mmol) and L-alanine benzyl ester hydrochloride salt (1eq; 0.45g; 
2.69mmol) to furnish the product 5.7h. Yield: 80% 
 
1H NMR (CDCl3, 500MHz): δppm 7.83-7.35 (m, 12H, naph and phenyl), 5.13-5.04 (m, 
2H, CH2Ph), 4.41-4.31 (m, 1H, CHCH3), 1.51-1.46 (m, 3H, CH3.ala). 
31P NMR (CDCl3, 
202 MHz): δppm 8.14, 7.88. 
 
 
Note: Data agrees with previously published papers. 85,103,156 
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Methyl((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin- 
1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (5.8a) 
 
 
 
MF: C19H22FIN3O9P 
MW: 613.2 
 
Compound 5.8a was prepared according to standard procedure C. 1-(3-fluoro-
4hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.265g; 0.713mmol), NMI (5eq; 0.283mL; 0.293g; 3.567mmol) and methyl-
2- (chloro(phenoxy) phosphorylamino)propanoate (5.7a) (3eq; 0.594g; 
2.140mmol)were reacted to obtain a residue that was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to obtain 
the product 5.8a as a yellowish oil. Yield: 7%.  
 
1H NMR (500 MHz, CDCl3): δppm 8.90 (s, 1H, 3-NH), 7.85 (d, J = 4.9 Hz, 1H, 6-CH), 7.26 
(td, J=7.9, 2.9 Hz, 2H, CH-phenyl), 7.16 (d, J=8.6 Hz, 2H, CH-phenyl), 7.11 (t, J = 7.4 Hz, 
1H, CH-phenyl), 5.78 (ddd, J = 30.9, 17.7, 1.4 Hz, 1H, 1'-CH), 4.91 (m, 1H, 2'-CH), 4.40 (d, 
J = 8.0 Hz, 2H, 5'-CH2), 4.29 (m, 1H, 4'-CH), 4.14 (t, J = 8.8 Hz, 1H, 3'-OH), 4.03 (m, 1H, 3'-
CH), 3.09 (dd, J = 7.0, 4.9 Hz, 1H, CH-ala), 3.65 (s, 3H, CH3-ester), 1.97 (d, J = 11.9 Hz, 
3H, CH3-ala). 13C NMR (125 MHz, CDCl3): δppm 171.3 (C=O, ala) 159.70 (C=O, uridine), 
158.3 (C=O, uridine), 149.46 (CH-uridine), 145.00 (C-O-Ar), 144.53 (Ar-CH), 129.88 (Ar-
CH), 120.14 (Ar-CH), 93.87, 93.73 (C-3’), 92.34, 92.22 (C-1'), 90.14, 88.91 (C-4'), 81.57, 
81.36 (C-5), 68.87 (C-3'), 64.71 (C-5’), 64.38 (CH3-ester), 58.49 (CH-ala),  20.94, 20.88 
(CH3-ala,). 
19F NMR (470  MHz, CDCl3): δppm -201.16, -202.58.
 31P NMR (202 MHz, 
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CDCl3): δppm 3.76, 3.30. MS (ESI)
+: 636.0 [M+Na+]. HPLC: Rt: 10.1 min (97%). 
*Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% 
CH3CN- (20’) 95% H2O/5% CH3CN]. 
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Ethyl-2-(((4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- 
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate (5.8b) 
 
 
 
MF: C20H24FIN3O9P 
MW: 627.3 
 
Compound 5.8b was prepared according to standard procedure C. 1-(3-fluoro-
4hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.159g; 0.427mmol), NMI (5eq; 0.169mL; 0.175g; 2.138mmol) and ethyl-2-
(chloro(phenoxy) phosphorylamino)propanoate (3.10) (4.2eq; 0.524g; 1.79mmol) were 
reacted to obtain a residue that was purified by silica gel column chromatography 
(CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to obtain the product 5.8b 
as a yellowish oil. Yield: 12%. 
 
 
1H-NMR (500 MHz, CDCl3): δppm 9.82 (s, 1H, 3-NH), 7.85 (d, J=5.1 Hz, 1H, 6-CH), 7.26 – 
7.21 (m, 2H, CH-phenyl), 7.16 (t, J=8.0 Hz, 2H, CH-phenyl), 7.07 (td, J=7.1, 3.3 Hz, 1H, 
CH-phenyl), 5.78 (ddd, J=28.1, 17.8, 1.5 Hz, 1H, 1'-CH), 4.92 (ddd, J = 56.6, 52.5, 3.4 Hz, 
1H, 2'-CH), 4.39 (d, 2H, 5'-CH2), 4.33 (m, 1H, 4'-CH), 4.25 (dd, J=11.7, 9.5 Hz, 1H, 3'-CH), 
4.16 (t, J=6.7 Hz, 1H, 3'-OH), 4.05 (t, J=7.8 Hz, 2H, CH2-ester), 3.97 (m, 1H, NH-ala), 
3.03 (dd, J=7.2, 4.6 Hz, 1H, CH-ala), 1.31 (m, 3H, CH3-ala), 1.15 (t, J=6.9 Hz, 3H, CH3-
ester). 13C-NMR (125 MHz, CDCl3): δppm 173.62 (C=O, ala), 160.29, 160.25 (C-4), 
150.36 (C-2), 149.90, 149.88 (C-phenyl), 145.07, 144.63 (C-6), 129.83 - 120.25 (Ar-C), 
93.87, 93.76 (C-5), 92.37, 92.25 (C-4'), 89.88, 89.05 (C-2'), 81.54, 81.35 (C-1'), 68.23 (C-
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3'), 65.08, 65.04 (C-5',), 61.85, 61.83 (CH2-ester), 53.46 (CH-ala), 20.90 (CH3-ala), 14.11 
(CH3-ester). 
19F  NMR (470 MHz, CDCl3): δppm -201.12, -202.39. 
31P-NMR (202 MHz, 
CDCl3): δ 3.20, 3.48.  MS(ESI)
+: 628.03 [M+H+]. HPLC: Rt: 10.5 min (95%). *Gradient: (0’) 
95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% 
H2O/5% CH3CN. 
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Isopropyl((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-
dihydropyrimidin- 1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-
alaninate. (5.8c) 
 
 
 
MF: C21H26FIN3O9P 
MW: 641.3 
 
Compound 5.8c was prepared according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.250g; 0.672mmol), NMI (5eq; 0.266mL; 0.275g; 3.359mmol) and 
isopropyl-2-(chloro(phenoxy) phosphorylamino)propanoate (5.7b) (3eq; 0.611g; 
2.016mmol) were reacted to obtain a residue that was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to obtain 
the product 5.8c as a yellowish oil. Yield: 3%. 
  
1H NMR (500 MHz, CDCl3): δppm 11.82 (s, 1H, 3-NH), 8.31 (d, J=4.9 Hz, 1H, 6-CH), 7.43–
7.21 (m, 2H, CH-phenyl), 7.18 (t, J=9.1 Hz, 2H, CH-phenyl), 7.07 (td, J=7.1, 3.9 Hz, 1H, 
CH-phenyl), 6.07 (ddd, J=25.3, 15.3, 1.5 Hz, 1H, 1'-CH), 5.43 (ddd, J=54.3, 53.5, 4.4 Hz, 
1H, 2'-CH), 4.98 (d, 2H, 5'-CH2), 4.71 (m, 1H, 4'-CH), 4.54 (dd, J=15.3, 9.4 Hz, 1H, 3'-CH), 
4.12 (t, J=5.7 Hz, 1H, 3'-OH), 4.11 (m, 1H, CH-ester), 3.94 (m, 1H, NH-ala), 3.39 (d, 
J=4.7Hz, 6H, 2x CH3-ester), 3.23 (dd, J=7.2, 4.6 Hz, 1H, CH-ala), 1.41 (m, 3H, CH3-ala). 
13C NMR (125 MHz, CDCl3): δppm 171.61 (C=O, ala), 161.31 (C-4), 159.26 (C-2), 153.90, 
152.18 (C-phenyl), 149.7, 148.69 (C-6), 131.23 -129.24 (Ar-C), 92.7(C-5), 92.14, 92.09 
(C-4'), 90.03 (C-2'), 89.53, 87.41 (C-1'), 72.51 (C-3'), 71.03 (C-5'), 55.83 (CH-ester), 52.31 
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(CH-ala), 21.23 (CH3-ala), 20.91 (CH3-ester). 
19F NMR (470 MHz, CDCl3): δppm -207.09, -
205.19.  31P NMR (202 MHz, CDCl3): δppm 3.42, 3.29. MS (ESI)
+ : 664.3 [M + Na+]. 
HPLC: Rt: 10.6 min (96%). *Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- 
(15’) 50% H2O/50% CH3CN- (20’) 95% H2O/5% CH3CN].  
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Neopentyl ((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-
alaninate. (5.8d) 
 
 
MF: C23H30FIN3O9P 
MW: 669.38 
 
Compound 5.8d was obtained according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.293g; 0.79mmol), NMI (5eq; 0.309mL; 0.320g; 3.98mmol) and neopentyl-
2-(chloro(phenoxy) phosphorylamino)propanoate (5.7c) (3eq; 0.800g; 2.39mmol) were 
used as reagents to obtain a crude that was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to obtain 
the product 5.8d as a yellowish oil. Yield: 3%. 
  
 1H NMR (500 MHz, CDCl3): δppm 9.76 (s, 1H, 3-NH), 7.70 (s, 1H, 6-CH), 7.27–7.22 (m, 
2H, CH-phenyl), 7.14 (t, J=7.4 Hz, 2H, CH-phenyl), 7.07 (t, J=7.4 Hz, 1H, CH-phenyl), 5.87 
(m, 1H, 1'-CH), 5.04 (dd, J=52.6, 4.6 Hz, 1H, 2'-CH), 4.40 (m, 2H, 5'-CH2), 4.35 (m, 1H, 
4'-CH), 4.29 (m, 1H, 3'-CH), 4.18 (m, 1H, 3'-OH), 3.81 (m, 1H, NH-ala), 3.95 (s, CH2-ester) 
3.39 (m, 1H, CH-ala), 1.38 (s, 9H, 3x CH3-ester), 1.27 (d, J=7.0 Hz, 3H, CH3-ala). 
13C NMR 
(125 MHz, CDCl3): δppm 172.73 (C=O, ala), 160.13, 160.08 (C-4), 150.80 (C-2), 149.68 
(C-phenyl), 145.35, 145.31 (C-6), 129.77 - 120.11 (Ar-C), 92.03, 91.83 (C-5),91.51, 91.22 
(C-4'), 89.25, 88.98 (C-2'), 82.36, 82.27 (C-1'), 82.02, 81.99 (CH2-ester), 69.65, 69.53 (C-
3'), 68.97, 68.84 (C-5'), 53.64, 53.58 (CH-ala), 27.92 (CH3-neopentyl), 21.10, 21.02 (CH3-
ala). 19F NMR (470 MHz, CDCl3): δppm -199.18, -203.16.  
31P NMR (202 MHz, CDCl3): 
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δppm 3.81, 3.74. MS (ESI)+: 692.5 [M + Na+]. HPLC: Rt: 11.1 min (95%). *Gradient: (0’) 
95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% 
H2O/5% CH3CN]. 
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Tert-butyl-2-(((4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- 
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (5.8e) 
 
 
MF: C22H28FIN3O9P 
MW: 655.4 
 
Compound 5.8e was prepared according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.271g; 0.729mmol), NMI (5eq; 0.289mL; 0.299g; 3.649mmol) and 
tertbutyl-2- (chloro(phenoxy) phosphorylamino)propanoate (5.7d)(3eq; 0.700g; 
2.189mmol) were used to obtain a crude that was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to obtain 
the product 5.8e as a yellowish oil. Yield: 6%. 
 
1H NMR (500 MHz, CDCl3): δppm 10.31 (s, 1H, 3-NH), 8.59 (s, 1H, 6-CH), 7.51-8.43 
(m, 2H, CH-phenyl), 7.29 (t, J=7.1 Hz, 2H, CH-phenyl), 7.13 (t, J=7.1 Hz, 1H, CH-phenyl), 
6.01 (m, 1H, 1'-CH), 5.04 (dd, J = 49.3, 3.9 Hz, 1H, 2'-CH), 4.40 (m, 2H, 5'-CH2), 4.29 (m, 
1H, 4'-CH), 4.23 (m, 1H, 3'-CH), 4.07 (m, 1H, 3'-OH), 3.96 (m, 1H, NH-ala), 3.27 (m, 1H, 
CH-ala), 1.36 (s, 9H, 3x CH3-ester), 1.21 (d, J=7.0 Hz, 3H, CH3-ala). 
13C NMR (125 MHz, 
CDCl3): δppm 179.7 (C=O, ala), 159.13,159.0 (C-4), 156.2 (C-2), 148.21 (C-phenyl), 
147.91, 147.43 (C-6), 125.21-124.92 (Ar-C), 98.32, 97.89 (C-5), 94.21, 93.97 (C-4'), 
92.21, 92.19 (C-2'), 85.71, 84.35 (C-1'), 82.34, 81.76 (C-ester), 69.21, 68.72 (C-3'), 
68.23, 68.19 (C-5'), 54.49, 53.48 (CH-ala), 25.09 (CH3-tert butyl), 23.65, 23.63 (CH3-
ala). 19F NMR (470 MHz, CDCl3): δppm -204.3, -203.91. 
31P NMR (202 MHz, CDCl3): 
δppm 3.91, 3.79. MS (ESI)+: 678.4 [M + Na+]. HPLC: Rt: 11.9 min (99%). *Gradient: (0’) 
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95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% 
H2O/5% CH3CN]. 
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Benzyl((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin- 
1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (5.8f) 
 
 
 
MF: C25H26FIN3O9P 
MW: 689.3 
 
Compound 5.8f was prepared according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.200g; 0.537mmol), NMI (5eq; 0.212mL; 0.220g; 2.68mmol) and benzyl 
(chloro(phenoxy)phosphoryl)-L-alaninate (4.5) (3eq; 0.570g; 1.61mmol)were reacted 
to obtain a product that was purified by silica gel column chromatography 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to afford 
the compound 5.8f as a yellowish oil. Yield: 11%. 
  
1H NMR (500 MHz, CDCl3): δ 10.59 (s, 1H, 3-NH), 7.91 (s, 1H, 6-CH), 7.41–7.38 (m, 2H, 
CH-phenyl), 7.32 (t, J=7.9 Hz, 2H, CH-phenyl), 7.37-7.35 (m, 2H, CH-benz), 7,25-7.23 
(m, 2H, CH-benz) 7.22 (t, 7.9 Hz, 1H, CH-benzyl), 7.13 (t, J=7.2 Hz, 1H, CH-phenyl), 5.99 
(m, 1H, 1'-CH), 5.42 (dd, J=49.6, 4.6 Hz, 1H, 2'-CH), 5.31 (m, 2H, CH2-benz), 4.68 (m, 2H, 
5'-CH2), 4.52 (m, 1H, 4'- CH), 4.27 (m, 1H, 3'-CH), 4.11 (m, 1H, 3'-OH), 3.89 (m, 1H, NH-
ala), 3.71 (m, 1H, CH-ala), 1.26 (d, J=7.0 Hz, 3H, CH3-ala). 
13C NMR (125 MHz, CDCl3): 
δppm 171.7 (C=O, ala), 167.31 (C-4), 158.13 (C-phenyl), 155,43 (C-benzyl), 149.09, 
149.92 (C-6), 145.65 (C-2), 129.98-120.32 (Ar-C), 92.61, 92.54 (C-5), 90.54,90.21(C-4'), 
87.76, 86.99 (C-2'), 85.13, 83.51 (C-1’), 80.07, 80.03 (C-ester), 69.21, 68.52 (C-3'), 67.54 
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(C-5’), 54.31 (CH-ala), 27.25 (CH3-ala). 
19F NMR (470 MHz, CDCl3): δppm -200.79, -
200.12. 31P NMR (202 MHz, CDCl3): δppm 3.90, 3.87. MS (ESI)
+: 690.3 [M + H+]. HPLC: 
Rt: 13.2 min (98%). *Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 
50% H2O/50% CH3CN- (20’) 95% H2O/5% CH3CN]. 
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Methyl((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alaninate. 
(5.8g) 
 
 
 
MF: C23H24FIN3O9P 
MW: 663.3 
 
Compound 5.8g was synthesised according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.400g; 1.07mmol), NMI (5eq; 0.424mL; 0.439g; 5.35mmol) and methyl-2- 
(chloro(naphthoxy) phosphorylamino)propanoate (5.7e) (3eq; 1.05g; 3.22mmol) were 
reacted to obtain a product that was purified by silica gel column chromatography 
(CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to afford the compound 5.8g 
as a yellowish solid. Yield: 4%. 
 
1H NMR (500 MHz, CDCl3): δppm 10.91 (d, J=41.4 Hz, 1H, 3-NH), 8.23 (d, J=4.9 Hz, 1H, 
6-CH), 7.91 (m, 2H, CH, naph), 7.86-7.4 (m, 5H, CH-naph), 5.54 (ddd, J=34.9, 17.6, 1.3 
Hz, 1H, 1'-CH), 4.90 (m, 1H,2'-CH), 4.60 (d, J=7.0 Hz, 2H, 5'-CH2), 4.31 (m, 1H, 4'-CH), 
4.12 (t, J=8 Hz, 1H, 3'-OH), 4.13 (m, 1H, 3'-CH), 3.98 (s, 3H, CH3-ester) 3.87 (d, J=11.7 
Hz, 1H, NH-ala), 3.11 (dd, J=8.0, 4.9 Hz, 1H, CH-ala), 1.28 (dd, J=10.1, 6.7 Hz, 3H, CH3-
ala),. 13C NMR (125 MHz, CDCl3): δ 163.10 (C=O, ala), 151.03 (C-naph), 145.13 (C-4), 
145.01 (C-2), 144.19 (C-6), 128.13-119.91 (Ar-C), 91.73 (C-5), 92.91, 92.52 (C-4'), 91.19, 
89.1 (C-2'), 81.12, 81.09 (C-1'), 65.37 (C-5'), 64.9, 64.31 (CH3-ester), 56.48 (CH-ala), 
51.75 (C-3'), 39.11 (C-2'), 21.93, 20.99 (CH3-ala). 
19F NMR (470 MHz, CDCl3): δppm -
201.10, -201.01. 31P NMR (202 MHz, CDCl3): δppm 3.75, 3.42. MS (ESI)
+ : 664.3 [M + 
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H+]. HPLC: Rt: 15.1 min (95%). *Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% 
H2O/50%CH3CN- (15’) 50% H2O/50%CH3CN- (20’) 95% H2O/5%CH3CN]. 
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Ethyl ((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)- yl)tetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-
alaninate. (5.8h) 
 
 
MF: C24H26FIN3O9P 
MW: 677.3 
 
Compound 5.8h was obtained according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq, 0.400g, 1.07mmol), NMI (5 eq; 0.424mL; 0.439g; 5.35mmol) and ethyl-2-
(chloro(naphtoxy)phosphorylamino)propanoate (3eq; 1.098g; 3.22mmol) were used as 
reagents to obtain a crude that was purified by silica gel column chromatography 
(CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to afford the compound 
5.8h as a yellowish oil. Yield: 5%. 
 
1H NMR (500 MHz, CDCl3): δppm 11.9 (d, J=40.3 Hz, 1H, 3-NH), 8.19 (d, J=4.7 Hz, 1H, 6-
CH), 7.83 (m, 2H, CH, naph), 7.81-7.2 (m 5H, CH-naph), 5.5 (ddd, J=32.7, 12.3, 1.4 Hz, 
1H, 1'-CH), 4.73 (m, 1H,2'-CH), 4.56 (d, J = 7.0 Hz, 2H, 5'-CH2), 4.21 (m, 1H, 4'-CH), 4.26 
(m, 3'-OH), 4.14 (m, 2H, CH2-ester), 4.11 (m, 1H, 3'-CH), 3.89 (d, J = 10.7 Hz, 1H, NH-
ala), 3.21 (dd, J = 7.0, 4.9 Hz, 1H, CH-ala), 1.27 (d, J = 6.7 Hz, 3H, CH3-ala), 1.18 (t, J = 7.9 
Hz, 3H, CH3-ester). 
13C NMR (125 MHz, CDCl3): δppm 167.92 (C=O, ala), 159.03 (C-
naph), 144.3 (C-4), 143.9 (C-2), 144.19 (C- 6), 123.03 - 121.02 (Ar-C), 90.74 (C-5), 92.49 
(C-4'), 91.21, 90.1 (C-2'), 83.1 (C-1'), 67.46 (C-5'), 62.9, 61.3 (CH3-ester), 61.9 (CH2-
ester), 54.93 (CH-ala), 50.31 (C-3'), 50.10 (C-2'), 22.15, 21.79 (CH3-ala). 
19F NMR  (470  
MHz, CDCl3): δppm -201.39, -201.31. 
31P NMR (202 MHz, CDCl3): δppm 3.74, 3.59. MS 
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(ESI)+: 700.3 [M + Na+]. HPLC: Rt: 16.4 min (96%). *Gradient: (0’) 95%H2O/5%CH3CN - 
(5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% H2O/5% CH3CN]. 
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Tertbutyl((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(naphthalen-1-
yloxy)phosphoryl)-L-alaninate 
 
 
 
MF: C26H30FIN3O9P 
MW: 705.4 
 
Compound 5.8i was synthesised according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1 eq; 0.158g; 0.426mmol) and NMI (5eq; 0.168mL; 0.175g; 0.213mmol) and 
isopropyl-2-(chloro(naphtoxy)phosphorylamino)propanoate (5.7g) (3eq; 1.05g; 
3.22mmol)were reacted to obtain a crude that was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to afford 
the compound 5.8i as a yellowish oil. Yield: 5%. 
1H NMR (500 MHz, CDCl3): δppm 11.89 (d, J = 42.3 Hz, 1H, 3-NH), 8.21 (d, J = 5.1 Hz, 
1H, 6-CH), 7.93 (m, 2H, CH, naph),7.21-7.20 (m, 5H, CH-naph), 5.43 (ddd, J = 34.5, 19.1, 
1.9 Hz, 1H, 1'- CH), 4.89 (m, 1H, 2'-CH), 4.45 (d, J = 7.3 Hz, 2H, 5'-CH2), 4.19 (m, 1H, 4'-
CH), 4.09 (t, J = 7 Hz, 1H, 3'-OH), 4.10 (m, 1H, 3'-CH), 3.91 (d, J = 10.9 Hz, 1H, NH-ala), 
3.87 (m, 1H, CH-i-propyl), 3.09 (dd, J = 7.0, 4.7 Hz, 1H, CH-ala), 1.33 (dd, J = 10.4, 4.1 
Hz, 3H, CH3-ala), 1.19 (d, J = 7.9 Hz, 6H, 2x CH3- i-propyl). 
13C NMR(125 MHz, CDCl3): 
δppm 167.12 (C=O, ala), 161.02 (C-naph), 154.11 (C-4), 149.81 (C-2), 147.23 (C-6), 
129.21 - 120.97 (Ar-C), 95.23 (C-5), 92.65, 92.34 (C-4'), 91.15, 88.76 (C-2'), 81.97, 81.54 
(C-1'), 71.35 (C-5'), 68.9, 68.29 (CH-i-propyl), 55.38 (CH-ala), 50.29 (C-3'), 41.11 (C-2'), 
27.88, 27.65 (CH3-ala,), 21.32-21.29 (CH3-i-propyl).  
19F NMR (470 MHz, CDCl3): δppm -
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200.32, -200.11. 31P NMR (202 MHz, CDCl3): δppm 3.56, 3.12. MS (ESI)
+: 728.5 [M + 
Na+]. HPLC: Rt: 16.6 min (97%). *Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% 
H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 95% H2O/5% CH3CN]. 
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Benzyl ((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alaninate. 
(5.8l) 
 
 
MF: C26H30FIN3O9P 
MW: 705.9 
Compound 5.8l was prepared according to standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(2.3) (1eq; 0.427g; 1.14mmol), NMI (5eq; 0.454mL; 0.468g; 5.7mmol) and isopropyl-2- 
(chloro(naphtoxy) phosphorylamino)propanoate (5.7g) (3eq; 1.05g; 3.22mmol) were 
used to obtain a crude that was purified by silica gel column chromatography 
(CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to afford the compound 5.8l as 
a yellowish oil. Yield: 3%. 
1H NMR (500 MHz, CDCl3): δppm 11.73 (d, J = 40.4 Hz, 1H, 3-NH), 8.64 (d, J = 4.7 Hz, 1H, 
6-CH), 8.01 (m, 2H, CH, naph), 7.92-7.86 (m,  5H, CH-naph), 6.12 (ddd, J = 39.1, 14.3, 1.9 
Hz, 1H, 1'- CH), 4.95 (m, 1H,2'-CH), 4.65 (d, J = 7.5 Hz, 2H, 5'-CH2), 4.22 (m, 1H, 4'-CH), 
4.17 (t, J = 7.8 Hz, 1H, 3'-OH), 4.13 (m, 1H, 3'-CH), 3.92 (m, CH-i-propyl), 3.87 (d, J = 9.6 
Hz, 1H, NH-ala), 3.64 (dd, J = 7.9, 4.7 Hz, 1H, CH-ala), 1.29 (dd, J = 10.5, 6.3 Hz, 3H, CH3-
ala), 1.21 (d, J = 7.9 Hz, 9H, 3x CH3-ester). 
13C NMR(125 MHz, CDCl3): δppm 171.08 (C=O, 
ala), 169.55 (C-naph), 155.17 (C-4), 153.00 (C-2), 149.23 (C-6), 131.82-129.27 (Ar-C), 
99.07 (C-5), 95.76, 95.03 (C-4'), 91.09, 89.77 (C- 2'), 86.54, 87.09 (C-1'), 67.02 (C-5'), 64.1, 
64.01 (CH-ester), 59.76 (CH-ala), 57.32 (C-3'), 39.87 (C-2'), 22.00, 20.15 (CH3-ala), 19.78, 
19.54 (CH3-ester).  
19F NMR (470 MHz, CDCl3): δppm -203.15, -202.65. 
31P NMR (202 
MHz, CDCl3): δ 3.91, 3.76. MS (ESI)
+ : 706.6 [M + H+]. HPLC: Rt: 16.9 min (97%). 
 
 8. Experimental 
193 
 
*Gradient: (0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% 
CH3CN- (20’) 95% H2O/5% CH3CN]. 
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Benzyl ((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin- 
1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate. (4.3) 
 
 
MF: C25H26FIN3O9P 
MW: 689.3 
 
Compound 4.3 was prepared according to the standard procedure C. 1-(3-fluoro-4-
hydroxy-5-(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 
(1.66) (1eq; 0.400g; 1.07mmol), NMI (5eq; 0.424mL; 0.439g; 5.35mmol), benzyl-2-
(chloro(naphtoxy)phosphorylamino) 
propanoate (4.5) (3eq; 1.05g; 3.22mmol) were reacted to obtain a residue that was 
purified by silica gel column chromatography (CH2Cl2/CH3OH from 100% CH2Cl2 to 95% 
CH2Cl2) to obtain the product 4.3 as a yellowish oil. Yield: 10%. 
 
1H NMR (500 MHz, CDCl3): δppm10.59 (s, 1H, 3-NH), 7.89 (s, 1H, 6-CH), 7.53–7.48 (m, 
2H, CH-phenyl), 7.45 (t, J=8Hz, 2H, CH-phenyl), 7.41-7.38 (m, 2H, CH-benz), 7,17-7.15 
(m, 2H, CH-benz), 7.13 (t, 8Hz, 1H, CH-benzyl), 7.12 (t, J=7.4 Hz, 1H, CH-phenyl), 5.99 
(m, 1H, 1'-CH), 5.79 (dd, J=47.6, 4.6 Hz, 1H, 2'-CH), 5.14 (m, 2H, CH2-benz), 4.90 (m, 2H, 
5'-CH2), 4.39 (m, 1H, 4'-CH), 4.27 (m, 1H, 3'-CH), 4.19 (m, 1H, 3'-OH), 4.02 (m, 1H, NH-
ala), 3.99 (m, 1H, CH-ala), 1.29 (d, J=7.0Hz, 3H, CH3-ala). 
13C NMR (125 MHz, CDCl3): 
δppm 171.9 (C=O, ala), 168.12 (C-4), 144.18 (C-2), 149.0 (C-phenyl), 147.91 (C-benzyl), 
145.5, 145.1 (C-6), 128.31-121.48 (Ar-C), 94.3 (C-5), 92.10 (C-4'), 89.13 (C-2'), 83.6, 
82.97 (C-1'), 81.08, 80.97 (C-ester), 69.61, 68.14 (C-3'), 67.23 (C-5'), 52.8 (CH-ala), 
21.98 (CH3-ala). 
19F NMR (470 MHz, CDCl3): δppm-200.91, -201.15. 
31P NMR (202 MHz, 
 
 8. Experimental 
195 
 
CDCl3): δppm3.90, 3.86. MS (ESI)
+: 690.3 [M + H+]. HPLC: Rt: 13.4 min (98%). [Gradient: 
(0’) 95%H2O/5%CH3CN - (5’) 50% H2O/50%CH3CN- (15’) 50% H2O/50% CH3CN- (20’) 
95% H2O/5% CH3CN]. 
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8.3.4 Experimental section from Chapter 6 
 
4-Methyl-2-oxo-2H-chromen-8-yl phosphorodichloridate 
 
MF: C10H7Cl2O4P 
MW: 293.04 
 
Phosphorus oxychloride (1eq, 0.434g, 0.264 mL, 2.83mmol) and 4-
methylumbelliferone 6.3a (1eq, 0.5g, 2.83mmol), were stirred in anhydrous Et2O 
under nitrogen atmosphere. Anhydrous TEA (2eq, 0.574g, 0.791mL, 5.676mmol)  was 
added dropwise at -78°C. The reaction mixture was then allowed to stir for 30min and 
then to slowly warm to rt and stirred for 1h. The reaction was monitored by 31P NMR. 
The crude mixture was then filtered under nitrogen atmosphere and reduced under 
pressure to furnish 6.4a as a yellowish oil which wasn’t further purified. Yield: 86%. 
 
31P NMR (CDCl3, 202 MHz): δppm 4.02.  
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2-Oxo-4-(trifluoromethyl)-2H-chromen-8-yl phosphorodichloridate 
 
MF: C10H4Cl2F3O4P 
MW: 347.01 
 
Phosphorus oxychloride (1eq, 0.330g, 0.202mL, 2.17mmol) and 7-hydroxy-4-
(trifluoromethyl)coumarin 6.3b (1eq, 0.5g, 2.17mmol), were stirred in anhydrous Et2O 
under nitrogen atmosphere. Anhydrous TEA was added dropwise at -78°C. The 
reaction mixture was then allowed to stir for 30min and then to slowly warm to rt and 
stirred for 1h. The reaction was monitored by 31P NMR. The crude mixture was then 
filtered under nitrogen atmosphere and reduced under pressure to furnish 6.4b as a 
yellowish oil which wasn’t further purified. Yield: 88%. 
 
31P NMR (CDCl3, 202 MHz): δppm 4.57.   
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Ethyl (chloro((4-methyl-2-oxo-2H-chromen-8-yl)oxy)phosphoryl)-L-alaninate 
 
MF: C15H17ClNO6P 
MW: 373.73 
 
Compound 6.5a was synthesised according to standard procedure B. 6.4a 
phosphorodichloridate (0.650 g, 2.21 mmol), L-alanine ethyl ester (0.339g, 2.21mmol) 
and TEA (0.447g, 0.616ml, 4.42mmol) were used to produce 6.5a which was used for 
next reaction without further purification. Yield: 71%. 
 
31P NMR (CDCl3, 202 MHz): δppm 8.32, 7.79.   
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Ethyl (chloro((2-oxo-4-(trifluoromethyl)-2H-chromen-8-yl)oxy)phosphoryl)-L-
alaninate 
 
MF: C15H14ClF3NO6P 
MW: 427.70 
 
Compound 6.5b was synthesised according to standard procedure B. 6.4b (0.6g, 
1.73mmol), L-alanine ethyl ester (0.265g, 1.73mmol) and TEA (0.351g, 0.483mL, 
3.46mmol) were used to produce 6.5b which was used for next reaction without 
further purification. Yield: 81%. 
 
31P NMR (CDCl3, 202 MHz): δppm 9.51, 7.88.   
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Ethyl ((((2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)((4-methyl-2-oxo-2H-chromen-8-
yl)oxy)phosphoryl)-L-alaninate. (6.6a) 
 
 
MF: C25H29FN3O10P 
MW: 581.49 
 
Compound 6.6a was synthesised according to standard procedure D. FLT (1.29) (1eq, 
0.146 g, 0.6 mmol), tBuMgCl (0.117 ml, 0.9 mmol) and 6.5a phosphorochloridate (2eq, 
0.450 g, 1.2 mmol) were used to produce 6.6a. It was purified by silica gel coulm 
chromatography (CH2Cl2/CH3OH from 100% CH2Cl2 to 95% CH2Cl2) to obtain a pale 
white solid. Yield: 5 %. 
  
1H-NMR (CDCl3, 500MHz): δppm 8.59, 8.53 (s, 1H, NH), 7.95-7.93 (m, 1H, ArH), 7.51, 
7.49 (q, J =1.83 H; J = 1.6 Hz, 1H, ArH), 7.37-7.34 (m, 2H, ArH), 7.28-7.23 (m, 1H, H-1’), 
6.97, 6.91, (t, J = 2, 8, 5 Hz, 1H, H-3’), 6.11-6.07 (m, 1H, ArH), 5.43, 5.36 (d, J = 1.8Hz, 
2H, H-2’), 5.08-5.01 (m, 1H, H-4’), 4.99-4.88 (m, 2H, H-5’), 4.67-4.56 (m, 2H, CH2 ester), 
4.06-3.89 (m, 2H, NH, CH-ala), 2.39 (d, J = 1.6 Hz, 3H, CH3-coum), 1.91, 1.85 (t, J = 1.6 
Hz, 3H, CH3 thym), 1.41, 1.39 (d, J = 6.5 Hz, 3H, CH3 ala), 1.12, 1.11 (t, J = 7 Hz, 3H, CH3 
ester). 13C NMR (CDCl3, 125MHz): δppm 175.83 (C=O-ala), 169.98, 167.43 (C=O-thym), 
157.65, 157. 10 (C=O- coum), 153.78, 153.75 (ArC), 152.52, 152.43, 151.98, 151.76 (Ar-
C), 151.05 (C=O-thym), 139.18, 138.79 (ArCH), 135.64, 134.34 (C-3’), 131.21, 130.11 (C-
2’), 129.15, 127.54 (Ar-CH), 115.77 (Ar-C), 115.14, 114.61, 113.88, 113.43 (ArCH), 
109.45, 109.21 (ArC), 107.11, 107.05, 89.43, 89.14 (C-1’), 83.21, 83.11 (C-4’), (71.88, 
69.76, C-5’), 69.22, 69.10 (CH2 ester), 49.88, 49.73 (CH- ala), 29.31-29.25 (CH3-coum), 
20.16 (CH3 ala), 19.43 (CH3-ester), 15.84, 14.34 (CH3-thym). 
31P NMR (CDCl3, 202 MHz): 
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δppm 3.01, 2.73.  19F NMR (470 MHz, CDCl3): δppm-175.2, -174.8. MS (ESI)
 +: 582.5 
[M+H+].   
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Ethyl ((((2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)((2-oxo-4-(trifluoromethyl)-2H-chromen-8-
yl)oxy)phosphoryl)-L-alaninate. (6.6b) 
 
 
 
MF: C25H26F4N3O10P 
MW: 635.46 
 
Compound 6.6b was prepared according to standard procedure D. FLT (1.29) (1eq, 
0.100g, 0.41mmol), tBuMgCl (0.08mL) and phosphorochloridate (0.349g, 0.82 mmol) 
were used to produce Protide 6.6b that was purified by silica gel column 
chromatography (CH2Cl2/CH3OH from 100% CH2Cl2 to 95% CH2Cl2) to obtain a pale 
white solid. Yield: 11%. 
 
1H-NMR (CDCl3, 500MHz): δppm 8.63, 8.61 (s, 1H, NH), 7.84-7.81 (m, 1H, ArH), 7.43, 
7.41 (m, 1H, ArH), 7.25-7.19 (m, 2H, ArH), 7.19-7.18 (m, 1H, H-1’), 6.76, 6.75, (t, J = 1.6, 
7, 4.3 Hz, 1H, H-3’), 6.03-6.00 (m, 1H, ArH), 5.64, 5.39 (d, J = 1.7 Hz, 2H, H-2’), 4.99-4.97 
(m, 1H, H-4’), 4.49-4.43 (m, 2H, H-5’), 4.25-4.21 (m, 2H, CH2- ester), 4.11 (m, 1H, NH), 
4.02 (m, 1H, CH-ala), 1.95, 1.89 (t, J = 1.5 Hz, 3H, CH3 thym), 1.54, 1.51 (d, J = 5 Hz, 3H, 
CH3 ala), 1.21, 1.19 (t, J = 7 Hz, 3H, CH3 ester). 
13C NMR (CDCl3, 125MHz): δppm 181.21 
(C=O-ala), 165.98, 164.12 (C=O-thym), 159.65, 158. 10 (C=O- coum), 153.12, 153.01 
(ArC), 152.76, 152.73, 151.86, 151.54 (Ar-C), 150.3 (C-CF3), 150.11 (C=O-thym), 141.18, 
140.9 (ArCH), 139.64, 139.99 (C-3’), 137.11, 137.02 (C-2’), 131.53, 131.32 (Ar-CH), 
121.99 (CF3), 118.23, 117.21, 117.10, 116.98 (ArCH), 110.32, 109.87 (ArC), 108.09, 
108.04,  89.43, 89.23 (C-1’), 85.76, 85.11 (C-4’), 75.99, 68.71, (C-5’), 68.19, 67.99 (CH2 
ester), 53.88, 53.53 (CH-ala), 20.99 (CH3-ala), 19.13 (CH3-ester), 15.99, 15.29 (CH3-
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thym). 31P NMR (CDCl3, 202 MHz): δppm: δ 3.12, 2.91. 
19F NMR (CDCl3, 470MHz): 
δppm - 64.78,-64.12,-174.3, -174.1.  MS (ESI+): 658.2 [M+Na+]. 
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1.18F counts against MBq standard curve. The activityof [18F]FIAU dissolved in PBS 
was measured and used to make serial dilutions. The range of concentrations was 
then measured using anautomatic gamma counter. 
 
2. Raw data for standard curve 
Sample 
 
Counts/min Mean 
 
MBq 
 
KBq 
 A B 
HEK 1 38029 33879 35954 0.001798 1.7977 
HEK 2 33052 32571 32811.5 0.001641 1.640575 
HEK 3 61659 52007 56833 0.002842 2.84165 
TK-HEK1 133924 124467 129195.5 0.00646 6.459775 
TK-HEK2 139935 139430 139682.5 0.006984 6.984125 
TK-HEK3 145572 117115 131343.5 0.006567 6.567175 
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3. Radioactivity measurements from cell washes. KBq of radioactivity from the 
samples were generated using the standard curve in Figure 4.15 
Sample 
Counts KBq Total 
Supernatan
t 1 
Supernatan
t 2 
Supernatan
t 1 
Supernatan
t 2 Count KBq 
TK- HEK1 2321157 192690 116.0579 9.6345 
251384
7 
125.692
4 
TK-HEK2 2317760 205327 115.888 10.26635 
252308
7 
126.154
4 
TK-HEK3 2315578 174083 115.7789 8.70415 
248966
1 
124.483
1 
HEK1 2269951 129205 113.4976 6.46025 
239915
6 
119.957
8 
HEK2 2271855 161629 113.5928 8.08145 
243348
4 
121.674
2 
HEK3 2251568 144151 112.5784 7.20755 
239571
9 119.786 
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4.  T-test to compare group means with the assumption of equal variances 
 HEK TK-HEK 
Mean 0.1164 1.3396 
St-Dev 0.0103 0.0859 
 
Hypothesis: 
HeKTK
HeKTK
H
H




:
:
1
0
 
 
Significance Level 
α = 0.05 
 
Pooled variance: 
   
 
0037425.0
233
0859.0130103.013 222 


pS  
0612.00037425.0 pS  
 
Test Statistic: 
48.24
3
1
3
1
00612
1164.03396.1



t  
 
Degrees of Freedom: 
4233 df  
 
Critical value: 
132.2ct  
 
Compare and decide: 
 132.248.24 ctt Reject Ho
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